



**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

## Management of people with early- or very early-stage hepatocellular carcinoma (Review)

Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS

Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS.  
Management of people with early- or very early-stage hepatocellular carcinoma.  
*Cochrane Database of Systematic Reviews* 2017, Issue 3. Art. No.: CD011650.  
DOI: 10.1002/14651858.CD011650.pub2.

[www.cochranelibrary.com](http://www.cochranelibrary.com)

## TABLE OF CONTENTS

HEADER . . . . .	1
ABSTRACT . . . . .	1
PLAIN LANGUAGE SUMMARY . . . . .	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . .	4
BACKGROUND . . . . .	6
OBJECTIVES . . . . .	7
METHODS . . . . .	8
RESULTS . . . . .	12
Figure 1. . . . .	13
Figure 2. . . . .	15
Figure 3. . . . .	16
Figure 4. . . . .	21
Figure 5. . . . .	25
Figure 6. . . . .	26
ADDITIONAL SUMMARY OF FINDINGS . . . . .	27
DISCUSSION . . . . .	36
AUTHORS' CONCLUSIONS . . . . .	38
ACKNOWLEDGEMENTS . . . . .	38
REFERENCES . . . . .	39
CHARACTERISTICS OF STUDIES . . . . .	47
DATA AND ANALYSES . . . . .	74
Analysis 1.1. Comparison 1 Surgery versus radiofrequency ablation, Outcome 1 Mortality at maximal follow-up. . . . .	78
Analysis 1.2. Comparison 1 Surgery versus radiofrequency ablation, Outcome 2 Cancer-related mortality at maximal follow-up. . . . .	79
Analysis 1.3. Comparison 1 Surgery versus radiofrequency ablation, Outcome 3 Mortality (> 1 year). . . . .	79
Analysis 1.4. Comparison 1 Surgery versus radiofrequency ablation, Outcome 4 Serious adverse events (number of participants). . . . .	80
Analysis 1.5. Comparison 1 Surgery versus radiofrequency ablation, Outcome 5 Serious adverse events (number of events). . . . .	80
Analysis 1.6. Comparison 1 Surgery versus radiofrequency ablation, Outcome 6 Any adverse events (number of participants). . . . .	81
Analysis 1.7. Comparison 1 Surgery versus radiofrequency ablation, Outcome 7 Any adverse events (number of events). . . . .	82
Analysis 1.8. Comparison 1 Surgery versus radiofrequency ablation, Outcome 8 HCC recurrence (local or distal). . . . .	83
Analysis 1.9. Comparison 1 Surgery versus radiofrequency ablation, Outcome 9 HCC recurrence (recurrence in liver). . . . .	84
Analysis 1.10. Comparison 1 Surgery versus radiofrequency ablation, Outcome 10 Length of hospital stay. . . . .	84
Analysis 1.11. Comparison 1 Surgery versus radiofrequency ablation, Outcome 11 Mortality at maximal follow-up (sensitivity analysis). . . . .	85
Analysis 2.1. Comparison 2 Non-surgical interventions, Outcome 1 Mortality at maximal follow-up. . . . .	86
Analysis 2.2. Comparison 2 Non-surgical interventions, Outcome 2 Cancer-related mortality at maximal follow-up. . . . .	87
Analysis 2.3. Comparison 2 Non-surgical interventions, Outcome 3 Mortality (> 1 year). . . . .	89
Analysis 2.4. Comparison 2 Non-surgical interventions, Outcome 4 Serious adverse events (number of participants). . . . .	90
Analysis 2.5. Comparison 2 Non-surgical interventions, Outcome 5 Serious adverse events (number of events). . . . .	92
Analysis 2.6. Comparison 2 Non-surgical interventions, Outcome 6 Any adverse events (number of participants). . . . .	93
Analysis 2.7. Comparison 2 Non-surgical interventions, Outcome 7 Any adverse events (number of events). . . . .	94
Analysis 2.8. Comparison 2 Non-surgical interventions, Outcome 8 HCC recurrence (local or distal). . . . .	95
Analysis 2.9. Comparison 2 Non-surgical interventions, Outcome 9 HCC recurrence (recurrence in liver). . . . .	96
Analysis 2.10. Comparison 2 Non-surgical interventions, Outcome 10 Length of hospital stay. . . . .	97
ADDITIONAL TABLES . . . . .	97
APPENDICES . . . . .	100
WHAT'S NEW . . . . .	105
CONTRIBUTIONS OF AUTHORS . . . . .	105

DECLARATIONS OF INTEREST . . . . .	106
SOURCES OF SUPPORT . . . . .	106
DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . .	106
NOTES . . . . .	106
INDEX TERMS . . . . .	107

[Intervention Review]

# Management of people with early- or very early-stage hepatocellular carcinoma

Avik Majumdar<sup>1</sup>, Davide Roccarina<sup>1</sup>, Douglas Thorburn<sup>1</sup>, Brian R Davidson<sup>2</sup>, Emmanuel Tsochatzis<sup>1</sup>, Kurinchi Selvan Gurusamy<sup>2</sup>

<sup>1</sup>Sheila Sherlock Liver Centre, Royal Free Hospital and the UCL Institute of Liver and Digestive Health, London, UK. <sup>2</sup>Department of Surgery, Royal Free Campus, UCL Medical School, London, UK

Contact address: Kurinchi Selvan Gurusamy, Department of Surgery, Royal Free Campus, UCL Medical School, Pond Street, London, NW3 2QG, UK. [k.gurusamy@ucl.ac.uk](mailto:k.gurusamy@ucl.ac.uk).

**Editorial group:** Cochrane Hepato-Biliary Group.

**Publication status and date:** Edited (no change to conclusions), published in Issue 4, 2017.

**Citation:** Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early- or very early-stage hepatocellular carcinoma. *Cochrane Database of Systematic Reviews* 2017, Issue 3. Art. No.: CD011650. DOI: 10.1002/14651858.CD011650.pub2.

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

Hepatocellular carcinoma (primary liver cancer) is classified in many ways. The Barcelona Clinic Liver Cancer (BCLC) group staging classifies the cancer based on patient's life expectancy. People with very early- or early-stage hepatocellular carcinoma have single tumour or three tumours of maximum diameter of 3 cm or less, Child-Pugh status A to B, and performance status 0 (fully functional). Management of hepatocellular carcinoma is uncertain.

### Objectives

To assess the comparative benefits and harms of different interventions used in the treatment of early or very early hepatocellular carcinoma through a network meta-analysis and to generate rankings of the available interventions according to their safety and efficacy. However, it was not possible to assess whether the potential effect modifiers were similar across different comparisons. Therefore, we did not perform the network meta-analysis and instead assessed the benefits and harms of different interventions versus each other or versus sham or no intervention using standard Cochrane methodology.

### Search methods

We searched CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, and trials registers to September 2016 to identify randomised clinical trials (RCTs) on hepatocellular carcinoma.

### Selection criteria

We included only RCTs, irrespective of language, blinding, or publication status, in participants with very early- or early-stage hepatocellular carcinoma, irrespective of the presence of cirrhosis, portal hypertension, aetiology of hepatocellular carcinoma, size and number of the tumours, and future remnant liver volume. We excluded trials including participants who were previously liver transplanted. We considered interventions compared with each other, sham, or no intervention.

### Data collection and analysis

We calculated the odds ratio, mean difference, rate ratio, or hazard ratio with 95% confidence intervals using both fixed-effect and random-effects models based on available-participant analysis with Review Manager 5. We assessed the risk of bias according to Cochrane, controlled risk of random errors with Trial Sequential Analysis using Stata, and the quality of the evidence using GRADE.

---

**Management of people with early- or very early-stage hepatocellular carcinoma (Review)**

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

## Main results

Eighteen trials met the inclusion criteria for this review. Four trials (593 participants; 574 participants included for one or more analyses) compared surgery versus radiofrequency ablation in people with early hepatocellular carcinoma, eligible to undergo surgery. Fourteen trials (2533 participants; 2494 participants included for various analyses) compared different non-surgical interventions in people with early hepatocellular carcinoma, not eligible to undergo surgery. Overall, the quality of evidence was low or very low for all outcomes for both comparisons.

### Surgery versus radiofrequency ablation

The majority of participants had cirrhotic livers, and the hepatocellular carcinoma was of viral aetiology. The trials did not report the participants' portal hypertension status or whether they received adjuvant antiviral treatment or adjuvant immunotherapy. The average follow-up ranged from 29 months to 42 months (3 trials).

There was no evidence of a difference in all-cause mortality at maximal follow-up for surgery versus radiofrequency ablation (hazard ratio 0.80, 95% confidence interval (CI) 0.60 to 1.08; 574 participants; 4 trials;  $I^2 = 68$ ). Cancer-related mortality was lower in the surgery group (20/115 (17.4%)) than in the radiofrequency ablation group (43/115 (37.4%)) (odds ratio 0.35, 95% CI 0.19 to 0.65; 230 participants; 1 trial). Serious adverse events (number of participants) was higher in the surgery group (14/60 (23.3%)) than in the radiofrequency ablation group (1/60 (1.7%)) (odds ratio 17.96, 95% CI 2.28 to 141.60; 120 participants; 1 trial). The number of serious adverse events was higher in the surgery group (adjusted rate 11.3 events per 100 participants) than in the radiofrequency ablation group (3/186 (1.6 events per 100 participants)) (rate ratio 7.02, 95% CI 2.29 to 21.46; 391 participants; 2 trials;  $I^2 = 0\%$ ). None of the trials reported health-related quality of life. One trial was funded by a party with vested interests; three trials were funded by parties without any vested.

### Non-surgical interventions

The majority of participants had cirrhotic livers, and the hepatocellular carcinoma was of viral aetiology. Most trials did not report the portal hypertension status of the participants, and none of the trials reported whether the participants received adjuvant antiviral treatment or adjuvant immunotherapy. The average follow-up ranged from 6 months to 37 months (11 trials). Trial participants, who were not eligible for surgery, were treated with radiofrequency ablation, laser ablation, microwave ablation, percutaneous acetic acid injection, percutaneous alcohol injection, a combination of radiofrequency ablation with systemic chemotherapy, a combination of radiofrequency ablation with percutaneous alcohol injection, a combination of transarterial chemoembolisation with percutaneous alcohol injection, or a combination of transarterial chemoembolisation with radiofrequency ablation.

The mortality at maximal follow-up was higher in the percutaneous acetic acid injection (hazard ratio 1.77, 95% CI 1.12 to 2.79; 125 participants; 1 trial) and percutaneous alcohol injection (hazard ratio 1.49, 95% CI 1.18 to 1.88; 882 participants; 5 trials;  $I^2 = 57\%$ ) groups compared with the radiofrequency ablation group. There was no evidence of a difference in all-cause mortality at maximal follow-up for any of the other comparisons. The proportion of people with cancer-related mortality at maximal follow-up was higher in the percutaneous alcohol injection group (adjusted proportion 16.8%) compared with the radiofrequency ablation group (20/232 (8.6%)) (odds ratio 2.18, 95% CI 1.22 to 3.89; 458 participants; 3 trials;  $I^2 = 0\%$ ). There was no evidence of a difference in any of the comparisons that reported serious adverse events (number of participants or number of events). None of the trials reported health-related quality of life. Five trials were funded by parties without any vested interest; the source of funding was not available in the remaining trials.

### Authors' conclusions

The evidence was of low or very low quality. There was no evidence of a difference in all-cause mortality at maximal follow-up between surgery and radiofrequency ablation in people eligible for surgery. All-cause mortality at maximal follow-up was higher with percutaneous acetic acid injection and percutaneous alcohol injection than with radiofrequency ablation in people not eligible for surgery. There was no evidence of a difference in all-cause mortality at maximal follow-up for the other comparisons. High-quality RCTs designed to assess clinically important differences in all-cause mortality and health-related quality of life, and having an adequate follow-up period (approximately five years) are needed.

## PLAIN LANGUAGE SUMMARY

### Treatment of very early- or early-stage primary liver cancer (hepatocellular carcinoma)

Management of people with early- or very early-stage hepatocellular carcinoma (Review)  
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## Background

Hepatocellular carcinoma (primary liver cancer) arises from the liver cells and is distinct from cancer arising from other parts of the body and spreading to the liver. The Barcelona Clinic Liver Cancer (BCLC) group staging classifies cancer based on patient's life expectancy. It is broadly based on the size of the cancer, number of cancers in the liver, how well the liver functions, and whether one's activities are affected by the cancer. People with very early- or early-stage hepatocellular carcinoma have single cancer or multiple small cancers confined to the liver, have good liver function, and no restriction of activities. There is significant uncertainty in the management of early-stage hepatocellular carcinoma. Therefore, we searched literature databases for randomised clinical trials (RCTs) on the topic until September 2016. We excluded trials in which participants had previously undergone liver transplantation. Apart from using standard Cochrane methods, which allow comparison of only two treatments at a time, we planned to use advanced methods described in full in the review.

## Study characteristics of included trials

Four trials (593 participants; 574 participants included for one or more analyses) compared surgery (removal of part of the liver containing cancer) versus radiofrequency ablation (cancer destruction using heat generated by electric current) in people with early hepatocellular carcinoma, eligible to undergo surgery; and 14 trials (2533 participants; 2494 participants included for various analyses) compared different non-surgical interventions in people with early hepatocellular carcinoma, not eligible to undergo surgery.

## Key results

### *Surgery versus radiofrequency ablation*

The majority of participants had cirrhotic livers, and the hepatocellular carcinoma was of viral cause. The trials did not report the participants' portal hypertension status or whether they received adjuvant antiviral treatment or adjuvant immunotherapy. Three trials reported average follow-up (range 29 months to 42 months). One trial was funded by a party with vested interests; three trials were funded by parties without any vested.

In people eligible for surgery, there was no evidence of a difference in death between radiofrequency ablation and surgery; although there were fewer deaths due to cancer in the surgery group. There were more serious complications in the the surgery group than in the radiofrequency ablation group. None of the trials reported health-related quality of life.

### *Non-surgical interventions*

The majority of participants had cirrhotic livers, and the hepatocellular carcinoma was of viral cause. Most trials did not report the portal hypertension status of the participants, and none reported whether the participants received adjuvant antiviral treatment or adjuvant immunotherapy. Eleven trials reported average follow-up (range 6 months to 37 months). Trial participants, who were not eligible for surgery, were treated with radiofrequency ablation, laser ablation (cancer destruction using laser), microwave ablation (cancer destruction using microwaves), percutaneous acetic acid injection (cancer destruction using vinegar), percutaneous alcohol injection (cancer destruction using alcohol), a combination of radiofrequency ablation with systemic chemotherapy, a combination of radiofrequency ablation with percutaneous alcohol injection, a combination of transarterial chemoembolisation (blocking the artery supplying the cancer with beads containing chemotherapy drugs) with percutaneous alcohol injection, or a combination of transarterial chemoembolisation with radiofrequency ablation. Five trials were funded by parties without any vested interest; the source of funding was not available in the remaining trials.

In people not eligible for surgery, the percentage of people who died during the follow-up period was higher in the percutaneous acetic acid injection and percutaneous alcohol injection groups than in the radiofrequency ablation group. There was no evidence of any difference in the percentage of people who died between any of the remaining comparisons. The percentage of people who died because of cancer was also higher in the percutaneous alcohol injection group than in the radiofrequency ablation group. There was no evidence of any difference in the percentage of people who died because of cancer between any of the remaining comparisons. None of the trials reported health-related quality of life at any time point.

## Quality of evidence

The overall quality of evidence was low or very low because of the way trials were conducted. Therefore, the conclusions made could overestimate the benefits or underestimate the harms of a given treatment. Further high-quality RCTs are needed.

## SUMMARY OF FINDINGS FOR THE MAIN COMPARISON *[Explanation]*

Surgery versus radiofrequency ablation for people with early- or very early-stage hepatocellular carcinoma					
<b>Patient or population:</b> people with early- or very early-stage hepatocellular carcinoma eligible for surgery					
<b>Settings:</b> secondary or tertiary care					
<b>Intervention:</b> surgery					
<b>Control:</b> radiofrequency ablation					
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)
	Assumed risk	Corresponding risk			
	Radiofrequency ablation	Surgery			
<b>All-cause mortality at maximal follow-up</b> Follow-up: 29 months to 42 months	300 per 1000	248 per 1000 (193 to 320)	HR 0.80 (0.60 to 1.08)	574 (4 trials)	⊕○○○ <b>very low</b> <sup>1,2,3,4</sup>
<b>Cancer-related mortality at maximal follow-up</b> Follow-up: 42 months	374 per 1000	173 per 1000 (102 to 280)	OR 0.35 (0.19 to 0.65)	230 (1 trial)	⊕⊕○○ <b>low</b> <sup>1,2</sup>
<b>Serious adverse events (number of participants)</b> Follow-up: postprocedural (very short term)	17 per 1000	233 per 1000 (37 to 706)	OR 17.96 (2.28 to 141.6)	120 (1 trial)	⊕⊕○○ <b>low</b> <sup>1,2</sup>
<b>Serious adverse events (number of events)</b> Follow-up: postprocedural (very short term)	108 per 1000	758 per 1000 (247 to 2318)	Rate ratio 7.02 (2.29 to 21.46)	391 (2 trials)	⊕⊕○○ <b>low</b> <sup>1,2</sup>
<b>Health-related quality of life</b>	None of the trials reported this outcome.				

\*The basis for the **assumed risk** for all-cause mortality is the approximate control group proportions at two to three years reported in the Kaplan-Meier curves in the trials that reported mortality at maximal-follow-up. We have assumed proportional hazards. The basis for the **assumed risk** for other outcomes is based on the mean control group proportion. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** confidence interval; **HR:** hazard ratio; **OR:** odds ratio; **RR:** rate ratio

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>1</sup>Downgraded one level because of within-study risk of bias: there was unclear or high risk of bias in the trial(s).

<sup>2</sup>Downgraded one level because of imprecision: the sample size was small.

<sup>3</sup>Downgraded one level because of imprecision: the confidence intervals overlapped clinically significant effect and clinically insignificant effect.

<sup>4</sup>Downgraded one level because of inconsistency: there was substantial unexplained heterogeneity.

## BACKGROUND

### Description of the condition

Hepatocellular carcinoma is primary cancer of the liver cells and is the major primary liver cancer (Bosetti 2014; NCBI 2014). An estimated 782,000 people develop hepatocellular carcinoma, and 746,000 people die because of primary liver cancer each year worldwide (IARC 2014a). It is the sixth most common cancer overall, with an age-standardised incidence rate of 10.1 per 100,000 population per year (IARC 2014b). It is the second most common cause of death from cancer worldwide (IARC 2014a). It is more common in men than women (IARC 2014a). There is global variation in the incidence of and mortality related to primary liver cancer. Approximately half of all primary liver cancers occur in China (395,000 people per year). Northern Europe has the lowest incidence of primary liver cancer (IARC 2014a). The incidence of hepatocellular carcinoma has increased in many countries (Davila 2004; Jepsen 2007; Pocobelli 2008; Taura 2009; von Hahn 2011; Witjes 2012; Bosetti 2014; Ladep 2014), which is attributed to hepatitis C virus infection (Davila 2004; Taura 2009). Alcohol-related liver disease and hepatitis B and C virus are considered to be major risk factors for hepatocellular carcinoma (Davila 2004; Bosetti 2014). Other risk factors include aflatoxin in foods (toxins produced by *Aspergillus* fungus), smoking, being overweight, and diabetes (Lee 2009; Polesel 2009; Chen 2012; Liu 2012; Bosetti 2014; Turati 2014). The incidence of hepatocellular carcinoma is higher in people with a family history of hepatocellular carcinoma, and lower in people with high intake of vegetables and coffee (Turati 2012; Sang 2013; Bosetti 2014; Yang 2014). The association between oral contraceptives and hepatocellular carcinoma is unclear, and there is currently no evidence of an increased risk in women using oral contraceptives when compared with women who do not use oral contraceptives, based on one meta-analysis of observational studies (Maheshwari 2007). Hepatocellular carcinoma usually develops in cirrhotic livers, although it may also develop in non-cirrhotic livers (Arnaoutakis 2014; Gaddikeri 2014). Hepatocellular carcinomas that develop in non-cirrhotic livers are usually solitary but larger compared to hepatocellular carcinomas that develop in cirrhotic livers (Gaddikeri 2014). The role of routine screening for hepatocellular carcinoma in people with chronic liver disease is controversial, with one systematic review concluding that there is no evidence of benefit of routine screening for people with hepatocellular carcinoma (Aghoram 2012; Kansagara 2014).

### Description of the intervention

Several classifications of hepatocellular carcinoma have been proposed, including clinical staging classifications, histopathological classifications, and molecular classifications (Wu 1996; Henderson

2003; Van Deusen 2005; Cillo 2006; Nanashima 2006; van Malenstein 2011a). Of these, the Barcelona Clinic Liver Cancer (BCLC) staging system, Llovet 1999 and Llovet 2003, and the Milan criteria, Mazzaferro 1996, are commonly used and are important classification systems for determining the management of hepatocellular carcinoma. Appendix 1 and Appendix 2 show these classification systems in detail. Stage 0 (very early hepatocellular carcinoma) and stage A (early hepatocellular carcinoma) of BCLC staging correspond approximately to tumours falling within the Milan criteria 1, although stage A of the BCLC staging system includes single tumour of any size, while to fall within Milan criteria 1 a single tumour should be less than 5 cm. This review examined the treatment options for people with very early hepatocellular carcinoma (single nodule less than 2 cm in diameter, Child-Pugh A cirrhosis, and performance status 0 (fully functional)) and early hepatocellular carcinoma (single tumour or two or three lesions less than 3 cm in diameter with no evidence of vascular invasion or extrahepatic spread, Child-Pugh A or B cirrhosis, and performance status 0) (stages 0 and A of the BCLC staging system). A separate review covers the treatment options for people with intermediate hepatocellular carcinoma (large multinodular tumours with no evidence of vascular invasion or extrahepatic spread; stage B BCLC staging system, Child-Pugh A or B cirrhosis, and performance status 0) (Roccarina 2017). There are currently no Cochrane systematic reviews that cover all of the treatments for advanced hepatocellular carcinoma (vascular invasion or extrahepatic spread; stage C BCLC staging system) or end-stage hepatocellular carcinoma (poor performance status or Child-Pugh C liver functional status; stage D BCLC staging system).

Various treatments are aimed at curing hepatocellular carcinoma. These can be broadly classified as surgical (liver resection and liver transplantation), ablative techniques, and transarterial embolisation (TAE) or transarterial chemoembolisation (TACE).

The surgical management of hepatocellular carcinoma is in the form of liver resection and liver transplantation (Bruix 2011; EASL 2012; Asham 2013). Liver resection is performed to ensure that all of the tumours are removed with adequate remnant liver to carry out the normal functions of the liver (Asham 2013). Liver resection is usually performed by open technique, although laparoscopic (keyhole) liver resection may be performed in select patients (Nguyen 2009). Complications related to liver resection include mortality, liver failure, bile leak, bleeding, liver abscess, abdominal abscess, wound infection, and general complications such as heart failure and renal failure (Nguyen 2009; Xiong 2012). Liver transplantation involves removal of the diseased liver and transplanting a liver graft from a donor (usually a cadaveric donor) (SRTR 2012; NHSBT 2014). Living-donor liver transplantation is associated with increased complications and re-transplantation and constitutes only a small proportion of the global liver transplantations (Wan 2014). Complications of liver transplantation include mortality, graft failure, graft rejection, biliary stricture, hepatic artery thrombosis, and wound infections (Gurusamy 2014; Wan 2014).

Ablation is usually in the form of radiofrequency ablation (Bruix 2011; EASL 2012; Asham 2013), however other modalities exist such as chemical ablation using percutaneous alcohol injections, percutaneous acetic acid injections, and thermal ablations such as microwave ablation, laser (light amplification by stimulated emission of radiation) ablation, cryoablation (tissue ablation by freezing), high-intensity focused ultrasound, and irreversible electroporation (NanoKnife) (Head 2004; Germani 2010; Sindram 2010; Chan 2013a). Complications related to radiofrequency ablation include mortality, liver failure, bleeding, liver abscess, bile duct injuries, and tumour dissemination through the needle tract ('seeding') or into the peritoneum (Chan 2013a; McDermott 2013). Transarterial embolisation involves embolisation of the hepatic artery without using any chemotherapeutic agents, while TACE involves injection of a chemotherapeutic agent prior to embolisation of the hepatic artery (Pleguezuelo 2008; Oliveri 2011). Major complications of TAE and TACE include mortality, liver failure, liver and splenic abscesses, acute cholecystitis, damage to the bile ducts, renal failure, and severe upper gastrointestinal bleeding (Pleguezuelo 2008; Oliveri 2011).

### How the intervention might work

Liver resection and liver transplantation work by removing the cancer. Chemical ablations using alcohol injections and acetic acid injections work by destruction of cancer tissue by the chemicals used (Sindram 2010). Thermal ablations cause destruction of cancer tissue by heat or cold (Sindram 2010). Transarterial embolisation and TACE cause ischaemia to the tumour, thereby inducing tumour necrosis (Pleguezuelo 2008; Oliveri 2011). Transarterial chemoembolisation combines the effect of chemotherapy agents, which inhibit the tumour, with the effect of ischaemia on the tumour, although the main effect of TACE may be due to the ischaemia rather than the chemotherapy delivered via the artery (Pleguezuelo 2008).

### Why it is important to do this review

Current guidelines on the management of hepatocellular carcinoma by the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) recommend the following for people with early and very early hepatocellular carcinoma (Bruix 2011; EASL 2012).

- Liver resection for single tumour provided that the portal pressure and bilirubin levels are normal.
- Liver transplantation for two or three nodules less than 3 cm or a single nodule in the presence of increased portal pressure or abnormal bilirubin levels provided that there are no associated diseases that preclude liver transplantation.
- Radiofrequency ablation for two or three nodules less than 3 cm or a single nodule in the presence of increased portal

pressure or abnormal bilirubin levels in the presence of associated diseases that preclude liver transplantation.

However, it should be noted that people with hepatocellular carcinoma must compete with other people waiting for liver transplantation. In 2012, pre-transplant deaths occurred at the rate of 5.8 deaths per 100 waitlist years in the USA (SRTR 2012), and in the financial year to the end of March 2014, 12% of people on the liver transplant waiting list in the UK died or became too unwell to be transplanted (NHSBT 2014). This indicates an organ shortage necessitating an organ allocation policy. The Milan criteria are now used for organ allocation in many countries. In the USA, eligible people with hepatocellular carcinoma are given exceptional status to limit their presence on the waiting list, as waiting increases the chance of tumour progression or dissemination (OPTN 2014). To be considered eligible for liver transplantation, people with hepatocellular carcinoma must fulfil the Milan criteria as well as having a minimum tumour size of 2 cm if they have a single tumour and a minimum tumour size of 1 cm each if they have two or three lesions (OPTN 2014). There thus appears to be a discrepancy in the recommendations by AASLD and EASL regarding organ allocation policy concerning people with early or very early hepatocellular carcinoma. Network meta-analysis allows the combination of the direct and indirect evidence and permits ranking of different interventions in terms of the different outcomes (Salanti 2011; Salanti 2012). No network meta-analysis on the different interventions for early or very early hepatocellular carcinoma has been performed. This systematic review and attempted network meta-analysis intended to provide the best level of evidence for the role of different treatment options used for people with early or very early hepatocellular carcinoma.

## OBJECTIVES

To assess the comparative benefits and harms of different interventions used in the treatment of early or very early hepatocellular carcinoma through a network meta-analysis and to generate rankings of the available interventions according to their safety and efficacy. However, it was not possible to assess whether the potential effect modifiers were similar across different comparisons. Therefore, we did not perform the network meta-analysis and instead assessed the benefits and harms of different interventions versus each other or versus sham or no intervention using standard Cochrane methodology.

When more trials become available with adequate description of potential effect modifiers, we will attempt to conduct network meta-analysis in order to generate rankings of the available interventions according to their safety and efficacy. Therefore, we have retained the planned methodology for network meta-analysis in Appendix 3. Once data appear allowing for the conduct of network

meta-analysis, [Appendix 3](#) will be moved back into the Methods section.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

We considered only randomised clinical trials irrespective of language, publication status, or date of publication. We excluded studies of other design because of the risk of bias in such studies, while being aware that such exclusions make us focus much more on potential benefits and not fully assess the risks of serious adverse events as well as the risks of adverse events.

#### Types of participants

We included randomised clinical trials with participants with early or very early hepatocellular carcinoma irrespective of the presence of cirrhosis, size of tumour(s), and number of tumours (provided that they met the criteria of early or very early hepatocellular carcinoma (i.e. BCLC stages 0 and A)), presence or absence of portal hypertension, aetiology of hepatocellular carcinoma, and the future remnant liver volume. We excluded randomised clinical trials in which participants were previously liver transplanted.

#### Types of interventions

We planned to include any of the following interventions that are possible treatments for early or very early hepatocellular carcinoma, either alone or in combination tested versus each other or versus sham or no intervention.

Some of the interventions that we considered were:

- liver resection;
- liver transplantation;
- radiofrequency ablation;
- microwave ablation;
- other ablations (laser ablation, cryoablation, high-intensity focused ultrasound, irreversible electroporation);
- alcohol injection;
- acetic acid injection;
- TAE;
- TACE.

The above list is not exhaustive. If we identified interventions of which we were unaware, we considered them as eligible and included them in the review if they are used primarily for the treatment of hepatocellular carcinoma. If liver resection or liver transplantation is combined with ablation, TAE, or TACE, we planned to

categorise the intervention as liver resection or liver transplantation, because liver resection and liver transplantation are the major components in such interventions, with ablation, TAE, or TACE playing an exclusively supportive role to liver resection or liver transplantation. However, we planned to exclude such interventions from a sensitivity analysis (see [Sensitivity analysis](#)). If we found a sufficient number of trials (at least one in each category) on one or more of the other methods of ablation (laser ablation, cryoablation, high-intensity focused ultrasound, irreversible electroporation), we considered the specific method of ablation with sufficient trials as a separate intervention (node).

#### Types of outcome measures

We assessed the comparative benefits and harms of available interventions aimed at treating people with early or very early hepatocellular carcinoma for the following outcomes.

#### Primary outcomes

1. Mortality at maximal follow-up (time to death):
  - i) all-cause mortality;
  - ii) cancer-related mortality.
2. Mortality:
  - i) short-term mortality (up to one year);
  - ii) medium-term mortality (one to five years).
3. Adverse events (within three months of cessation of treatment). Depending on the availability of data, we planned to attempt to classify adverse events as serious and non-serious. We defined a serious adverse event as any event that would increase mortality; was life-threatening; required hospitalisation; resulted in persistent or significant disability; was a congenital anomaly/birth defect; or any important medical event that might jeopardise the person or require intervention to prevent it. We defined a non-serious adverse event as any untoward medical occurrence not necessarily having a causal relationship with the treatment but resulting in a dose reduction or discontinuation of treatment (any time after commencement of treatment) ([ICH-GCP 1997](#)). We used the definition employed by study authors for non-serious and serious adverse events:
  - i) proportion of participants with serious adverse events;
  - ii) number of serious adverse events;
  - iii) proportion of participants with any type of adverse event;
  - iv) number of any type of adverse event.
4. Quality of life as defined in the included trials using a validated scale such as EQ-5D or 36-Item Short Form Health Survey (SF-36) ([EuroQol 2014](#); [Ware 2014](#)):
  - i) short term (up to one year);
  - ii) medium term (one to five years);
  - iii) long term (beyond five years).

We considered long-term quality of life more important than short- or medium-term quality of life, although short- or medium-term quality of life were also important primary outcomes.

### Secondary outcomes

1. Disease recurrence (maximum follow-up):
  - i) proportion of participants with hepatocellular carcinoma recurrence (includes recurrence in the liver and metastatic disease);
  - ii) proportion of participants with local recurrence (recurrence in the liver).
2. Length of hospital stay for the treatment and treatment-related complications. If treatment was performed in two or more sessions, we planned to calculate the total length of hospital stay for all the sessions. Similarly, we planned to include length of hospital stay for readmissions within 30 days of treatment because of treatment-related complications in the length of hospital stay.

### Search methods for identification of studies

#### Electronic searches

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE (OvidSP), Embase (OvidSP), and Science Citation Index Expanded (Web of Knowledge) from inception to 30 September 2016 for randomised clinical trials comparing two or more of the above interventions (Royle 2003). We searched for all possible comparisons formed by the interventions of interest. To identify further ongoing or completed trials, we also searched the World Health Organization International Clinical Trials Registry Platform search portal ([apps.who.int/trialsearch/](http://apps.who.int/trialsearch/)), which searches various trial registers, including ISRCTN ([www.isrctn.com/](http://www.isrctn.com/)) and ClinicalTrials.gov ([clinicaltrials.gov/](http://clinicaltrials.gov/)). Appendix 4 shows the search strategies used and the time spans of the searches.

#### Searching other resources

We searched the references of the identified trials and the existing Cochrane reviews on hepatocellular carcinoma to identify additional trials for inclusion.

### Data collection and analysis

#### Selection of studies

Two review authors (KG, AM, or DR between them) independently identified the trials for inclusion by screening the titles and

abstracts. We sought full-text articles for any references that at least one of the review authors identified for potential inclusion. We selected trials for inclusion based on the full-text articles. A list of the excluded full-text references with reasons for their exclusion can be found in the [Characteristics of excluded studies](#) table. We have also listed any ongoing trials identified primarily through the search of the clinical trial registers for further follow-up. Any discrepancies were resolved through discussion.

#### Data extraction and management

Two review authors (KG and AM or DR) independently extracted the following data.

- Outcome data (for each outcome and for each treatment arm whenever applicable):
  - number of participants randomised;
  - number of participants included for the analysis;
  - number of participants with events for binary outcomes, mean and standard deviation for continuous outcomes, number of events for count outcomes, and the number of participants with events and the mean follow-up period for time-to-event outcomes;
  - definition of outcomes or scale used if appropriate.
- Data on potential effect modifiers:
  - participant characteristics such as age, sex, comorbidities, proportion of people with or without cirrhosis, tumour size, number of tumours, presence of portal hypertension, aetiology of hepatocellular carcinoma, and adjuvant treatments such as immunotherapy;
  - details of the intervention and control (including dose, frequency, and duration);
  - risk of bias (assessment of risk of bias in included studies).
- Other data:
  - year and language of publication;
  - country in which the participants were recruited;
  - year(s) in which the trial was conducted;
  - inclusion and exclusion criteria;
  - follow-up time points of the outcome.

If available, we planned to obtain separate data for people with and without cirrhosis; single tumour less than 5 cm compared to single tumour 5 cm or greater compared to multiple tumours; presence compared to absence of portal hypertension; and viral versus non-viral aetiology. We contacted the authors for unclear or missing information. If there was any doubt as to whether trials shared the same participants, completely or partially (by identifying common authors and centres), we planned to contact the trial authors to clarify whether the trial report was duplicated. Any differences in opinion were resolved through discussion.

#### Assessment of risk of bias in included studies

We followed the guidance given in the *Cochrane Handbook for Systematic Reviews of Interventions* and described in the Cochrane Hepato-Biliary Group Module to assess the risk of bias in included trials (Higgins 2011; Gluud 2016). Specifically, we assessed the risk of bias in included trials for the following domains using the methods below (Schulz 1995; Moher 1998; Kjaergard 2001; Wood 2008; Savović 2012a; Savović 2012b; Lundh 2017).

#### **Allocation sequence generation**

- Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent person not otherwise involved in the trial.
- Uncertain risk of bias: the method of sequence generation was not specified.
- High risk of bias: the sequence generation method was not random.

#### **Allocation concealment**

- Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (e.g. if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes).
- Uncertain risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment.
- High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants.

#### **Blinding of participants and personnel**

- Low risk of bias: blinding was performed adequately, or the care that participants received was not likely to be influenced by lack of blinding.
- Uncertain risk of bias: there was insufficient information to assess whether blinding was likely to induce bias on the results.
- High risk of bias: no blinding or incomplete blinding, and the care that participants received was likely to be influenced by lack of blinding.

#### **Blinding of outcome assessors**

- Low risk of bias: blinding was performed adequately, or the assessment of outcomes was not likely to be influenced by lack of blinding.
- Uncertain risk of bias: there was insufficient information to assess whether blinding was likely to induce bias on the results.

- High risk of bias: no blinding or incomplete blinding, and the assessment of outcomes was likely to be influenced by lack of blinding.

#### **Incomplete outcome data**

- Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, were employed to handle missing data.
- Uncertain risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.
- High risk of bias: the results were likely to be biased due to missing data.

#### **Selective outcome reporting**

- Low risk of bias: the trial reported the following predefined outcomes: at least medium-term or long-term mortality and treatment-related adverse events. If the original trial protocol was available, the outcomes should be those called for in that protocol. If the trial protocol was obtained from a trial registry (e.g. ClinicalTrials.gov), the outcomes sought should be those enumerated in the original protocol if the trial protocol was registered before or at the time that the trial was begun. If the trial protocol was registered after the trial was begun, those outcomes were not to be considered to be reliable.
- Unclear risk of bias: not all predefined or clinically relevant and reasonably expected outcomes were reported fully, or it was unclear whether data on these outcomes were recorded or not.
- High risk of bias: one or more predefined or clinically relevant and reasonably expected outcomes were not reported, despite the fact that data on these outcomes should have been likely to have been available and even recorded.

#### **For-profit bias**

- Low risk of bias: the trial appeared to be free of industry sponsorship or other type of for-profit support that could manipulate the trial design, conductance, or results of the trial.
- Uncertain risk of bias: the trial may or may not be free of for-profit bias, as no information on clinical trial support or sponsorship was provided.
- High risk of bias: the trial was sponsored by industry or received other type of for-profit support.

#### **Other bias**

- Low risk of bias: the trial appeared to be free of other components (e.g. inappropriate control or dose or administration of control) that could put it at risk of bias.

- Uncertain risk of bias: the trial may or may not be free of other components that could put it at risk of bias.
- High risk of bias: there were other factors in the trial that could put it at risk of bias (e.g. inappropriate control or dose or administration of control).

We considered a trial to be at low risk of bias if the trial was assessed as at low risk of bias across all domains. Otherwise, we considered trials at uncertain risk of bias or at high risk of bias regarding one or more domains as at high risk of bias. As blinding of healthcare providers is impossible for all of the comparisons, and blinding of participants is unlikely for comparisons involving surgery, we planned to assess the potential influence of lack of blinding on the outcomes carefully. Because of the potential influence of lack of blinding, we planned to classify the trials as at high risk of bias for all outcomes other than mortality.

### Measures of treatment effect

For dichotomous variables (e.g. short-term mortality, medium-term mortality, and proportion of participants with adverse events), we calculated the odds ratio with 95% confidence interval (CI). For continuous variables (e.g. hospital stay and quality of life reported on the same scale), we planned to calculate the mean difference with 95% CI. We planned to use standardised mean difference values with 95% CI for quality of life if included trials use different scales. For count outcomes (e.g. number of adverse events), we calculated the rate ratio with 95% CI. For time-to-event data (e.g. mortality at maximal follow-up), we used hazard ratio with 95% CI.

### Unit of analysis issues

#### Cluster randomised clinical trials

As expected, we found no cluster randomised clinical trials. However, had we found them, we planned to include them provided that the effect estimate adjusted for cluster correlation was available.

#### Cross-over randomised clinical trials

As expected, we found no cross-over randomised clinical trials. Had we identified any, we planned to only include the outcomes after the period of first intervention because the first intervention may have a permanent impact on the outcome (i.e. have a residual effect).

#### Trials with multiple treatment groups

We collected data for all trial intervention groups that met the inclusion criteria.

### Dealing with missing data

We performed an intention-to-treat analysis whenever possible (Newell 1992). Otherwise, we used the data that were available to us (e.g. a trial may have reported only per-protocol analysis results). As 'per-protocol' analyses may be biased, we planned to conduct best-worst case scenario analyses (good outcome in intervention group and bad outcome in control group) and worst-best case scenario analyses (bad outcome in intervention group and good outcome in control group) as sensitivity analyses whenever possible.

For continuous outcomes, we planned to impute the standard deviation from P values according to guidance in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). If the data were likely to be normally distributed, we planned to use the median for meta-analysis when the mean was not available. If it was not possible to calculate the standard deviation from the P value or the confidence intervals, we planned to impute the standard deviation using the largest standard deviation in other trials for that outcome. This form of imputation may decrease the weight of the study for calculation of mean differences and may bias the effect estimate to no effect for calculation of standardised mean differences (Higgins 2011).

### Assessment of heterogeneity

We planned to assess clinical and methodological heterogeneity by carefully examining the characteristics and design of the included trials. We planned to assess the presence of clinical heterogeneity by comparing effect estimates in people with and without cirrhosis, presence of portal hypertension, aetiology of hepatocellular carcinoma, and adjuvant treatment with immunotherapy. Different study designs and risk of bias may contribute to methodological heterogeneity.

We used the  $I^2$  test and Chi<sup>2</sup> test for heterogeneity, and overlapping of CIs to assess heterogeneity. If we identified substantial heterogeneity (clinical, methodological, or statistical), we planned to explore and address heterogeneity in a subgroup analysis (see [Subgroup analysis and investigation of heterogeneity](#) section).

### Assessment of reporting biases

We planned to use visual asymmetry on a funnel plot to explore reporting bias when at least 10 trials could be included for a direct comparison (Egger 1997; Macaskill 2001). In the presence of heterogeneity that could be explained by subgroup analysis, we planned to produce a funnel plot for each subgroup when there was an adequate number of trials. We planned to use the linear regression approach described by Egger 1997 to determine funnel plot asymmetry.

We also considered selective reporting as evidence of reporting bias.

## Data synthesis

We performed the meta-analyses according to the recommendations of Cochrane (Higgins 2011), using the software package Review Manager 5 (RevMan 2014). We used a random-effects model and a fixed-effect model (DerSimonian 1986; DeMets 1987). In the case of a discrepancy between the two models, we reported both results; otherwise, we reported only the results from the fixed-effect model.

## Calculation of required information size and Trial Sequential Analysis

For calculation of the required information size, see Appendix 5. We performed Trial Sequential Analysis to control the risk of random errors when at least two trials were included for all-cause mortality at maximal follow-up and health-related quality of life, the two outcomes that determine whether the treatment should be given (Wetterslev 2008; Thorlund 2011; TSA 2011). We used an alpha error as per guidance of Jakobsen 2014, power of 90% (beta error of 10%), a relative risk reduction of 20%, a control group proportion observed in the trials, and the heterogeneity observed in the meta-analysis. As the only outcome was mortality at maximal follow-up, which is a time-to-event outcome, we performed the Trial Sequential Analysis using Stata/SE 14.2 employing methods suggested by Miladinovic 2013.

## Subgroup analysis and investigation of heterogeneity

We planned to assess the differences in the effect estimates between the following subgroups.

- Trials at low risk of bias compared to trials at high risk of bias.
- People with and without cirrhosis.
- Very early compared to early hepatocellular carcinoma.
- Presence compared to absence of portal hypertension.
- Viral aetiology compared to non-viral aetiology.
- Use of immunotherapy or antiviral therapy as adjuvant therapy compared to no use.

We planned to use the Chi<sup>2</sup> test for subgroup differences to identify subgroup differences.

## Sensitivity analysis

If a trial reported only per-protocol analysis results, we planned to re-analyse the results using the best-worst case scenario and worst-best case scenario analyses as sensitivity analyses whenever possible. In addition, we planned to exclude trials in which liver resection or liver transplantation was combined with ablation, TAE, or TACE.

## Presentation of results and GRADE assessments

We have reported all-cause mortality, cancer-related mortality, serious adverse events, and health-related quality of life, the outcomes that determine the management of people with early- or very early-stage hepatocellular carcinoma, in a 'Summary of findings' table format, downgrading the quality of evidence for risk of bias, inconsistency, indirectness, imprecision, and publication bias using GRADE (Guyatt 2011). We have presented only comparisons in which at least two trials were included for one or more of these outcomes.


# RESULTS

## Description of studies

### Results of the search

We identified 7717 references through electronic searches of CENTRAL (N = 615), MEDLINE (N = 3753), Embase (N = 809), Science Citation Index Expanded (N = 2277), World Health Organization International Clinical Trials Registry Platform (N = 85), and ClinicalTrials.gov (N = 178). After removing 1684 duplicates, we obtained 6033 references. We then excluded 5969 clearly irrelevant references through screening titles and reading abstracts. We retrieved 64 references for further assessment. We identified no references through scanning reference lists of the identified randomised trials. We excluded 44 references for the reasons listed in the Characteristics of excluded studies table. A total of 20 references (18 trials) met the inclusion criteria. The reference flow is summarised in the study flow diagram (Figure 1).

**Figure 1. Study flow diagram.**



### Included studies

Eighteen trials met the inclusion criteria for this review: four trials (593 participants; 574 participants included for one or more analyses) compared surgery versus radiofrequency ablation in people with early hepatocellular carcinoma who were eligible to undergo surgery, while 14 trials (2533 participants; 2494 participants included for various analyses) compared different non-surgical interventions in people with early hepatocellular carcinoma who were not eligible to undergo surgery (this was clear from the inclusion criteria in the trials). We have listed the comparisons included in the trials and the follow-up period in the trials in [Table 1](#).

### Participants eligible for surgery

All four included trials compared surgery with radiofrequency ablation ([Chen 2006](#); [Huang 2010](#); [Fang 2014](#); [Lee 2014](#)). It should be noted that none of the trials included liver transplantation or sham treatment or no treatment as one of the comparison groups. The average age in the trials that reported this information ranged from 51 years to 56 years. The proportion of females in the trials that reported this information ranged from 18.6% to 28.7%. Three trials included participants with and without cirrhosis ([Chen 2006](#); [Huang 2010](#); [Fang 2014](#)). The fourth trial did not report the cirrhosis status of participants ([Lee 2014](#)). The proportion of participants who had cirrhosis was 61.7% and 84.2% in the two trials that reported this information ([Huang 2010](#); [Fang 2014](#)). One trial included participants with early hepatocellular carcinoma but did not include participants with very early hepatocellular carcinoma ([Lee 2014](#)). The remaining trials did not report the proportion of participants with very early hepatocellular carcinoma. The proportion of participants with viral aetiology was 89.2% and 93.5% in the two trials that reported this information ([Huang 2010](#); [Fang 2014](#)). The remaining two trials did not report this information ([Chen 2006](#); [Lee 2014](#)). None of the trials reported the proportion of participants who received adjuvant antiviral therapy or adjuvant immunotherapy. The mean or median follow-up in the trials ranged from 29 months to 42 months in the three trials that provided this information ([Chen 2006](#); [Huang 2010](#); [Fang 2014](#)).

### Source of funding

Three trials did not receive any additional funding or were funded by parties without any vested interest in the results ([Chen 2006](#); [Huang 2010](#); [Fang 2014](#)). One trial was funded by a party with vested interest in the results ([Lee 2014](#)).

### Participants not eligible for surgery

Fourteen trials included only participants who were not eligible for surgery and compared various non-surgical interventions: radiofrequency ablation, laser ablation, microwave ablation, percutaneous acetic acid injection, percutaneous alcohol injection, a combination of radiofrequency ablation with systemic chemotherapy, a combination of radiofrequency ablation with percutaneous alcohol injection, a combination of transarterial chemoembolisation with percutaneous alcohol injection, or a combination of transarterial chemoembolisation with radiofrequency ablation. None of the trials included sham treatment or no treatment as one of the comparison groups. The average age in the trials that reported this information ranged from 49 years to 72 years. The proportion of females in the trials that reported this information ranged from 11.1% to 42.3%. Eight trials only included participants who had cirrhosis ([Bolondi 1996](#); [Shibata 2002](#); [Lencioni 2003](#); [Lin 2005](#); [Brunello 2008](#); [Giorgio 2011](#); [Orlacchio 2014](#); [Costanzo 2015](#)). The proportion of participants with cirrhosis was 85.3% and 88.5% in the two trials that included both cirrhotic and non-cirrhotic participants and reported the proportion of participants with cirrhosis ([Koda 2001](#); [Shiina 2005](#); [Huang 2010](#); [Fang 2014](#)). The remaining four trials did not report this information ([Gan 2004](#); [Chen 2005](#); [Aikata 2006](#); [El Kady 2013](#)). One trial included participants with early hepatocellular carcinoma, but did not include participants with very early hepatocellular carcinoma ([El Kady 2013](#)). The proportion of participants with very early hepatocellular carcinoma in the only trial that reported this information was 25% ([Giorgio 2011](#)). The remaining trials did not report the proportion of participants with very early hepatocellular carcinoma. Only one trial reported the proportion of participants with portal hypertension (all 30 participants in this trial had portal hypertension) ([Orlacchio 2014](#)). One trial included hepatocellular carcinoma of viral aetiology only ([Giorgio 2011](#)). The proportion of participants with viral aetiology ranged from 80.4% to 98.6% in the remaining seven trials that reported this information ([Koda 2001](#); [Shibata 2002](#); [Lencioni 2003](#); [Lin 2005](#); [Shiina 2005](#); [Brunello 2008](#); [Orlacchio 2014](#)). None of the trials reported the proportion of participants who received adjuvant antiviral therapy or adjuvant immunotherapy. The mean or median follow-up in the trials ranged from 6 months to 37 months in the 11 trials that provided this information ([Bolondi 1996](#); [Koda 2001](#); [Shibata 2002](#); [Lencioni 2003](#); [Gan 2004](#); [Lin 2005](#); [Shiina 2005](#); [Brunello 2008](#); [Giorgio 2011](#); [El Kady 2013](#); [Orlacchio 2014](#)).

### Source of funding

Five trials did not receive any special funding or received funding from parties without vested interest in the results ([Brunello 2008](#);

Giorgio 2011; El Kady 2013; Orlacchio 2014; Costanzo 2015).  
The source of funding was not reported in the remaining trials.


### Excluded studies

None of the trials met the inclusion criteria.

### Risk of bias in included studies

The risk of bias is summarised in [Figure 2](#), [Figure 3](#), and [Table 2](#).  
None of the trials was at low risk of bias for all domains; hence,  
we considered all trials to be at high risk of bias.

**Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.**



**Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.**

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	For-profit bias	Other bias
Aikata 2006	?	?	?	?	?	+	?	+
Bolondi 1996	?	?	?	?	?	-	?	+
Brunello 2008	+	+	-	-	+	+	+	+
Chen 2005	?	?	?	?	?	+	?	+
Chen 2006	+	?	?	?	-	+	+	+
Costanzo 2015	+	?	-	-	+	+	+	+
El Kady 2013	+	?	?	?	+	+	+	+
Fang 2014	?	?	?	?	?	+	+	+
Gan 2004	?	?	?	?	-	-	?	+
Giorgio 2011	+	+	-	+	+	+	+	+
Huang 2010	+	+	-	-	+	+	+	+
Koda 2001	?	?	?	?	?	+	?	+
Lee 2014	?	?	?	?	?	+	-	+
Lencioni 2003	+	?	?	?	-	+	?	+
Lin 2005	+	?	?	?	+	+	?	+
Orlacchio 2014	+	?	-	-	+	+	+	+
Shibata 2002	?	?	?	?	+	-	?	+
Shiina 2005	+	?	-	-	+	+	?	+

## Allocation

### Surgery versus radiofrequency ablation

Two trials were at low risk of bias for random sequence generation (Chen 2006; Huang 2010). The remaining trials were at unclear risk of bias for random sequence generation. One trial was at low risk of bias for allocation concealment (Huang 2010). The remaining trials were at unclear risk of bias for allocation concealment. We considered one trial that was at low risk of bias for random sequence generation and allocation concealment to be at low risk of allocation bias (Huang 2010).

### Non-surgical interventions

Eight trials were at low risk of bias for random sequence generation (Lencioni 2003; Lin 2005; Shiina 2005; Brunello 2008; Giorgio 2011; El Kady 2013; Orlacchio 2014; Costanzo 2015); none of the trials was at high risk of bias for random sequence generation; and six trials were at unclear risk of bias for random sequence generation (Bolondi 1996; Koda 2001; Shibata 2002; Gan 2004; Chen 2005; Aikata 2006).

Two trials were at low risk of bias for allocation concealment (Brunello 2008; Giorgio 2011); none of the trials was at high risk of bias for allocation concealment; and 12 trials were at unclear risk of bias for allocation concealment (Bolondi 1996; Koda 2001; Shibata 2002; Lencioni 2003; Gan 2004; Chen 2005; Lin 2005; Shiina 2005; Aikata 2006; El Kady 2013; Orlacchio 2014; Costanzo 2015).

Overall, two trials were at low risk of selection bias (Brunello 2008; Giorgio 2011); no trials were at high risk of selection bias; and 12 trials were at unclear risk of selection bias (Bolondi 1996; Koda 2001; Shibata 2002; Lencioni 2003; Gan 2004; Chen 2005; Lin 2005; Shiina 2005; Aikata 2006; El Kady 2013; Orlacchio 2014; Costanzo 2015).

## Blinding

### Surgery versus radiofrequency ablation

One trial was at high risk of bias for blinding of participants and healthcare providers (Huang 2010). The remaining trials were at unclear risk of bias for blinding of participants and healthcare providers. One trial was at high risk of bias for blinding of outcome assessors (Huang 2010). The remaining trials were at unclear risk of bias for blinding of outcome assessors. Overall, one trial was at high risk of performance bias and detection bias. The remaining trials were at unclear risk of performance bias and detection bias.

### Non-surgical interventions

Five trials were at high risk of bias for blinding of participants and health professionals (Shiina 2005; Brunello 2008; Giorgio 2011; Orlacchio 2014; Costanzo 2015); the remaining nine trials were at unclear risk of bias for blinding of participants and health professionals (Bolondi 1996; Koda 2001; Shibata 2002; Lencioni 2003; Gan 2004; Chen 2005; Lin 2005; Aikata 2006; El Kady 2013).

The trials had the same risk of bias for blinding of outcome assessors domain as for the blinding of participants and health professionals domain.

## Incomplete outcome data

### Surgery versus radiofrequency ablation

One trial was at low risk of bias for incomplete outcome data (attrition bias) (Huang 2010). One trial was at high risk of bias for incomplete outcome data (attrition bias) (Chen 2006). The remaining trials were at unclear risk of bias for incomplete outcome data (attrition bias).

### Non-surgical interventions

Eight trials were at low risk of bias for incomplete outcome data (attrition bias) (Shibata 2002; Lin 2005; Shiina 2005; Brunello 2008; Giorgio 2011; El Kady 2013; Orlacchio 2014; Costanzo 2015); two trials were at high risk of bias for incomplete outcome data (attrition bias) (Lencioni 2003; Gan 2004); and four trials were at unclear risk of bias for incomplete outcome data (attrition bias) (Bolondi 1996; Koda 2001; Chen 2005; Aikata 2006).

## Selective reporting

### Surgery versus radiofrequency ablation

All four trials were at low risk of bias for selective reporting (reporting bias) (Chen 2006; Huang 2010; Fang 2014; Lee 2014).

### Non-surgical interventions

Eleven trials were at low risk of bias for selective reporting (reporting bias) (Koda 2001; Lencioni 2003; Chen 2005; Lin 2005; Shiina 2005; Aikata 2006; Brunello 2008; Giorgio 2011; El Kady 2013; Orlacchio 2014; Costanzo 2015); three trials were at high risk of bias for selective reporting (reporting bias) (Bolondi 1996; Shibata 2002; Gan 2004); and none of the trials was at unclear risk of bias for selective reporting (reporting bias).

## Other potential sources of bias

### Surgery versus radiofrequency ablation

For-profit bias: Three trials did not receive any additional funding or were funded by parties without any vested interest in the results (Chen 2006; Huang 2010; Fang 2014). One trial was funded by parties with vested interest in the results (Lee 2014).

We noted no other bias in any of the trials.

### Non-surgical interventions

For-profit bias: Five trials were at low risk of for-profit bias (Brunello 2008; Giorgio 2011; El Kady 2013; Orlacchio 2014; Costanzo 2015); none of the trials was at high risk of for-profit bias; nine trials were at unclear risk of for-profit bias (Bolondi 1996; Koda 2001; Shibata 2002; Lencioni 2003; Gan 2004; Chen 2005; Lin 2005; Shiina 2005; Aikata 2006).

All the trials were at low risk of other bias.

## Effects of interventions

See: [Summary of findings for the main comparison Surgery versus radiofrequency ablation for people with early- or very early-stage hepatocellular carcinoma](#); [Summary of findings 2 Percutaneous alcohol injection versus radiofrequency ablation for people with early- or very early-stage hepatocellular carcinoma](#); [Summary of findings 3 Laser ablation versus radiofrequency ablation for people with early- or very early-stage hepatocellular carcinoma](#); [Summary of findings 4 Transarterial embolisation plus radiofrequency ablation versus radiofrequency ablation for people with early- or very early-stage hepatocellular carcinoma](#); [Summary of findings 5 Transarterial embolisation plus percutaneous alcohol injection versus percutaneous alcohol injection for people with early- or very early-stage hepatocellular carcinoma](#)

## Surgery versus radiofrequency ablation

### Mortality at maximal follow-up

A total of four trials including 574 participants reported mortality at maximal follow-up (Chen 2006; Huang 2010; Fang 2014; Lee 2014). There was no evidence of difference in mortality at maximal follow-up between the groups (hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.60 to 1.08; 574 participants; 4 trials;  $I^2 = 68$ ) (Analysis 1.1).

### Cancer-related mortality at maximal follow-up

One trial including 230 participants reported cancer-related mortality at maximal follow-up (Huang 2010). The cancer-related mortality was lower in the surgery group (20/115 (17.4%)) than in the radiofrequency ablation group (43/115 (37.4%)) (odds ratio (OR) 0.35, 95% CI 0.19 to 0.65; 230 participants; 1 trial) (Analysis 1.2).

### Mortality (< 1 year)

None of the trials reported this outcome.

### Mortality (> 1 year)

One trial including 230 participants reported mortality (> 1 year) (Huang 2010). The mortality (> 1 year) was lower in the surgery group (28/115 (24.3%)) than in the radiofrequency ablation group (52/115 (45.2%)) (OR 0.39, 95% CI 0.22 to 0.68; 230 participants; 1 trial) (Analysis 1.3).

### Serious adverse events (number of participants)

One trial including 120 participants reported serious adverse events (number of participants) (Fang 2014). The serious adverse events (number of participants) was higher in the surgery group (14/60 (23.3%)) than in the radiofrequency ablation group (1/60 (1.7%)) (OR 17.96, 95% CI 2.28 to 141.60; 120 participants; 1 trial) (Analysis 1.4).

### Serious adverse events (number of events)

Two trials including 391 participants reported number of serious adverse events (Chen 2006; Huang 2010). The number of serious adverse events was higher in the surgery group (adjusted rate: 11.3 events per 100 participants) than in the radiofrequency ablation group (3/186 (1.6 events per 100 participants)) (rate ratio 7.02, 95% CI 2.29 to 21.46; 391 participants; 2 trials;  $I^2 = 0\%$ ) (Analysis 1.5).

### Any adverse events (number of participants)

Two trials including 183 participants reported any adverse events (number of participants) (Fang 2014; Lee 2014). The adverse events (number of participants) was higher in the surgery group than in the radiofrequency ablation group using the fixed-effect model (OR 3.83, 95% CI 1.70 to 8.60; 183 participants; 2 trials;  $I^2 = 76\%$ ); there was no evidence of difference between the groups (surgery: adjusted proportion: 35.2% versus radiofrequency ablation: 11/94 (11.7%)) using the random-effects model (OR 4.09, 95% CI 0.61 to 27.41; 183 participants; 2 trials;  $I^2 = 76\%$ ) (Analysis 1.6).

### Any adverse events (number of events)

Two trials including 391 participants reported number of any adverse events (Chen 2006; Huang 2010). The number of any adverse events was higher in the surgery group (adjusted rate: 47.5 events per 100 participants) than in the radiofrequency ablation group (20/186 (10.8 events per 100 participants)) (RR 4.42, 95% CI 2.74 to 7.15; 391 participants; 2 trials;  $I^2 = 0\%$ ) (Analysis 1.7).

### Health-related quality of life

None of the trials reported health-related quality of life at any time point.

### Hepatocellular carcinoma recurrence (local or distal)

Three trials including 413 participants reported hepatocellular carcinoma recurrence (local or distal) (Huang 2010; Fang 2014; Lee 2014). The hepatocellular carcinoma recurrence (local or distal) was lower in the surgery group (adjusted proportion: 41.2%) than in the radiofrequency ablation group (119/209 (56.9%)) (OR 0.53, 95% CI 0.35 to 0.78; 413 participants; 3 trials;  $I^2 = 36\%$ ) (Analysis 1.8).

### Hepatocellular carcinoma recurrence (recurrence in the liver)

Two trials including 350 participants reported hepatocellular carcinoma recurrence (recurrence in liver) (Huang 2010; Fang 2014). The proportion of people with hepatocellular carcinoma recurrence (recurrence in liver) was lower in the surgery group (adjusted proportion: 29.7%) than in the radiofrequency ablation group (81/175 (46.3%)) (OR 0.49, 95% CI 0.31 to 0.78; 350 participants; 2 trials;  $I^2 = 6\%$ ) (Analysis 1.9).

### Length of hospital stay

Three trials including 530 participants reported the length of hospital stay (Chen 2006; Huang 2010; Fang 2014). The length of hospital stay was longer in the surgery group than in the radiofrequency ablation group (mean difference (MD) 8.42 days, 95% CI 7.84 to 9.01; 530 participants; 3 trials;  $I^2 = 86\%$ ) (Analysis 1.10).

### Overall summary of comparisons in which there was some evidence of difference

- Cancer-related mortality was lower in the surgery group than in the radiofrequency ablation group (OR 0.35, 95% CI 0.19 to 0.65; 230 participants; 1 trial).
- Mortality (> 1 year) was lower in the surgery group than in the radiofrequency ablation group (OR 0.39, 95% CI 0.22 to 0.68; 230 participants; 1 trial).
- Serious adverse events (number of participants) and number of serious adverse events was higher in the surgery group

than in the radiofrequency ablation group (OR 17.96, 95% CI 2.28 to 141.60; 120 participants; 1 trial and RR 7.02, 95% CI 2.29 to 21.46; 391 participants; 2 trials;  $I^2 = 0\%$ ).

- Number of any adverse events was higher in the surgery group than in the radiofrequency ablation group (RR 4.42, 95% CI 2.74 to 7.15; 391 participants; 2 trials;  $I^2 = 0\%$ ).
- The proportion of people with hepatocellular carcinoma recurrence (local or distal) and hepatocellular carcinoma recurrence (recurrence in liver) was lower in the surgery group than in the radiofrequency ablation group (OR 0.53, 95% CI 0.35 to 0.78; 413 participants; 3 trials;  $I^2 = 36\%$  and OR 0.49, 95% CI 0.31 to 0.78; 350 participants; 2 trials;  $I^2 = 6\%$ ).
- Length of hospital stay was longer in the surgery group than in the radiofrequency ablation group (MD 8.42 days, 95% CI 7.84 to 9.01; 530 participants; 3 trials;  $I^2 = 86\%$ ).

### Subgroup analyses

Because of the paucity of data, we did not perform any subgroup analyses.

### Sensitivity analysis

Because of the paucity of data, we did not perform a sensitivity analysis of imputing information based on different scenarios, that is it was unclear whether there were any postrandomisation dropouts in many trials, as well as to which group these postrandomisation dropouts belonged even when the number of postrandomisation dropouts was reported. We did not impute standard deviation, therefore we did not perform a sensitivity analysis to assess the impact of imputing the standard deviation.

We performed a sensitivity analysis excluding the trial in which 19 participants from the radiofrequency ablation group were excluded because they underwent surgical resection (Chen 2006). As it was not possible to perform a sensitivity analysis for the primary outcome of mortality at maximal follow-up by imputing the information based on different scenarios (this being a time-to-event outcome), we performed a post hoc sensitivity analysis by excluding this trial. Excluding this trial did not alter the conclusions (Analysis 1.11).

### Reporting bias

We did not assess reporting bias by creating a funnel plot because of the few trials included for each comparison.


### Using fixed-effect model versus random-effects model

The interpretation of results was not altered based on the model used for analysis for any of the analyses.

### **Trial Sequential Analysis**

We performed a Trial Sequential Analysis for all-cause mortality at maximal follow-up. As shown in [Figure 4](#), the cumulative Z-curves (blue lines) did not cross any of the trial sequential monitoring boundaries (red lines). They did not cross the conventional alpha boundary of 2.5% (green lines) either, suggesting a high risk of random error.

**Figure 4. Trial Sequential Analysis of all-cause mortality at maximal follow-up for surgery versus radiofrequency ablation. We used an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20% (upper figure) and that observed in trials (20%) (lower figure), control group proportion (Pc) observed in the trials (30% mortality in about 2 to 3 years), and I2 of 0% (upper figure) and that observed in the trials (I2 = 68%) (lower figure). The accrued sample size (574) is only a fraction of the information size (IS) (3351 trial participants) or heterogeneity-adjusted information size (HIS) (5966 trial participants). As shown in all the comparisons, the cumulative Z-curves (blue line) do not cross any of the trial sequential monitoring boundaries (red lines), and neither do they cross the conventional alpha boundary of 2.5% (green line).**



## Quality of the evidence

The overall quality of the evidence was low or very low for all outcomes ([Summary of findings for the main comparison](#)). All of the trials were at high risk of bias. However, for all-cause mortality, the issue of bias due to blinding does not arise; therefore, we downgraded the quality of the evidence one level for all-cause mortality and two levels for the remaining comparisons. There was no issue of indirectness, as all of the outcomes were clinical outcomes and only direct comparisons were used. The sample size was small (all comparisons downgraded one level) and the confidence intervals overlapped clinically significant effect and clinically insignificant effect for most comparisons (downgraded one level). In addition, there was substantial heterogeneity for some of the outcomes, resulting in further downgrading by one level. We did not explore publication bias because of the few trials included in this review.

## Comparison of non-surgical interventions

### Mortality at maximal follow-up

Ten trials including 1417 participants reported mortality at maximal follow-up ([Bolondi 1996](#); [Koda 2001](#); [Lencioni 2003](#); [Chen 2005](#); [Lin 2005](#); [Shiina 2005](#); [Aikata 2006](#); [Brunello 2008](#); [Giorgio 2011](#); [Costanzo 2015](#)).

Mortality at maximal follow-up was higher in the percutaneous acetic acid injection group (HR 1.77, 95% CI 1.12 to 2.79; 125 participants; 1 trial) and the percutaneous alcohol injection group (HR 1.49, 95% CI 1.18 to 1.88; 882 participants; 5 trials;  $I^2 = 57%$ ) than in the radiofrequency ablation group. There was no evidence of difference in any of the remaining comparisons ([Analysis 2.1](#)).

### Cancer-related mortality at maximal follow-up

Five trials including 717 participants reported cancer-related mortality at maximal follow-up across all comparisons ([Koda 2001](#); [Lencioni 2003](#); [Lin 2005](#); [Shiina 2005](#); [Costanzo 2015](#)). Cancer-related mortality at maximal follow-up was higher in the percutaneous alcohol injection group (adjusted proportion: 16.8%) than in the radiofrequency ablation group (20/232 (8.6%)) (OR 2.18, 95% CI 1.22 to 3.89; 458 participants; 3 trials;  $I^2 = 0%$ ). There was no evidence of difference in any of the remaining comparisons ([Analysis 2.2](#)).

### Mortality (< 1 year)

Two trials including 74 participants reported mortality (< 1 year) ([El Kady 2013](#); [Orlacchio 2014](#)). There were no deaths within one year in either trial.

### Mortality (> 1 year)

Six trials including 852 participants reported mortality (> 1 year) across all comparisons ([Koda 2001](#); [Lencioni 2003](#); [Lin 2005](#); [Shiina 2005](#); [Brunello 2008](#); [Costanzo 2015](#)). Mortality (> 1 year) was higher in the percutaneous alcohol injection group (adjusted proportion: 29.7%) than in the radiofrequency ablation group (62/302 (20.5%)) (OR 1.69, 95% CI 1.15 to 2.49; 598 participants; 4 trials;  $I^2 = 0%$ ). There was no evidence of difference in any of the remaining comparisons ([Analysis 2.3](#)).

### Serious adverse events (number of participants)

Eleven trials including 934 participants reported serious adverse events (number of participants) across all comparisons ([Koda 2001](#); [Shibata 2002](#); [Lencioni 2003](#); [Gan 2004](#); [Chen 2005](#); [Lin 2005](#); [Aikata 2006](#); [Brunello 2008](#); [El Kady 2013](#); [Orlacchio 2014](#); [Costanzo 2015](#)). There was no evidence of difference in any of the comparisons ([Analysis 2.4](#)).

### Serious adverse events (number of events)

Two trials including 278 participants reported number of serious adverse events across all comparisons ([Shiina 2005](#); [Aikata 2006](#)). There was no evidence of difference in any of the comparisons ([Analysis 2.5](#)).

### Any adverse events (number of participants)

Three trials including 611 participants reported any adverse events (number of participants) across all comparisons ([Lin 2005](#); [Brunello 2008](#); [Giorgio 2011](#)). There was no evidence of difference in any of the comparisons ([Analysis 2.6](#)).

### Any adverse events (number of events)

Six trials including 732 participants reported number of any adverse events across all comparisons ([Koda 2001](#); [Lencioni 2003](#); [Shiina 2005](#); [El Kady 2013](#); [Orlacchio 2014](#); [Costanzo 2015](#)). The number of any adverse events was lower in the TACE plus percutaneous alcohol injection group (adjusted rate: 438.5 events per 100 participants) than in the percutaneous alcohol injection group (215/26 (826.9 events per 100 participants)) (RR 0.53, 95% CI 0.42 to 0.67; 52 participants; 1 trial). There was no evidence of difference in any of the remaining comparisons ([Analysis 2.7](#)).

### Health-related quality of life

None of the trials reported this outcome.

### Hepatocellular carcinoma recurrence (local or distal)

Three trials including 511 participants reported hepatocellular carcinoma recurrence (local or distal) across all comparisons (Shiina 2005; Brunello 2008; Costanzo 2015). The proportion of people with hepatocellular carcinoma recurrence (local or distal) was higher in the percutaneous alcohol injection group (adjusted proportion: 68.3%) than in the radiofrequency ablation group (110/188 (58.5%)) (OR 1.58, 95% CI 1.02 to 2.45; 371 participants; 2 trials;  $I^2 = 0\%$ ). There was no evidence of difference in any of the remaining comparisons (Analysis 2.8).

### Hepatocellular carcinoma recurrence (recurrence in liver)

Four trials including 439 participants reported hepatocellular carcinoma recurrence (recurrence in liver) across all comparisons (Gan 2004; Shiina 2005; El Kady 2013; Costanzo 2015). There was no evidence of difference in any of the comparisons (Analysis 2.9).

### Length of hospital stay

One trial including 232 participants reported the length of hospital stay across all comparisons (Shiina 2005). The length of hospital stay was longer in the percutaneous alcohol injection group than in the radiofrequency ablation group in this trial (MD 15.30 days, 95% CI 13.23 to 17.37; 232 participants; 1 trial).

### Overall summary of comparisons in which there was some evidence of difference

- Mortality at maximal follow-up was higher in the percutaneous acetic acid injection group (HR 1.77, 95% CI 1.12 to 2.79; 125 participants; 1 trial) and the percutaneous alcohol injection group (HR 1.49, 95% CI 1.18 to 1.88; 882 participants; 5 trials;  $I^2 = 57\%$ ) than in the radiofrequency ablation group.
  - Cancer-related mortality at maximal follow-up was higher in the percutaneous alcohol injection group than in the radiofrequency ablation group (OR 2.18, 95% CI 1.22 to 3.89; 458 participants; 3 trials;  $I^2 = 0\%$ ).
  - Mortality (> 1 year) was higher in the percutaneous alcohol injection group than in the radiofrequency ablation group (OR 1.69, 95% CI 1.15 to 2.49; 598 participants; 4 trials;  $I^2 = 0\%$ ).
  - Number of any adverse events was lower in the TACE plus percutaneous alcohol injection group than the percutaneous alcohol injection group (RR 0.53, 95% CI 0.42 to 0.67; 52 participants; 1 trial).
  - The proportion of people with hepatocellular carcinoma recurrence (local or distal) was higher in the percutaneous alcohol

injection group than in the radiofrequency ablation group (OR 1.58, 95% CI 1.02 to 2.45; 371 participants; 2 trials;  $I^2 = 0\%$ ).

- Length of hospital stay was longer in the percutaneous alcohol injection group than in the radiofrequency ablation group (MD 15.30 days, 95% CI 13.23 to 17.37; 232 participants; 1 trial).

### Subgroup analyses

Because of the paucity of data, we did not perform any subgroup analyses.

### Sensitivity analysis

Because of the paucity of data, we did not perform a sensitivity analysis of imputing information based on different scenarios, and we did not perform a sensitivity analysis to assess the impact of imputing the standard deviation.

### Reporting bias

We did not assess reporting bias by creating a funnel plot because of the few trials included for each comparison.

### Using fixed-effect model versus random-effects model

The interpretation of results was not altered based on the model used for analysis.

### Trial Sequential Analysis

The required sample size for identifying a 20% relative risk reduction in the different outcomes based on an alpha error of 5%, a beta error of 20%, and the control group (radiofrequency ablation) proportion observed across all trials were as follows.


- Cancer-related mortality at maximal follow-up (control group proportion: 9.6%): 6722 people
  - Mortality < 1 year (control group proportion: 0%): not estimable
  - Mortality > 1 year (control group proportion: 21.5%): 2648 people
  - Serious adverse events (proportion) (control group proportion: 2.0%): 34,688 people
  - Adverse events (proportion) (control group proportion: 6.6%): 10,066 people
  - Hepatocellular carcinoma recurrence (local or distal) (control group proportion: 60.5%): 530 people
  - Hepatocellular carcinoma recurrence (liver) (control group proportion: 49.5%): 790 people

The above mentioned are sample sizes uncorrected for heterogeneity. In the presence of heterogeneity of 25%, for example, the required information size for cancer-related mortality at maximal follow-up is  $6772/(1 - 0.25) = 8963$  people.


As seen in the various analyses, only a small fraction of the above sample sizes has been reached in the comparisons in which there was no evidence of difference, therefore one cannot rule out alpha and beta errors in any of these comparisons.

We performed a Trial Sequential Analysis for all-cause mortality at maximal follow-up for various comparisons. As shown in [Figure 5](#) and [Figure 6](#), the cumulative Z-curves (blue lines) did not cross any of the trial sequential monitoring boundaries (red lines) for any of the comparisons. They did not cross the conventional alpha boundary of 2.5% (green lines) either, suggesting a high risk of random error.

**Figure 5. Trial Sequential Analysis of all-cause mortality at maximal follow-up for percutaneous alcohol injection versus radiofrequency ablation. We used an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20% (upper figure) and that observed in trials (49%) (lower figure), control group proportion observed in the trials ( $P_c = 30\%$  mortality in about 2 to 3 years), and heterogeneity of 0% (upper figure) and that observed in the trials ( $I^2 = 57\%$ ) (lower figure). The accrued sample size (882 trial participants) is only a fraction of the information size (IS) (3351) or heterogeneity-adjusted information size (HIS) (970 trial participants). As shown in all the comparisons, the cumulative Z-curves (blue line) do not cross any of the trial sequential monitoring boundaries (red lines), and neither do they cross the conventional alpha boundary of 2.5% (green line).**



**Figure 6. Trial Sequential Analysis of all-cause mortality at maximal follow-up for transarterial chemoembolisation (TACE) versus percutaneous alcohol injection (PAI) versus PAI.** We used an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20% (upper figure) and that observed in trials (lower figure), control group proportion observed in the trials (30% mortality in about 2 to 3 years), and heterogeneity of 0% (upper figure) and that observed in the trials ( $I^2 = 75%$ ) (lower figure). The accrued sample size (202 trial participants) is only a fraction of the information size (IS) (3351) or heterogeneity-adjusted information size (HIS) (13,240 trial participants). As shown in all the comparisons, the cumulative Z-curves (blue line) do not cross any of the trial sequential monitoring boundaries (red lines). They crossed the conventional alpha boundary of 2.5% (green line).



### **Quality of the evidence**

As for the surgery versus radiofrequency ablation comparison, the overall quality of the evidence was also low or very low for all outcomes for the comparison of non-surgical interventions ([Summary of findings 2](#); [Summary of findings 3](#); [Summary of findings 4](#); [Summary of findings 5](#)). All of the trials were at high risk of bias. As before, we downgraded the quality of the evidence one level for all-cause mortality and two levels for the remaining comparisons for risk of bias; one level for imprecision because of small sample size (all comparisons); one level for imprecision because the confidence intervals overlapped clinically significant effect and clinically insignificant effect for most comparisons; and one level for comparisons with substantial heterogeneity.

## ADDITIONAL SUMMARY OF FINDINGS *[Explanation]*

Percutaneous alcohol injection versus radiofrequency ablation for people with early- or very early-stage hepatocellular carcinoma					
<p><b>Patient or population:</b> people with early- or very early-stage hepatocellular carcinoma ineligible for surgery  <b>Settings:</b> secondary or tertiary care  <b>Intervention:</b> percutaneous alcohol injection  <b>Control:</b> radiofrequency ablation</p>					
Outcomes	Illustrative risks* (95% CI)		Relative effect (95% CI)	No. of participants (trials)	Quality of the evidence (GRADE)
	Assumed risk	Corresponding risk			
	Radiofrequency ablation	Percutaneous alcohol injection			
<b>Mortality at maximal follow-up</b> Follow-up: 23 months to 37 months	300 per 1000	447 per 1000 (354 to 564)	HR 1.49 (1.18 to 1.88)	882 (5 trials)	⊕○○○ <b>very low</b> <sup>1,2,3</sup>
<b>Cancer-related mortality at maximal follow-up</b> Follow-up: 23 months to 37 months	96 per 1000	188 per 1000 (115 to 292)	OR 2.18 (1.22 to 3.89)	458 (3 trials)	⊕⊕○○ <b>low</b> <sup>1,2</sup>
<b>Serious adverse events (number of participants)</b> Follow-up: 23 months to 36 months	20 per 1000	13 per 1000 (4 to 47)	OR 0.67 (0.19 to 2.40)	365 (3 trials)	⊕○○○ <b>very low</b> <sup>1,2,3</sup>
<b>Serious adverse events (number of events)</b> Follow-up: 37 months	34 per 1000	26 per 1000 (6 to 118)	Rate ratio 0.78 (0.17 to 3.47)	232 (1 trial)	⊕○○○ <b>very low</b> <sup>1,2,3</sup>
<b>Health-related quality of life</b>	None of the trials reported this outcome.				

\*The basis for the **assumed risk** for all-cause mortality is the approximate control group proportions at two to three years reported in the Kaplan-Meier curves in the trials that reported mortality at maximal-follow-up. We have assumed proportional hazards. The basis for the **assumed risk** for other outcomes is based on the mean control group proportion. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** confidence interval; **HR:** hazard ratio; **OR:** odds ratio; **RR:** rate ratio

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>1</sup>Downgraded one level because of within-study risk of bias: there was unclear or high risk of bias in the trial(s).

<sup>2</sup>Downgraded one level because of imprecision: the sample size was small.

<sup>3</sup>Downgraded one level because of imprecision: the confidence intervals overlapped clinically significant effect and clinically insignificant effect.

Laser ablation versus radiofrequency ablation for people with early- or very early-stage hepatocellular carcinoma					
<b>Patient or population:</b> people with early- or very early-stage hepatocellular carcinoma ineligible for surgery <b>Settings:</b> secondary or tertiary care <b>Intervention:</b> laser ablation <b>Control:</b> radiofrequency ablation					
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No. of participants (trials)	Quality of the evidence (GRADE)
	Assumed risk	Corresponding risk			
	Radiofrequency ablation	Laser ablation			
<b>Mortality at maximal follow-up</b> Follow-up: not stated	300 per 1000	468 per 1000 (262 to 731)	HR 1.77 (0.85 to 3.68)	140 (1 trial)	⊕○○○ very low <sup>1,2,3</sup>
<b>Cancer-related mortality at maximal follow-up</b> Follow-up: not stated	96 per 1000	118 per 1000 (49 to 258)	OR 1.26 (0.49 to 3.27)	140 (1 trial)	⊕○○○ very low <sup>1,2,3</sup>
<b>Serious adverse events (number of participants)</b> Follow-up: 12 months in 1 trial and not stated in another trial	20 per 1000	20 per 1000 (1 to 250)	OR 1.00 (0.06 to 16.31)	170 (2 trials)	⊕○○○ very low <sup>1,2,3</sup>
<b>Serious adverse events (number of events)</b>	None of the trials reported this outcome.				
<b>Health-related quality of life</b>	None of the trials reported this outcome.				

\*The basis for the **assumed risk** for all-cause mortality is the approximate control group proportions at two to three years reported in the Kaplan-Meier curves in the trials that reported mortality at maximal-follow-up. We have assumed proportional hazards. The basis for the **assumed risk** for other outcomes is based on the mean control group proportion. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** confidence interval; **HR:** hazard ratio; **OR:** odds ratio

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>1</sup>Downgraded one level because of within-study risk of bias: there was unclear or high risk of bias in the trial(s).

<sup>2</sup>Downgraded one level because of imprecision: the sample size was small.

<sup>3</sup>Downgraded one level because of imprecision: the confidence intervals overlapped clinically significant effect and clinically insignificant effect.

Transarterial embolisation plus radiofrequency ablation versus radiofrequency ablation for people with early- or very early-stage hepatocellular carcinoma					
<b>Patient or population:</b> people with early- or very early-stage hepatocellular carcinoma ineligible for surgery <b>Settings:</b> secondary or tertiary care <b>Intervention:</b> transarterial embolisation plus radiofrequency ablation <b>Control:</b> radiofrequency ablation					
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No. of participants (trials)	Quality of the evidence (GRADE)
	Assumed risk	Corresponding risk			
	Radiofrequency ablation	Transarterial embolisation plus radiofrequency ablation			
<b>Mortality at maximal follow-up</b> Follow-up: not stated	300 per 1000	329 per 1000 (157 to 602)	HR 1.12 (0.48 to 2.58)	44 (1 trial)	⊕○○○ very low <sup>1,2,3</sup>
<b>Cancer-related mortality at maximal follow-up</b>	None of the trials reported this outcome.				
<b>Serious adverse events (number of participants)</b> Follow-up: 6 months in 1 trial and not stated in another trial	20 per 1000	41 per 1000 (4 to 341)	OR 2.11 (0.18 to 25.35)	84 (2 trials)	⊕○○○ very low <sup>1,2,3</sup>
<b>Serious adverse events (number of events)</b> Follow-up: not stated	There were no events in either group.			44 (1 trial)	⊕○○○ very low <sup>1,2,3</sup>
<b>Health-related quality of life</b>	None of the trials reported this outcome.				

\*The basis for the **assumed risk** for all-cause mortality is the approximate control group proportions at two to three years reported in the Kaplan-Meier curves in the trials that reported mortality at maximal-follow-up. We have assumed proportional hazards. The basis for the **assumed risk** for other outcomes is based on the mean control group proportion. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** confidence interval; **HR:** hazard ratio; **OR:** odds ratio

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>1</sup>Downgraded one level because of within-study risk of bias: there was unclear or high risk of bias in the trial(s).

<sup>2</sup>Downgraded one level because of imprecision: the sample size was small.

<sup>3</sup>Downgraded one level because of imprecision: the confidence intervals overlapped clinically significant effect and clinically insignificant effect.

Transarterial embolisation plus percutaneous alcohol injection versus percutaneous alcohol injection for people with early- or very early-stage hepatocellular carcinoma					
<b>Patient or population:</b> people with early- or very early-stage hepatocellular carcinoma ineligible for surgery <b>Settings:</b> secondary or tertiary care <b>Intervention:</b> transarterial embolisation plus percutaneous alcohol injection <b>Control:</b> percutaneous alcohol injection					
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No. of participants (trials)	Quality of the evidence (GRADE)
	Assumed risk	Corresponding risk			
	Percutaneous alcohol injection	Transarterial embolisation plus percutaneous alcohol injection			
<b>Mortality at maximal follow-up</b> Follow-up: 19 months to 30 months	300 per 1000	251 per 1000 (207 to 302)	HR 0.81 (0.65 to 1.01)	202 (2 trials)	⊕○○○ very low <sup>1,2,3,4</sup>
<b>Cancer-related mortality at maximal follow-up</b> Follow-up: 30 months	192 per 1000	16 per 1000 (0 to 251)	OR 0.07 (0.00 to 1.41)	52 (1 trial)	⊕○○○ very low <sup>1,2,3</sup>
<b>Serious adverse events (number of participants)</b> Follow-up: 30 months	1 per 1000	5 per 1000 (0 to 106)	OR 5.41 (0.25 to 118.34)	52 (1 trial)	⊕○○○ very low <sup>1,2,3</sup>
<b>Serious adverse events (number of events)</b>	None of the trials reported this outcome.				
<b>Health-related quality of life</b>	None of the trials reported this outcome.				

\*The basis for the **assumed risk** for all-cause mortality is the approximate control group proportions at two to three years reported in the Kaplan-Meier curves in the trials that reported mortality at maximal-follow-up. We have assumed proportional hazards. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** confidence interval; **HR:** hazard ratio; **OR:** odds ratio

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>1</sup>Downgraded one level because of within-study risk of bias: there was unclear or high risk of bias in the trial(s).

<sup>2</sup>Downgraded one level because of imprecision: the sample size was small.

<sup>3</sup>Downgraded one level because of imprecision: the confidence intervals overlapped clinically significant effect and clinically insignificant effect.

<sup>4</sup>Downgraded one level because of inconsistency: there was substantial unexplained heterogeneity.

## DISCUSSION

### Summary of main results

We included a total of 18 trials in this review. Four trials (593 participants; 574 participants included for one or more analyses) compared surgery versus radiofrequency ablation in people with early hepatocellular carcinoma who were eligible to undergo surgery (Chen 2006; Huang 2010; Fang 2014; Lee 2014), while 14 trials (2533 participants; 2494 participants included for various analyses) compared different non-surgical interventions in people with early hepatocellular carcinoma who were not eligible to undergo surgery (Bolondi 1996; Koda 2001; Shibata 2002; Lencioni 2003; Gan 2004; Chen 2005; Lin 2005; Shiina 2005; Aikata 2006; Brunello 2008; Giorgio 2011; El Kady 2013; Orlacchio 2014; Costanzo 2015). Non-surgical interventions compared in the trials that included participants not eligible for surgery included radiofrequency ablation, laser ablation, microwave ablation, percutaneous acetic acid injection, percutaneous alcohol injection, a combination of radiofrequency ablation with systemic chemotherapy, a combination of radiofrequency ablation with percutaneous alcohol injection, a combination of transarterial chemoembolisation with percutaneous alcohol injection, and a combination of transarterial chemoembolisation with radiofrequency ablation.

### Surgery versus radiofrequency ablation

There was no evidence of difference in mortality at maximal follow-up between surgery and radiofrequency ablation. Of the outcomes in which at least two trials were included, the proportion of people with hepatocellular carcinoma recurrence (local or distal) and hepatocellular carcinoma recurrence (recurrence in liver) were lower in the surgery group than in the radiofrequency ablation group (OR 0.53, 95% CI 0.35 to 0.78; 413 participants; 3 trials;  $I^2 = 36%$  and OR 0.49, 95% CI 0.31 to 0.78; 350 participants; 2 trials;  $I^2 = 6%$ ), while the numbers of serious adverse events and any adverse events were lower in the radiofrequency ablation group than in the surgery group (RR 7.02, 95% CI 2.29 to 21.46; 391 participants; 2 trials;  $I^2 = 0%$  and RR 4.42, 95% CI 2.74 to 7.15; 391 participants; 2 trials;  $I^2 = 0%$ ). In addition, the length of hospital stay was shorter in the radiofrequency ablation group than in the surgery group (MD 8.42 days, 95% CI 7.84 to 9.01; 530 participants; 3 trials;  $I^2 = 86%$ ). Overall, it appears that surgery offers lower cancer recurrence but radiofrequency ablation is less invasive. Clearly, lower cancer recurrence is more important to most patients than fewer complications or quicker recovery, unless the difference in health-related quality of life compensates for the lower cancer recurrence. As none of the trials reported health-related quality of life, we are unable to comment on this. In addition, it should be noted the trial sequential monitoring boundaries were not crossed for cancer recurrence (Figure 5), indicating that there is a high risk of random error in these outcomes. Furthermore, it should be noted that lower cancer recurrence by itself does

not mean that the survival is longer, for example patients may be able to undergo additional treatments after cancer recurrence and the overall survival may be improved. There was no evidence of difference in mortality at maximal follow-up between surgery and radiofrequency ablation. This may be due to additional treatments that people might have received after cancer recurrence, or is more likely due to the short follow-up period in the trials. The average follow-up period in the three trials that reported this information was between 29 months and 42 months (Table 1). However, the Kaplan-Meier curves in the trials suggest that most deaths occur beyond three to four years. Trials of longer follow-up and adequate sample size are needed to determine whether radiofrequency ablation provides equivalent survival in people with early- or very early-stage hepatocellular carcinoma who are eligible for surgery. Consequently, there is lot of uncertainty around this issue.

### Non-surgical interventions

In people who were not eligible for surgery, mortality at maximal follow-up was higher in the percutaneous acetic acid injection group (HR 1.77, 95% CI 1.12 to 2.79; 125 participants; 1 trial) and the percutaneous alcohol injection group (HR 1.49, 95% CI 1.18 to 1.88; 882 participants; 5 trials;  $I^2 = 57%$ ) than in the radiofrequency ablation group. There was no evidence of a difference in mortality at maximal follow-up for any of the other comparisons.

Among the remaining outcomes, for the comparisons in which at least two trials were included, the only outcomes with evidence of difference were cancer-related mortality at maximal follow-up, which was higher in the percutaneous alcohol injection group than in the radiofrequency ablation group (OR 2.18, 95% CI 1.22 to 3.89; 458 participants; 3 trials;  $I^2 = 0%$ ); mortality (> 1 year), which was higher in the percutaneous alcohol injection group than in the radiofrequency ablation group (OR 1.69, 95% CI 1.15 to 2.49; 598 participants; 4 trials;  $I^2 = 0%$ ); and hepatocellular carcinoma recurrence (local or distal), which was again higher in the percutaneous alcohol injection group than in the radiofrequency ablation group (OR 1.58, 95% CI 1.02 to 2.45; 371 participants; 2 trials;  $I^2 = 0%$ ). Overall, it appears that radiofrequency ablation provides better cancer control and survival than percutaneous alcohol injection. However, it should be noted that there is a high risk of random error as shown by the Trial Sequential Analysis (Figure 4).

Because of the risk of bias, short period of follow-up, and small samples in the trials, resulting in high risk of random errors, it is not possible to say with certainty how people with early hepatocellular carcinoma should be managed.

### Overall completeness and applicability of evidence

This review included only people with very early- or early-stage hepatocellular carcinoma, that is BCLC A stage (single tumour or three tumours of maximum diameter of 3 cm or less, Child-Pugh status A to B, and performance status 0). This review is therefore applicable only to people with very early- or early-stage hepatocellular carcinoma. The findings of the comparison between surgical resection and radiofrequency ablation are applicable only to people who are eligible for surgical resection, while the findings of the comparison between non-surgical interventions are applicable only to people who are not eligible for surgical resection.

The participants in the trials included in this review had viral or non-viral aetiologies and cirrhotic or non-cirrhotic livers. Hence, the review is applicable to people with viral or non-viral aetiologies and people with cirrhotic and non-cirrhotic livers. The proportion of people with portal hypertension was not clearly reported in any of the trials, except [Orlacchio 2014](#), although a proportion of participants had features suggestive of portal hypertension such as oesophageal varices or ascites. It therefore appears that the findings of the review are applicable to people with portal hypertension. The proportion of people who received adjuvant antiviral or immunotherapy was also not reported, consequently it is unclear whether the findings of the review are applicable to people who receive such therapy.

### Quality of the evidence

The overall quality of the evidence was low or very low for all outcomes included in the comparison of surgery versus radiofrequency ablation in people who are eligible for surgery and the comparison of various non-surgical interventions in people who were not eligible for surgery. All of the trials were at high risk of bias. As the issue of blinding may not arise for all-cause mortality, we downgraded the quality of the evidence one level for all-cause mortality and two levels for the remaining comparisons. Indirectness was not an issue, as all of the outcomes were clinical outcomes, and only direct comparisons were used. The sample sizes were small (all comparisons downgraded one level), and the confidence intervals overlapped clinically significant effect and clinically insignificant effect for most comparisons (downgraded one level). In addition, there was substantial heterogeneity for some of the outcomes, resulting in further downgrading by one level. We did not explore publication bias because of the few trials included in this review; this could have led to one further downgrading. The average follow-up period in the different trials varied. The Kaplan-Meier curves in some of the trials that provided this information suggest that most deaths occur beyond three to four years in people with early or very early hepatocellular carcinoma. The short period of follow-up in the trials and the variability in the follow-up is another limitation of this review.

### Potential biases in the review process

We selected a range of databases and used no language restrictions. At least two review authors independently selected the trials and extracted the data, thereby minimising errors. We conducted the systematic review according to the guidance found in the *Cochrane Handbook for Systematic Reviews of Interventions* ([Higgins 2011](#)). We included only randomised clinical trials, which provide the best estimates of treatment effect, in this review. These are the strengths of the review process.

As discussed in the previous section, the quality of the evidence was low or very low, which was mainly due to the risk of bias and sparse data. This is the major limitation of this review. In addition, we have not included non-randomised studies in this review. In general, the participants included randomised clinical trials are carefully selected, while those seen in the clinic have multiple comorbidities. As a result, the complication rates reported in this review may be lower than those in actual clinical practice. Furthermore, it is possible that none of the participants in the randomised clinical trials developed rare complications because of the small sample sizes in the trials included in this review.

Randomised clinical trials are known to focus mostly on benefits and do not collect and report harms in a detailed manner. According to our choice of studies (i.e. only randomised clinical trials), it is possible that we missed a large number of studies addressing the reporting of harms. Accordingly, this review is biased towards benefits ignoring harms. We did not search for interventions and trials registered at regulatory authorities (e.g. US Food and Drug Administration and European Medicines Agency, etc.), which may have resulted in us overlooking trials. As such trials are usually unpublished, the lack of inclusion of such trials could make our comparisons look more advantageous than they really are.

We planned to perform a network meta-analysis. However, it was not possible to assess whether the potential effect modifiers were similar across different comparisons, and performing a network meta-analysis in this scenario can be misleading. We therefore did not perform the network meta-analysis, and instead assessed the comparative benefits and harms of different interventions using standard Cochrane methodology.

### Agreements and disagreements with other studies or reviews

There has been one network meta-analysis, [Lan 2016](#), and several systematic reviews comparing the different interventions included in this topic ([Liu 2010](#); [Zhou 2010](#); [Xu 2012b](#); [Shen 2013](#); [Dong 2014](#); [Fu 2014](#); [Qi 2014](#); [Yi 2014](#); [He 2016](#)). We disagree with the network meta-analysis that the combination therapy of TACE and radiofrequency ablation is the most effective strategy for early-stage hepatocellular carcinoma ([Lan 2016](#)), because the comparison of TACE and radiofrequency ablation versus radiofrequency ablation alone was based on two small trials at high risk of bias

(Aikata 2006; El Kady 2013), and only one of these trials reported mortality at maximal follow-up (Aikata 2006). We are unable to comment on the findings of Weis 2015 on comparisons between percutaneous acetic acid injection and percutaneous alcohol injection because we were unable to obtain the data for the participants who met early-stage hepatocellular carcinoma according to BCLC criteria (it should be noted that many authors defined hepatocellular carcinoma as early despite not meeting the BCLC 0 or BCLC A criteria). We also disagree with the authors who concluded that surgery was better than radiofrequency ablation in people with early-stage hepatocellular carcinoma (Liu 2010; Zhou 2010; Xu 2012b; Dong 2014; Qi 2014; Yi 2014; He 2016). We agree with the authors who concluded that radiofrequency ablation was better than percutaneous ablation in people with early-stage hepatocellular carcinoma (Shen 2013), although some uncertainty remains around this issue. The possible reasons for the differences in conclusions from other studies include restricting trials to randomised clinical trials only and taking the risk of random errors, systematic errors, and heterogeneity into account while arriving at conclusions.

We agree with Fu 2014 that further trials on surgery versus radiofrequency ablation are required to determine the relative benefits and harms of surgery and radiofrequency ablation.

Several systematic reviews also exist in other patient groups of hepatocellular carcinoma. Oliveri 2011 found there was no evidence to support or refute TACE or TAE in people with unresectable hepatocellular carcinoma. We agree that there is insufficient evidence to support or refute one treatment over the other. However, we disagree with Weis 2013 that surgery offered better survival than radiofrequency ablation. The difference in conclusions may be due to two additional trials that we included in this review. We are unable to comment on the findings of Abdel-Rahman 2016 on the role of radioembolisation in people with unresectable hepatocellular carcinoma because the trials included in this review did not belong to early stage.

## AUTHORS' CONCLUSIONS

### Implications for practice

The evidence was of low or very low quality. In people who are

eligible for surgery, there was no evidence of difference in all-cause mortality at maximal follow-up between surgery and radiofrequency ablation. In people who are not eligible for surgery, all-cause mortality at maximal follow-up was higher with percutaneous acetic acid injection and percutaneous alcohol injection than with radiofrequency ablation. There was no evidence of difference in all-cause mortality at maximal follow-up in other comparisons.

### Implications for research

High-quality randomised clinical trials designed to measure clinically important differences in all-cause mortality and following the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials), Chan 2013b, and CONSORT guidelines, Schulz 2010, are needed. Future trials on early hepatocellular carcinoma should follow up participants for at least four to five years because most deaths occur beyond three years. They should also include other patient-oriented outcomes such as health-related quality of life.

## ACKNOWLEDGEMENTS

We thank the Cochrane Comparing of Multiple Interventions Methods Group and the Cochrane Hepato-Biliary Group for their support and advice.

Cochrane Review Group funding acknowledgement: The Danish State is the largest single funder of the Cochrane Hepato-Biliary Group through its investment in The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Denmark.

Disclaimer: The views and opinions expressed in this review are those of the authors and do not necessarily reflect those of the Danish State or The Copenhagen Trial Unit.

Peer reviewers of review: Stephen L Chang, Hong Kong; Christian Rolfo, UK; Andrea Cipriani, UK; Tim Meyer, UK; Riad Salem, USA.

Contact editor: Christian Gluud, Denmark.

Sign-off editor: Christian Gluud, Denmark.

## REFERENCES

### References to studies included in this review

#### Aikata 2006 *{published data only}*

Aikata H, Shirakawa H, Takaki S, Uka K, Miki D, Yamashina K. Radiofrequency ablation combined with transcatheter arterial chemoembolization for small hepatocellular carcinomas. *Hepatology (Baltimore, Md.)* 2006;**44**(4 (Suppl 1)):494a.

#### Bolondi 1996 *{published data only}*

Bolondi L, Sofia S, Piscaglia F, Gramantieri L, Siringo S, Livraghi T, et al. Efficacy of transarterial chemoembolization (TACE) associated to percutaneous ethanol injection (PEI) in the treatment of small hepatocellular carcinoma (HCC). *Journal of Hepatology* 1996;**25**(Suppl 1):S118.

#### Brunello 2008 *{published data only}*

Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. *Scandinavian Journal of Gastroenterology* 2008;**43**(6):727–35.

#### Chen 2005 *{published data only}*

Chen MS, Zhang YJ, Li JQ, Liang HH, Zhang YQ, Zheng Y. Randomized clinical trial of percutaneous radiofrequency ablation plus absolute ethanol injection compared with radiofrequency ablation alone for small hepatocellular carcinoma. *Chung-Hua Chung Liu Tsa Chih* 2005;**27**(10): 623–5.

#### Chen 2006 *{published data only}*

Chen MS, Li JQ, Liang HH, Lin XJ, Guo RP, Zheng Y, et al. Comparison of effects of percutaneous radiofrequency ablation and surgical resection on small hepatocellular carcinoma. *Zhonghua Yi Xue Za Zhi* 2005;**85**(2):80–3.  
\* Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. *Annals of Surgery* 2006;**243**(3):321–8.

#### Costanzo 2015 *{published data only}*

Costanzo GG, Tortora R, D'Adamo G, Luca M, Lampasi F, Addario L, et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. *Journal of Gastroenterology and Hepatology* 2015;**30**(3):559–65.

#### El Kady 2013 *{published data only}*

El-Kady NM, Esmat G, Mahmoud EH, Darweesh SK, Mahmoud SHI, Elagawy WA. Hypertonic saline-enhanced radiofrequency versus chemoembolization sequential radiofrequency in the treatment of large hepatocellular carcinoma. *European Journal of Gastroenterology & Hepatology* 2013;**25**(5):628–33.

#### Fang 2014 *{published data only}*

Fang Y, Chen W, Liang X, Li D, Lou H, Chen R, et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small

hepatocellular carcinoma. *Journal of Gastroenterology and Hepatology* 2014;**29**(1):193–200.

#### Gan 2004 *{published data only}*

Gan YH, Yie SL, Ren ZG, Xia JL, Zhang BH, Wang YH, et al. Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma. *Chung-Hua Chung Liu Tsa Chih* 2004;**26**(8):496–8.

#### Giorgio 2011 *{published data only}*

Giorgio A, Di Sarno A, De Stefano G, Scognamiglio U, Farella N, Mariniello A, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. *Anticancer Research* 2011;**31**(6):2291–5.

#### Huang 2010 *{published data only}*

Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. *Annals of Surgery* 2010;**252**(6):903–12.

#### Koda 2001 *{published data only}*

Koda M, Murawaki Y, Mitsuda A, Oyama K, Okamoto K, Idobe Y, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma - a randomized control study. *Cancer* 2001;**92**(6):1516–24.

#### Lee 2014 *{published data only}*

Lee HW, Suh KS, Kim H, Choi YR, Suh SW, Jeong J, et al. A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma. *Hepatology (Baltimore, Md.)* 2014;**60**:855a–6a.

#### Lencioni 2003 *{published data only}*

\* Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. *Radiology* 2003;**228**(1):235–40.  
Olschewski M, Lencioni R, Allgaier H, Cioni D, Deibert P, Frings H, et al. A randomized comparison of radiofrequency thermal ablation and percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. *Proceedings of the American Society of Clinical Oncology* 2001;**20** (Pt 1): 126a.

#### Lin 2005 *{published data only}*

Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. *Gut* 2005;**54**(8):1151–6.

#### Orlacchio 2014 *{published data only}*

Orlacchio A, Bolacchi F, Chegai F, Bergamini A, Costanzo E, Del Giudice C, et al. Comparative evaluation of percutaneous laser and radiofrequency ablation in patients

with HCC smaller than 4 cm. *Radiologia Medica* 2014;**119**(5):298–308.

**Shibata 2002** {published data only}

Shibata T, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. *Radiology* 2002;**223**(2):331–7.

**Shiina 2005** {published data only}

Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. *Gastroenterology* 2005;**129**(1):122–30.

## References to studies excluded from this review

**Abdelaziz 2014** {published data only}

Abdelaziz A, Elbaz T, Shousha HI, Mahmoud S, Ibrahim M, Abdelmaksoud A, et al. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. *Surgical Endoscopy* 2014;**28**(12):3429–34.

**Azab 2011** {published data only}

Azab M, Zaki S, El-Shetey AG, Abdel-Moty MF, Alnoomani NM, Gomaa AA, et al. Radiofrequency ablation combined with percutaneous ethanol injection in patients with hepatocellular carcinoma. *Arab Journal of Gastroenterology* 2011;**12**(3):113–8.

**Casaccia 2015** {published data only}

Casaccia M, Santori G, Bottino G, Diviacco P, Negri AD, Moraglia E, et al. The procedure outcome of laparoscopic resection for 'small' hepatocellular carcinoma is comparable to laparoscopic radiofrequency ablation. *Journal of Minimal Access Surgery* 2015;**11**(4):231–5.

**Chen 2014** {published data only}

Chen KY, Chen GH, Wang HN, Li H, Xiao JF, Duan XP, et al. Increased survival in hepatocellular carcinoma with iodine-125 implantation plus radiofrequency ablation: a prospective randomized controlled trial. *Journal of Hepatology* 2014;**61**(6):1304–11.

**Feng 2012** {published data only}

Feng K, Yan J, Li X, Xia F, Ma K, Wang S, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. *Journal of Hepatology* 2012;**57**(4):794–802.

**Ferrari 2007** {published data only}

Ferrari FS, Megliola A, Scorzelli A, Stella A, Vigni F, Drudi FM. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long-term results. *Radiologia Medica* 2007;**112**(3):377–93.

**Fukushima 2015** {published data only}

Fukushima T, Ikeda K, Kawamura Y, Sorin Y, Hosaka T, Kobayashi M, et al. Randomized controlled trial comparing the efficacy of impedance control and temperature control of radiofrequency interstitial thermal ablation for treating small hepatocellular carcinoma. *Oncology* 2015;**89**(1):47–52.

**Gallo 1998** {published data only}

Gallo C, Daniele B, Gaeta GB, Perrone F, Pignata S. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. *Lancet* 1998;**352**(9121):17–20.

**Goldberg 2002** {published data only}

Goldberg SN, Kamel IR, Kruskal JB, Reynolds K, Monsky WL, Stuart KE, et al. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. *American Journal of Roentgenology* 2002;**179**(1):93–101.

**Habib 2002** {published data only}

Habib N, Salama H, Abd El Latif Abu Median A, Isac Anis I, Abd Al Aziz RA, Sarraf C, et al. Clinical trial of e1b-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. *Cancer Gene Therapy* 2002;**9**(3):254–9.

**Hirakawa 2013** {published data only}

Hirakawa M, Ikeda K, Kobayashi M, Kawamura Y, Hosaka T, Sezaki H, et al. Randomized controlled trial of a new procedure of radiofrequency ablation using an expandable needle for hepatocellular carcinoma. *Hepatology Research* 2013;**43**(8):846–52.

**Hou 2009** {published data only}

Hou YB, Chen MH, Yan K, Wu JY, Yang W. Adjuvant percutaneous radiofrequency ablation of feeding artery of hepatocellular carcinoma before treatment. *World Journal of Gastroenterology* 2009;**15**(21):2638–43.

**Huang 2005** {published data only}

Huang GT, Lee PH, Tsang YM, Lai MY, Yang PM, Hu RH, et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. *Annals of Surgery* 2005;**242**(1):36–42.

**Huo 2003** {published data only}

Huo TI, Huang YH, Wu JC, Chiang JH, Lee PC, Chang FY, et al. Sequential transarterial chemoembolization and percutaneous acetic acid injection therapy versus repeated percutaneous acetic acid injection for unresectable hepatocellular carcinoma: a prospective study. *Annals of Oncology* 2003;**14**(11):1648–53.

**Hyun 2016** {published data only}

Hyun D, Cho SK, Shin SW, Park KB, Park HS, Choo SW, et al. Early stage hepatocellular carcinomas not feasible for ultrasound-guided radiofrequency ablation: comparison of transarterial chemoembolization alone and combined therapy with transarterial chemoembolization and radiofrequency ablation. *Cardiovascular and Interventional Radiology* 2016;**39**(3):417–25.

**Kobayashi 2007** {published data only}

Kobayashi M, Ikeda K, Kawamura Y, Hosaka T, Sezaki H, Yatsuji H, et al. Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma - direct ablative effects and a long-term outcome. *Liver International* 2007;**27**(3):353–9.

- Kuansheng 2011** *{published data only}*  
Kuansheng M, Feng K, Yan J, Wang S, Bie P. A randomized controlled study of radiofrequency ablation and surgical resection for early-stage hepatocellular carcinomas less than 4 cm in diameter. *Hepatology (Baltimore, Md.)* 2011;**54** (S1):418a.
- Lau 1999** *{published data only}*  
Lau WY, Leung TW, Ho SK, Chan M, Machin D, Lau J, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. *Lancet* 1999;**353**(9155):797–801.
- Lau 2008** *{published data only}*  
Lau WY, Lai ECH, Leung TWT, Yu SCH. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial - update on 5-year and 10-year survival. *Annals of Surgery* 2008;**247**(1):43–8.
- Lin 2004** *{published data only}*  
Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. *Gastroenterology* 2004;**127**(6):1714–23.
- Livraghi 1999** *{published data only}*  
Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. *Radiology* 1999;**210**(3):655–61.
- Lo 2007** *{published data only}*  
Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. *Annals of Surgery* 2007;**245**(6):831–42.
- Lu 2006a** *{published data only}*  
Lu MD, Kuang M, Liang LJ, Xie XY, Peng BG, Liu GJ, et al. Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial. *Chung-Hua i Hsueh Tsa Chih* 2006;**86**(12): 801–5.
- Mizuki 2010** *{published data only}*  
Mizuki A, Tatemichi M, Tsukada N, Nagamatsu R, Kawaguchi M, Itoshima T, et al. Addition of transcatheter arterial chemoembolization decreased local recurrence but had no survival benefit to percutaneous ethanol injection therapy for patients with small hepatocellular carcinoma: a multicenter randomized control study. *Oncology Letters* 2010;**1**(5):855–9.
- Muehlbacher 2014** *{published data only}*  
Muehlbacher J, Rasoul-Rockenschaub S, Pokorny H, Gnant M, Gollackner B, Steiner B, et al. Neoadjuvant chemotherapy in liver transplantation for HCC: fifteen-year outcome of a RCT. *Transplantation* 2014;**98**:166–7.
- Ohnishi 1998** *{published data only}*  
Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. *Hepatology (Baltimore, Md.)* 1998;**27**(1):67–72.
- Okusaka 2011** *{published data only}*  
Okusaka T, Makuuchi M, Matsui O, Kumada H, Tanaka K, Kaneko S, et al. Clinical benefit of peretinoin for the suppression of hepatocellular carcinoma (HCC) recurrence in patients with Child-Pugh grade A (CP-A) and small tumor: a subgroup analysis in a phase II/III randomized, placebo-controlled trial. *Journal of Clinical Oncology* 2011; **29**(4 Suppl 1):Abstract 165.
- Peng 2012** *{published data only}*  
Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, Chen MS. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. *Radiology* 2012;**262**(2):689–700.
- Pinter 2015** *{published data only}*  
Pinter M, Ulbrich G, Sieghart W, Kolblinger C, Reiberger T, Li S, et al. Hepatocellular carcinoma: a phase II randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo. *Radiology* 2015;**277**(3):903–12.
- Shen 2005** *{published data only}*  
Shen SQ, Xiang JJ, Xiong CL, Wu SM, Zhu SS. Intraoperative radiofrequency thermal ablation combined with portal vein infusion chemotherapy and transarterial chemoembolization for unresectable HCC. *Hepato-gastroenterology* 2005;**52**(65):1403–7.
- Shibata 2006** *{published data only}*  
Shibata T, Maetani Y, Isoda H, Hiraoka M. Radiofrequency ablation for small hepatocellular carcinoma: prospective comparison of internally cooled electrode and expandable electrode. *Radiology* 2006;**238**(1):346–53.
- Shibata 2009** *{published data only}*  
Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment?. *Radiology* 2009;**252**(3): 905–13.
- Shiozawa 2015** *{published data only}*  
Shiozawa K, Watanabe M, Ikehara T, Matsukiyo Y, Kogame M, Kishimoto Y, et al. Comparison of percutaneous radiofrequency ablation and CyberKnife for initial solitary hepatocellular carcinoma: A pilot study. *World Journal of Gastroenterology* 2015;**21**(48):13490–9.
- Sun 2016** *{published data only}*  
Sun X, Li R, Zhang BT, Yang YJ, Cui ZF. Treatment of liver cancer of middle and advanced stages using ultrasound-guided percutaneous ethanol injection combined with radiofrequency ablation: a clinical analysis. *Oncology Letters* 2016;**11**(3):2096–100.
- van Malenstein 2011** *{published data only}*  
van Malenstein H, Maleux G, Vandecaveye V, Heye S, Laleman W, van Pelt J, et al. A randomized phase ii study of

drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. *Onkologie* 2011; **34**(7):368–76.

**Wu 2015** {published data only}

Wu X, Li B, Qiu J, Shen J, Zheng Y, Li Q, et al. Hepatectomy versus hepatectomy with lymphadenectomy in hepatocellular carcinoma: a prospective, randomized controlled clinical trial. *Journal of Clinical Gastroenterology* 2015;**49**(6):520–8.

**Xu 2012a** {published data only}

Xu F, Huang YQ, Li YS, Wu L, Yang JM. Is postoperative adjuvant transcatheter arterial chemoembolization necessary for small hepatocellular carcinoma patients: a randomized controlled trial. *Academic Journal of Second Military Medical University* 2012;**33**(3):274–9.

**Xu 2013** {published data only}

Xu F, Huang Y-Q, Li Y-S, Wu L, Yang JM. Role of adjuvant tace in prevention of early recurrence for HCC in BCLC stage A1 after radical hepatectomy, a RCT. *HPB: the Official Journal of the International Hepato-Pancreato-Biliary Association* 2013;**15**(Suppl 2):131–2.

**Xu 2015** {published data only}

Xu J, Zhao Y. Comparison of percutaneous microwave ablation and laparoscopic resection in the prognosis of liver cancer. *International Journal of Clinical and Experimental Pathology* 2015;**8**(9):11665–9.

**Yi 2014** {published data only}

Yi Y, Zhang Y, Wei Q, Zhao L, Han J, Song Y, et al. Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone. *Chinese Journal of Cancer Research* 2014;**26**(1):112–8.

**Yu 2014** {published data only}

Yu W, Wang W, Rong W, Wang L, Xu Q, Wu F, et al. Adjuvant radiotherapy in centrally located hepatocellular carcinomas after hepatectomy with narrow margin (< 1 cm): a prospective randomized study. *Journal of the American College of Surgeons* 2014;**218**(3):381–92.

**Yu 2016** {published data only}

Yu J, Liang P, Yu X, Cheng Z, Han Z, Liu F. Comparison of cooled-probe microwave and radiofrequency ablation treatment in incipient hepatocellular carcinoma: a phase III randomized controlled trial with 6-year follow-up. *Journal of Clinical Oncology* 2016;**34**(Suppl):Abstract 4068.

**Zhang 2002** {published data only}

Zhang Z, Wu M, Chen H, Chen D, He J. Percutaneous radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. *Zhonghua Wai Ke Za Zhi* 2002;**40**(11):826–9.

**Zhang 2007** {published data only}

Zhang YJ, Liang HH, Chen MS, Guo RP, Li JQ, Zheng Y, et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. *Radiology* 2007;**244**(2):599–607.

## Additional references

**Abdel-Rahman 2016**

Abdel-Rahman OM, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. *Cochrane Database of Systematic Reviews* 2016, Issue 2. [DOI: 10.1002/14651858.CD011313.pub2]

**Aghoram 2012**

Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. *Cochrane Database of Systematic Reviews* 2012, Issue 9. [DOI: 10.1002/14651858.CD002799.pub2]

**Arnaoutakis 2014**

Arnaoutakis DJ, Mavros MN, Shen F, Alexandrescu S, Firoozmand A, Popescu I, et al. Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. *Annals of Surgical Oncology* 2014;**21**(1):147–54.

**Asham 2013**

Asham EH, Kaseb A, Ghobrial RM. Management of hepatocellular carcinoma. *Surgical Clinics of North America* 2013;**93**(6):1423–50.

**Bosetti 2014**

Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. *Best Practice & Research: Clinical Gastroenterology* 2014;**28**(5):753–70.

**Bruix 2011**

Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology (Baltimore, Md.)* 2011; **53**(3):1020–2.

**Chaimani 2012**

Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. *Research Synthesis Methods* 2012;**3**(2): 161–76.

**Chaimani 2013**

Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. *PLoS ONE* 2013;**8**(10):e76654.

**Chan 2013a**

Chan AC, Cheung TT, Fan ST, Chok KS, Chan SC, Poon RT, et al. Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. *Annals of Surgery* 2013;**257**(4):686–92.

**Chan 2013b**

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krlež a-Jerić K, et al. SPIRIT 2013 statement: Defining standard protocol items for clinical trials. *Annals of Internal Medicine* 2013;**158**(3):200–7.

**Chen 2012**

Chen Y, Wang X, Wang J, Yan Z, Luo J. Excess body weight and the risk of primary liver cancer: an updated meta-

- analysis of prospective studies. *European Journal of Cancer* 2012;**48**(14):2137–45.
- Cillo 2006**  
Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanusi G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. *Journal of Hepatology* 2006;**44**(4):723–31.
- Davila 2004**  
Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. *Gastroenterology* 2004;**127**(5):1372–80.
- Del Re 2013**  
Del Re AC, Spielmans GI, Flückiger C, Wampold BE. Efficacy of new generation antidepressants: differences seem illusory. *PLoS One* 2013;**8**(6):e63509.
- DeMets 1987**  
DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. *Statistics in Medicine* 1987;**6**(3):341–50.
- DerSimonian 1986**  
DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled Clinical Trials* 1986;**7**(3):177–88.
- Dias 2010**  
Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. *Statistics in Medicine* 2010;**29**(7-8):932–44.
- Dias 2012a**  
Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU technical support document 3: Heterogeneity: subgroups, meta-regression, bias and bias-adjustment, September 2011 (last updated April 2012). [www.nicedsu.org.uk/TSD3%20Heterogeneity.final%20report.08.05.12.pdf](http://www.nicedsu.org.uk/TSD3%20Heterogeneity.final%20report.08.05.12.pdf) (accessed 27 March 2014).
- Dias 2012b**  
Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 1: Introduction to evidence synthesis for decision making, April 2011 (last updated April 2012). [www.nicedsu.org.uk/TSD1%20Introduction.final.08.05.12.pdf](http://www.nicedsu.org.uk/TSD1%20Introduction.final.08.05.12.pdf) (accessed 27 March 2014).
- Dias 2014a**  
Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: A generalised linear modelling framework for pair wise and network meta-analysis of randomised controlled trials, August 2011 (last updated April 2014). [www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf](http://www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf) (accessed 8 October 2014).
- Dias 2014b**  
Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU technical support document 4: Inconsistency in networks of evidence based on randomised controlled trials, May 2011 (last updated April 2014). [www.nicedsu.org.uk/TSD4%20Inconsistency.final.15April2014.pdf](http://www.nicedsu.org.uk/TSD4%20Inconsistency.final.15April2014.pdf) (accessed 8 October 2014).
- Dong 2014**  
Dong W, Zhang T, Wang ZG, Liu H. Clinical outcome of small hepatocellular carcinoma after different treatments: a meta-analysis. *World Journal of Gastroenterology* 2014;**20**(29):10174–82.
- EASL 2012**  
European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *Journal of Hepatology* 2012;**56**(4):908–43.
- Egger 1997**  
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ (Clinical Research Ed.)* 1997;**315**(7109):629–34.
- EuroQol 2014**  
EuroQol. About EQ-5D, 2014. [www.euroqol.org/about-eq-5d.html](http://www.euroqol.org/about-eq-5d.html) (accessed 8 October 2014).
- Fu 2014**  
Fu C, Liu N, Deng Q, Li X, Ma K, Bie P. Radiofrequency ablation vs. surgical resection on the treatment of patients with small hepatocellular carcinoma: a system review and meta-analysis of five randomized controlled trials. *Hepato-gastroenterology* 2014;**61**(134):1722–9.
- Gaddikeri 2014**  
Gaddikeri S, McNeely MF, Wang CL, Bhargava P, Dighe MK, Yeh MMC, et al. Hepatocellular carcinoma in the noncirrhotic liver. *American Journal of Roentgenology* 2014;**203**(1):W34–47.
- Germani 2010**  
Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis. *Journal of Hepatology* 2010;**52**(3):380–8.
- Gluud 2016**  
Gluud C, Nikolova D, Klingenberg SL. Cochrane Hepato-Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2016, Issue 10. Art. No.: LIVER.
- Gurusamy 2014**  
Gurusamy KS, Nagendran M, Davidson BR. Methods of preventing bacterial sepsis and wound complications after liver transplantation. *Cochrane Database of Systematic Reviews* 2014, Issue 3. [DOI: 10.1002/14651858.CD006660.pub3]
- Guyatt 2011**  
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. *Journal of Clinical Epidemiology* 2011;**64**(4):383–94.
- He 2016**  
He ZX, Xiang P, Gong JB, Cheng NS, Zhang W. Radiofrequency ablation versus resection for Barcelona Clinic Liver Cancer very early/early stage hepatocellular

carcinoma: a systematic review. *Therapeutics and Clinical Risk Management* 2016;**12**:295–303.

#### Head 2004

Head HW, Dodd GD 3rd. Thermal ablation for hepatocellular carcinoma. *Gastroenterology* 2004;**127**(5 Suppl 1):S167–78.

#### Henderson 2003

Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. *HPB: the Official Journal of the International Hepato-Pancreato-Biliary Association* 2003;**5**(4):243–50.

#### Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from [handbook.cochrane.org](http://handbook.cochrane.org).

#### Higgins 2012

Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies. *Research Synthesis Methods* 2012;**3**(2):98–110.

#### IARC 2014a

International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012. Liver cancer estimated incidence, mortality and prevalence worldwide in 2012. [globocan.iarc.fr/Pages/fact\\_sheets/cancer.aspx](http://globocan.iarc.fr/Pages/fact_sheets/cancer.aspx) (accessed 17 October 2014).

#### IARC 2014b

International Agency for Research on Cancer. World 2012 (estimated cancer incidence, all ages: both sexes). [globocan.iarc.fr/old/summary/table\\_pop.html.asp?selection=224900&title=World&sex=0&type=0&window=1&sort=0&submit=%C2%A0Execute](http://globocan.iarc.fr/old/summary/table_pop.html.asp?selection=224900&title=World&sex=0&type=0&window=1&sort=0&submit=%C2%A0Execute) (accessed 17 October 2014).

#### ICH-GCP 1997

International Conference on Harmonisation Expert Working Group. *International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR & ICH Guidelines*. Vol. 1, Philadelphia (PA): Barnett International/PAREXEL, 1997.

#### Jakobsen 2014

Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. *BMC Medical Research Methodology* 2014;**14**(1):120.

#### Jepsen 2007

Jepsen P, Vilstrup H, Tarone RE, Friis S, Sorensen HT. Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. *International Journal of Cancer* 2007;**121**(7):1624–6.

#### Kansagara 2014

Kansagara D, Papak J, Pasha AS, O'Neil M, Freeman M, Relevo R, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. *Annals of Internal Medicine* 2014;**161**(4):261–9.

#### Kjaergard 2001

Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. *Annals of Internal Medicine* 2001;**135**(11):982–9.

#### Ladep 2014

Ladep NG, Khan SA, Crossey MM, Thillainayagam AV, Taylor-Robinson SD, Toledano MB. Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations. *World Journal of Gastroenterology* 2014;**20**(6):1544–53.

#### Lan 2016

Lan T, Chang L, Rahmathullah MN, Wu L, Yuan YF. Comparative efficacy of interventional therapies for early-stage hepatocellular carcinoma: a prisma-compliant systematic review and network meta-analysis. *Medicine* 2016;**95**(15):e3185.

#### Lee 2009

Lee YC, Cohet C, Yang YC, Stayner L, Hashibe M, Straif K. Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. *International Journal of Epidemiology* 2009;**38**(6):1497–511.

#### Liu 2010

Liu JG, Wang YJ, Du Z. Radiofrequency ablation in the treatment of small hepatocellular carcinoma: a meta-analysis. *World Journal of Gastroenterology* 2010;**16**(27):3450–6.

#### Liu 2012

Liu Y, Chang CC, Marsh GM, Wu F. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. *European Journal of Cancer* 2012;**48**(14):2125–36.

#### Llovet 1999

Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Seminars in Liver Disease* 1999;**19**(3):329–38.

#### Llovet 2003

Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet* 2003;**362**(9399):1907–17.

#### Lu 2006b

Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. *Journal of the American Statistical Association* 2006;**101**(474):447–59.

#### Lundh 2017

Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. *Cochrane Database of Systematic Reviews* 2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3]

**Macaskill 2001**

Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. *Statistics in Medicine* 2001;**20**(4):641–54.

**Maheshwari 2007**

Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. *Journal of Hepatology* 2007;**47**(4):506–13.

**Mazzaferro 1996**

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *New England Journal of Medicine* 1996;**334**(11):693–9.

**McDermott 2013**

McDermott S, Gervais DA. Radiofrequency ablation of liver tumors. *Seminars in Interventional Radiology* 2013;**30**(1):49–55.

**Miladinovic 2013**

Miladinovic J, Hozo I, Djulbegovic B. Trial sequential boundaries for cumulative meta-analyses. *Stata Journal* 2013;**13**(1):77–91.

**Mills 2012**

Mills EJ, Ioannidis JP, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. *JAMA* 2012;**308**(12):1246–53.

**Moher 1998**

Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? *Lancet* 1998;**352**(9128):609–13.

**Nanashima 2006**

Nanashima A, Sumida Y, Abo T, Shindou H, Fukuoka H, Takeshita H, et al. Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. *Journal of Gastroenterology* 2006;**41**(3):250–6.

**NCBI 2014**

NCBI. Carcinoma, hepatocellular, 2014. [www.ncbi.nlm.nih.gov/mesh/68006528](http://www.ncbi.nlm.nih.gov/mesh/68006528) (accessed 17 October 2014).

**Newell 1992**

Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. *International Journal of Epidemiology* 1992;**21**(5):837–41.

**Nguyen 2009**

Nguyen KT, Gamblin TC, Geller DA. World review of laparoscopic liver resection - 2,804 patients. *Annals of Surgery* 2009;**250**(5):831–41.

**NHSBT 2014**

NHS Blood and Transplant. Organ donation. Activity report 2013–2014. [www.organdonation.nhs.uk/statistics/transplant`activity`report/](http://www.organdonation.nhs.uk/statistics/transplant%20activity%20report/) (accessed 8 October 2014).

**Oliveri 2011**

Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. *Cochrane Database of Systematic Reviews* 2011, Issue 3. [DOI: 10.1002/14651858.CD004787.pub2]

**OpenBUGS 3.2.3 [Computer program]**

Members of OpenBUGS Project Management Group. OpenBUGS. Version 3.2.3. Members of OpenBUGS Project Management Group, 2014.

**OPTN 2014**

Organ Procurement and Transplantation Network. Policies, 2014. [optn.transplant.hrsa.gov/ContentDocuments/OPTN`Policies.pdf](http://optn.transplant.hrsa.gov/ContentDocuments/OPTN`Policies.pdf) (accessed 17 October 2014).

**Pleguezuelo 2008**

Pleguezuelo M, Marelli L, Misseri M, Germani G, Calvaruso V, Xirouchakis E, et al. TACE versus TAE as therapy for hepatocellular carcinoma. *Expert Review of Anticancer Therapy* 2008;**8**(10):1623–41.

**Pocobelli 2008**

Pocobelli G, Cook LS, Brant R, Lee SS. Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. *Liver International* 2008;**28**(9):1272–9.

**Polesel 2009**

Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C, et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. *Annals of Oncology* 2009;**20**(2):353–7.

**Puhan 2014**

Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. *BMJ (Clinical Research Ed.)* 2014;**349**:g5630.

**Qi 2014**

Qi X, Tang Y, An D, Bai M, Shi X, Wang J, et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: a meta-analysis of randomized controlled trials. *Journal of Clinical Gastroenterology* 2014;**48**(5):450–7.

**RevMan 2014 [Computer program]**

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

**Roccarina 2017**

Roccarina D, Majumdar A, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. *Cochrane Database of Systematic Reviews* 2017, Issue 3. [DOI: 10.1002/14651858.CD011649.pub2]

**Royle 2003**

Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus

- exhaustive searches. *International Journal of Technology Assessment in Health Care* 2003;**19**(4):591–603.
- Salanti 2011**  
Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. *Journal of Clinical Epidemiology* 2011;**64**(2):163–71.
- Salanti 2012**  
Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. *Research Synthesis Methods* 2012;**3**(2):80–97.
- Sang 2013**  
Sang LX, Chang B, Li XH, Jiang M. Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis. *BMC Gastroenterology* 2013;**13**:34.
- Savović 2012a**  
Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials: combined analysis of meta-epidemiological studies. *Health Technology Assessment* 2012;**16**(35):1–82.
- Savović 2012b**  
Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials. *Annals of Internal Medicine* 2012;**157**(6):429–38.
- Schulz 1995**  
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;**273**(5):408–12.
- Schulz 2010**  
Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *PLoS Medicine* 2010;**7**(3):e1000251.
- Severini 1993**  
Severini TA. Bayesian interval estimates which are also confidence intervals. *Journal of the Royal Statistical Society. Series B (Methodological)* 1993;**55**(2):533–40.
- Shen 2013**  
Shen A, Zhang H, Tang C, Chen Y, Wang Y, Zhang C, et al. Systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm. *Journal of Gastroenterology and Hepatology* 2013;**28**(5):793–800.
- Sindram 2010**  
Sindram D, Lau KN, Martinie JB, Iannitti DA. Hepatic tumor ablation. *Surgical Clinics of North America* 2010;**90**(4):863–76.
- SRTR 2012**  
Scientific Registry of Transplant Recipients. OPTN/SRTR 2012 annual data report: liver. [srr.transplant.hrsa.gov/](http://srr.transplant.hrsa.gov/)
- annual reports/2012/pdf/03\_liver\_13.pdf (accessed 8 October 2014).
- Stata/SE 14.2 [Computer program]**  
StataCorp LP. Stata/SE 14.2 for Windows [64-bit x86-64]. Version 14. College Station (TX): StataCorp LP, 2017.
- Taura 2009**  
Taura N, Yatsushashi H, Nakao K, Ichikawa T, Ishibashi H. Long-term trends of the incidence of hepatocellular carcinoma in the Nagasaki prefecture, Japan. *Oncology Reports* 2009;**21**(1):223–7.
- Thorlund 2011**  
Thorlund K, Engström J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). [ctu.dk/tsa/files/tsa\\_manual.pdf](http://ctu.dk/tsa/files/tsa_manual.pdf) 2011 (accessed 30 November 2016).
- Thorlund 2012**  
Thorlund K, Mills EJ. Sample size and power considerations in network meta-analysis. *Systematic Reviews* 2012;**1**:41.
- TSA 2011 [Computer program]**  
Copenhagen Trial Unit. TSA - Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011.
- Turati 2012**  
Turati F, Edefonti V, Talamini R, Ferraroni M, Malvezzi M, Bravi F, et al. Family history of liver cancer and hepatocellular carcinoma. *Hepatology (Baltimore, Md.)* 2012;**55**(5):1416–25.
- Turati 2014**  
Turati F, Galeone C, Rota M, Pelucchi C, Negri E, Bagnardi V, et al. Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. *Annals of Oncology* 2014;**25**(8):1526–35.
- Turner 2012**  
Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. *International Journal of Epidemiology* 2012;**41**(3):818–27.
- Van Deusen 2005**  
Van Deusen MA, Abdalla EK, Vauthey JN, Roh MS. Staging classifications for hepatocellular carcinoma. *Expert Review of Molecular Diagnostics* 2005;**5**(3):377–83.
- van Malenstein 2011a**  
van Malenstein H, van Pelt J, Verslype C. Molecular classification of hepatocellular carcinoma anno 2011. *European Journal of Cancer* 2011;**47**(12):1789–97.
- van Valkenhoef 2012**  
van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. *Research Synthesis Methods* 2012;**3**(4):285–99.
- von Hahn 2011**  
von Hahn T, Ciesek S, Wegener G, Plentz RR, Weismuller TJ, Wedemeyer H, et al. Epidemiological trends in incidence and mortality of hepatobiliary cancers in

- Germany. *Scandinavian Journal of Gastroenterology* 2011;**46**(9):1092–8.
- Wan 2014**  
Wan P, Yu X, Xia Q. Operative outcomes of adult living donor liver transplantation and deceased donor liver transplantation: a systematic review and meta-analysis. *Liver Transplantation* 2014;**20**(4):425–36.
- Ware 2014**  
Ware JE. SF-36® health survey update, 2014. [www.sf-36.org/tools/sf36.shtml](http://www.sf-36.org/tools/sf36.shtml) (accessed on 8 October 2014).
- Weis 2013**  
Weis S, Franke A, Mössner J, Jakobsen JC, Schoppmeyer K. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. *Cochrane Database of Systematic Reviews* 2013, Issue 12. [DOI: 10.1002/14651858.CD003046.pub3]
- Weis 2015**  
Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. *Cochrane Database of Systematic Reviews* 2015, Issue 1. [DOI: 10.1002/14651858.CD006745.pub3]
- Wetterslev 2008**  
Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. *Journal of Clinical Epidemiology* 2008;**61**(1):64–75.
- Witjes 2012**  
Witjes CD, Karim-Kos HE, Visser O, van den Akker SA, de Vries E, Ijzermans JN, et al. Hepatocellular carcinoma in a low-endemic area: rising incidence and improved survival. *European Journal of Gastroenterology & Hepatology* 2012;**24**(4):450–7.
- Wood 2008**  
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ (Clinical Research Ed.)* 2008;**336**(7644):601–5.
- Wu 1996**  
Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. *American Journal of Pathology* 1996;**149**(4):1167–75.
- Xiong 2012**  
Xiong JJ, Altaf K, Javed MA, Huang W, Mukherjee R, Mai G, et al. Meta-analysis of laparoscopic vs open liver resection for hepatocellular carcinoma. *World Journal of Gastroenterology* 2012;**18**(45):6657–68.
- Xu 2012b**  
Xu G, Qi FZ, Zhang JH, Cheng GF, Cai Y, Miao Y. Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. *World Journal of Surgical Oncology* 2012;**10**:163.
- Yang 2014**  
Yang Y, Zhang D, Feng N, Chen G, Liu J, Chen G, et al. Increased intake of vegetables, but not fruit, reduces risk for hepatocellular carcinoma: a meta-analysis. *Gastroenterology* 2014;**147**(5):1031–42.
- Zhou 2010**  
Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. *BMC Gastroenterology* 2010;**10**:78.
- \* Indicates the major publication for the study

## CHARACTERISTICS OF STUDIES

### Characteristics of included studies [ordered by study ID]

#### Aikata 2006

Methods	Randomised clinical trial	
Participants	Country: Japan Number randomised: 44 Postrandomisation dropouts: not stated Revised sample size: 44 Average age: not stated Females: not stated Cirrhosis: not stated Very early HCC: not stated Portal hypertension: not stated Viral aetiology: not stated Immunotherapy/antiviral adjuvant therapy: not stated Average follow-up period in months (for all groups): not stated Criteria for early or very early HCC and other inclusion criteria: <ul style="list-style-type: none"> <li>• &lt; 3 cm solitary hypervascular nodules</li> </ul>	
Interventions	Participants were randomly assigned to 2 groups: Group 1: TACE plus radiofrequency ablation (n = 21). Further details: cisplatinium TACE, internally cooled electrode (brand not stated) for radiofrequency ablation. Group 2: Radiofrequency ablation (n = 23). Further details: internally cooled electrode (brand not stated)	
Outcomes	The outcomes reported were: <ul style="list-style-type: none"> <li>• mortality,</li> <li>• adverse events.</li> </ul>	
Notes	Reasons for postrandomisation dropouts: not stated	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Comment: this information was not available.
Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available.

**Aikata 2006** (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: this information was not available.
Selective reporting (reporting bias)	Low risk	Comment: important clinical outcomes were reported.
For-profit bias	Unclear risk	Comment: this information was not available.
Other bias	Low risk	Comment: no other bias noted.

**Bolondi 1996**

Methods	Randomised clinical trial	
Participants	Country: Italy Number randomised: 150 Postrandomisation dropouts: not stated Revised sample size: 150 Average age: not stated Females: not stated Cirrhosis: 150 (100%) Very early HCC: not stated Portal hypertension: not stated Viral aetiology: not stated Immunotherapy/antiviral adjuvant therapy: not stated Average follow-up period in months (for all groups): mean: 19 months Criteria for early or very early HCC and other inclusion criteria: <ul style="list-style-type: none"> <li>• &lt; 5 cm unifocal lesions</li> </ul>	
Interventions	Participants were randomly assigned to 2 groups: Group 1: PEI plus TACE (n = 66). Further details not available for TACE or PEI. Group 2: PEI (n = 84). Further details not available.	
Outcomes	The outcomes reported were: mortality.	
Notes	Reasons for postrandomisation dropouts: not stated	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Comment: this information was not available.

**Bolondi 1996** (Continued)

Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: this information was not available.
Selective reporting (reporting bias)	High risk	Comment: important clinical outcomes expected to be measured in such trials were not reported
For-profit bias	Unclear risk	Comment: this information was not available.
Other bias	Low risk	Comment: no other bias noted.

**Brunello 2008**

Methods	Randomised clinical trial
Participants	<p>Country: Italy            Number randomised: 139            Postrandomisation dropouts: 0 (0%)            Revised sample size: 139            Average age: 70 years            Females: 47 (33.8%)            Cirrhosis: 139 (100%)            Very early HCC: not stated            Portal hypertension: not stated            Viral aetiology: 114 (82%)            Immunotherapy/antiviral adjuvant therapy: not stated            Average follow-up period in months (for all groups): all participants: 36 months            Criteria for early or very early HCC and other inclusion criteria:</p> <ul style="list-style-type: none"> <li>• 1 to 3 nodules, &lt; 3 cm diameter</li> <li>• Child-Pugh class A or B</li> </ul> <p>Exclusion criteria:</p> <ul style="list-style-type: none"> <li>• Hypovascular HCC</li> <li>• Lesions not detectable by ultrasound</li> <li>• Lesions close to the gallbladder, hilum of liver, colon, or stomach</li> <li>• Venous invasion</li> <li>• Metastatic disease</li> <li>• Liver transplantation</li> </ul>

**Brunello 2008** (Continued)

Interventions	Participants were randomly assigned to 2 groups: Group 1: PEI (n = 69). Further details: 2 to 20 mL ethanol (95%). Group 2: radiofrequency ablation (n = 70). Further details: Cool-tip or StarBurst system for radiofrequency ablation
Outcomes	The outcomes reported were: <ul style="list-style-type: none"> <li>• mortality,</li> <li>• adverse events,</li> <li>• HCC recurrence.</li> </ul>
Notes	Authors provided additional information in February 2017.

***Risk of bias***

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote: "computerized random generator"
Allocation concealment (selection bias)	Low risk	Quote: "closed, sequentially numbered envelopes"
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "the healthcare providers were blinded until the opening of the sealed envelopes containing the assignation from the randomized list. The same for the patients, who were informed about their treatment (PEI or RF) after the opening of the envelope and were thereafter scheduled for the appropriate treatment" (author replies)
Blinding of outcome assessment (detection bias) All outcomes	High risk	Comment: after treatment, evaluations of computed tomography by a "blinded" observer were considered not feasible because of different radiological signs produced by the 2 techniques
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias)	Low risk	Comment: important clinical outcomes were reported.
For-profit bias	Low risk	Quote: "The work of Eva Pagano was supported by the Compagnia di San Paolo."
Other bias	Low risk	Comment: no other bias noted.

Methods	Randomised clinical trial	
Participants	Country: China Number randomised: 86 Postrandomisation dropouts: not stated Revised sample size: 86 Average age: 49 years Females: 13 (15.1%) Cirrhosis: not stated Very early HCC: not stated Portal hypertension: not stated Viral aetiology: not stated Immunotherapy/antiviral adjuvant therapy: not stated Average follow-up period in months (for all groups): not stated Criteria for early or very early HCC and other inclusion criteria: <ul style="list-style-type: none"> <li>• Single nodule &lt; 5 cm</li> </ul>	
Interventions	Participants were randomly assigned to 2 groups: Group 1: radiofrequency ablation plus PEI (n = 45). Further details: radiofrequency ablation using RF 2000 (RadioTherapeutics), PEI with absolute alcohol: volume 1 to 2 times the tumour diameter. Group 2: radiofrequency ablation (n = 41). Further details: radiofrequency ablation using RF 2000 (RadioTherapeutics)	
Outcomes	The outcomes reported were: <ul style="list-style-type: none"> <li>• mortality,</li> <li>• adverse events.</li> </ul>	
Notes	Reasons for postrandomisation dropouts: not stated	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Comment: this information was not available.
Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: this information was not available.

**Chen 2005** (Continued)

Selective reporting (reporting bias)	Low risk	Comment: important clinical outcomes were reported.
For-profit bias	Unclear risk	Comment: this information was not available.
Other bias	Low risk	Comment: no other bias noted.

**Chen 2006**

Methods	Randomised clinical trial	
Participants	<p>Country: China            Number randomised: 180            Postrandomisation dropouts: 19 (10.6%)            Revised sample size: 180            Average age: 51 years            Females: 30 (16.7%)            Cirrhosis: not stated            Very early HCC: not stated            Portal hypertension: not stated            Viral aetiology: not stated            Immunotherapy/antiviral adjuvant therapy: not stated            Average follow-up period in months (for all groups): mean: 29 months            Criteria for early or very early HCC and other inclusion criteria:</p> <ul style="list-style-type: none"> <li>● Single nodule &lt; 5 cm</li> <li>● No vascular involvement</li> <li>● No extrahepatic metastases</li> <li>● Child-Pugh class A</li> </ul>	
Interventions	<p>Participants were randomly assigned to 2 groups:            Group 1: surgery (n = 90).            Further details: open surgical resection.            Group 2: radiofrequency ablation (n = 71).            Further details: radiofrequency ablation using RF 2000 or LeVein (RadioTherapeutics)</p>	
Outcomes	<p>The outcomes reported were:</p> <ul style="list-style-type: none"> <li>● mortality,</li> <li>● adverse events,</li> <li>● length of hospital stay.</li> </ul>	
Notes		
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote: "Randomization was done by using random numbers generated from a computer in a central registry for this study"

**Chen 2006** (Continued)

Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	High risk	Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias)	Low risk	Comment: important clinical outcomes were reported.
For-profit bias	Low risk	Quote: "Supported by the grant of Sciences and Technology Committee of Guangdo Province, China, 2002."
Other bias	Low risk	Comment: no other bias noted.

**Costanzo 2015**

Methods	Randomised clinical trial
Participants	<p>Country: Italy            Number randomised: 140            Postrandomisation dropouts: 0 (0%)            Revised sample size: 140            Average age: 70 years            Females: 40 (28.6%)            Cirrhosis: 140 (100%)            Very early HCC: not stated            Portal hypertension: not stated            Viral aetiology: not stated            Immunotherapy/antiviral adjuvant therapy: not stated            Average follow-up period in months (for all groups): not stated            Criteria for early or very early HCC and other inclusion criteria:</p> <ul style="list-style-type: none"> <li>● Milan criteria</li> <li>● Child A or B</li> <li>● No vascular invasion</li> <li>● No distant metastases</li> </ul>
Interventions	<p>Participants were randomly assigned to 2 groups:            Group 1: laser (n = 70).            Further details: laser: EchoLaser, Elesta s.r.l.            Group 2: radiofrequency ablation (n = 70).            Further details: radiofrequency ablation: Cool-tip, Valleylab</p>

Costanzo 2015 (Continued)

Outcomes	The outcomes reported were: <ul style="list-style-type: none"> <li>• mortality,</li> <li>• cancer-related mortality,</li> <li>• adverse events,</li> <li>• HCC recurrence.</li> </ul>
Notes	Authors provided additional information in February 2017.

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "computer-generated random numbers"
Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Comment: blinding of participants and personnel was not performed (author replies)
Blinding of outcome assessment (detection bias) All outcomes	High risk	Comment: blinding of outcome assessors was not performed (author replies)
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias)	Low risk	Comment: important clinical outcomes were reported.
For-profit bias	Low risk	Comment: no special source of funding (author replies)
Other bias	Low risk	Comment: no other bias noted.

**El Kady 2013**

Methods	Randomised clinical trial
Participants	Country: Egypt Number randomised: 40 Postrandomisation dropouts: 0 (0%) Revised sample size: 40 Average age: 52 years Females: 11 (27.5%) Cirrhosis: not stated Very early HCC: 0 (0%) Portal hypertension: not stated Viral aetiology: not stated

	<p>Immunotherapy/antiviral adjuvant therapy: not stated</p> <p>Average follow-up period in months (for all groups): 6</p> <p>Criteria for early or very early HCC and other inclusion criteria:</p> <ul style="list-style-type: none"> <li>• Single nodule &gt; 3 cm</li> <li>• No portal vein involvement</li> <li>• No extrahepatic metastasis</li> </ul>
Interventions	<p>Participants were randomly assigned to 2 groups:</p> <p>Group 1: TACE plus radiofrequency ablation (n = 20).</p> <p>Further details: TACE using 50 mg of adriamycin or cisplatin and 10 mL of ethiodised oil (Lipiodol), radiofrequency ablation with RITA 1500X RF generator and RITA StarBurst XL (RITA Medical Systems, Mountain View, CA, USA).</p> <p>Group 2: radiofrequency ablation (n = 20).</p> <p>Further details: radiofrequency ablation with RITA 1500X RF generator and RITA StarBurst XL (RITA Medical Systems, Mountain View, CA, USA)</p>
Outcomes	<p>The outcomes reported were:</p> <ul style="list-style-type: none"> <li>• mortality,</li> <li>• adverse events,</li> <li>• HCC recurrence.</li> </ul>
Notes	Reasons for postrandomisation dropouts: not stated

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Patients were randomized (computer-based randomization) into two groups"
Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "After assigning the patients to the groups there were no drop-outs, as the patient was assigned and managed on the same day" (author replies)
Selective reporting (reporting bias)	Low risk	Comment: important clinical outcomes were reported.
For-profit bias	Low risk	Quote: "The conduct of the research (collection, analysis, and interpretation of data) and preparation of the article were totally funded by the authors"

El Kady 2013 (Continued)

Other bias	Low risk	Comment: no other bias noted.
------------	----------	-------------------------------

Fang 2014

Methods	Randomised clinical trial
Participants	<p>Country: China            Number randomised: 120            Postrandomisation dropouts: not stated            Revised sample size: 120            Average age: 53 years            Females: 32 (26.7%)            Cirrhosis: 101 (84.2%)            Very early HCC: not stated            Portal hypertension: not stated            Viral aetiology: 107 (89.2%)            Immunotherapy/antiviral adjuvant therapy: not stated            Average follow-up period in months (for all groups): mean: 40 months            Criteria for early or very early HCC and other inclusion criteria:</p> <ul style="list-style-type: none"> <li>• <math>\leq 3</math> lesions, <math>\leq 3</math> cm</li> <li>• Child-Pugh class A or B</li> <li>• No vascular invasion</li> <li>• No distant metastases</li> <li>• No clinically significant portal hypertension</li> </ul>
Interventions	<p>Participants were randomly assigned to 2 groups:            Group 1: surgery (n = 60).            Further details: surgery, not stated whether open or laparoscopic resection.            Group 2: radiofrequency ablation (n = 60).            Further details: radiofrequency ablation with Tyco radiofrequency ablation device, Valleylab</p>
Outcomes	<p>The outcomes reported were:</p> <ul style="list-style-type: none"> <li>• mortality,</li> <li>• adverse events,</li> <li>• HCC recurrence,</li> <li>• length of hospital stay.</li> </ul>
Notes	Reasons for postrandomisation dropouts: not stated

*Risk of bias*

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: this information was not available.
Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.

**Fang 2014** (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: this information was not available.
Selective reporting (reporting bias)	Low risk	Comment: important clinical outcomes were reported.
For-profit bias	Low risk	Quote: "This work was fully supported by grants from Zhejiang Science and Technology Agency funding 2010C13025-1 (H.M. Pan), National Natural Science Foundation of China 81272593 (H.M. Pan), Zhejiang Provincial Natural Science Foundation of China LY13H160013 (Y. Fang) and Zhejiang Provincial Natural Science Foundation of China LQ13H160009 (W. Chen)"
Other bias	Low risk	Comment: no other bias noted.

**Gan 2004**

Methods	Randomised clinical trial
Participants	<p>Country: China            Number randomised: 38            Postrandomisation dropouts: 11 (28.9%)            Revised sample size: 27            Average age: 53 years            Females: 3 (11.1%)            Cirrhosis: not stated            Very early HCC: not stated            Portal hypertension: not stated            Viral aetiology: not stated            Immunotherapy/antiviral adjuvant therapy: not stated            Average follow-up period in months (for all groups): all participants were followed up for 12 months            Criteria for early or very early HCC and other inclusion criteria:</p> <ul style="list-style-type: none"> <li>• 1 to 2 nodules, <math>\leq 3</math> cm</li> <li>• No portal vein involvement</li> <li>• No distant metastases</li> <li>• Life expectancy &gt; 3 months</li> </ul>
Interventions	<p>Participants were randomly assigned to 2 groups:            Group 1: radiofrequency ablation plus systemic chemotherapy (n = 15).            Further details: radiofrequency ablation with RF 2000 (RadioTherapeutics); chemother-</p>

**Gan 2004** (Continued)

	apy with epirubicin 50 mg, cisplatin 40 mg, and floxuridine 500 mg. Group 2: radiofrequency ablation (n = 12). Further details: radiofrequency ablation: RF 2000 (RadioTherapeutics)	
Outcomes	The outcomes reported were: <ul style="list-style-type: none"> <li>• adverse events,</li> <li>• HCC recurrence.</li> </ul>	
Notes	Reasons for postrandomisation dropouts: follow-up less than 1 year	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Comment: this information was not available.
Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	High risk	Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias)	High risk	Comment: important clinical outcomes expected to be measured in such trials were not reported
For-profit bias	Unclear risk	Comment: this information was not available.
Other bias	Low risk	Comment: no other bias noted.

**Giorgio 2011**

Methods	Randomised clinical trial
Participants	Country: Italy Number randomised: 285 Postrandomisation dropouts: 0 (0%) Revised sample size: 285 Average age: 70 years Females: 78 (27.4%) Cirrhosis: 285 (100%) Very early HCC: 71 (24.9%)

	<p>Portal hypertension: not stated  Viral aetiology: 285 (100%)  Immunotherapy/antiviral adjuvant therapy: not stated  Average follow-up period in months (for all groups): mean: 37 months  Criteria for early or very early HCC and other inclusion criteria:</p> <ul style="list-style-type: none"> <li>• Single nodule, <math>\leq 3</math> cm</li> </ul>
Interventions	<p>Participants were randomly assigned to 2 groups:  Group 1: PEI (n = 143).  Further details: PEI using 4 to 20 mL of 95% ethanol depending upon tumour volume.  Group 2: radiofrequency ablation (n = 142).  Further details: radiofrequency ablation generator details not stated</p>
Outcomes	<p>The outcomes reported were:</p> <ul style="list-style-type: none"> <li>• mortality,</li> <li>• adverse events.</li> </ul>
Notes	<p>Although mortality was reported, this was a severely biased estimate, as 14 people who could not undergo radiofrequency ablation were excluded. We therefore did not use the survival information  Authors provided additional information in February 2017.</p>

***Risk of bias***

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "random number generator"
Allocation concealment (selection bias)	Low risk	Quote: "The person randomising the patient were unaware of what the next treatment allocation was. It was used a centralised randomisation service to ensuring allocation concealment. So it was not possible for the investigators to know the allocation sequence in advance" (author replies)
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "The patients and healthcare providers were not blinded due to the nature of the treatments used in to the study (PEI versus RFA)" (author replies)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "The outcome assessors were blinded as they did not know the patient was referring to the results" (author replies)
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias)	Low risk	Comment: important clinical outcomes were reported.

**Giorgio 2011** (Continued)

For-profit bias	Low risk	Quote: “The study was not funded. It was self-financed by the hospital” (author replies)
Other bias	Low risk	Comment: no other bias noted.

**Huang 2010**

Methods	Randomised clinical trial	
Participants	<p>Country: China            Number randomised: 230            Postrandomisation dropouts: 0 (0%)            Revised sample size: 230            Average age: 56 years            Females: 66 (28.7%)            Cirrhosis: 142 (61.7%)            Very early HCC: not stated            Portal hypertension: not stated            Viral aetiology: 215 (93.5%)            Immunotherapy/antiviral adjuvant therapy: not stated            Average follow-up period in months (for all groups): median: 42 months            Criteria for early or very early HCC and other inclusion criteria:</p> <ul style="list-style-type: none"> <li>● Milan criteria</li> <li>● Child A or B</li> <li>● No vascular invasion</li> <li>● No distant metastases</li> </ul>	
Interventions	<p>Participants were randomly assigned to 2 groups:            Group 1: surgery (n = 115).            Further details: not stated whether open or laparoscopic resection.            Group 2: radiofrequency ablation (n = 115).            Further details: radiofrequency ablation using Cool-tip (Radionics)</p>	
Outcomes	<p>The outcomes reported were:</p> <ul style="list-style-type: none"> <li>● mortality,</li> <li>● cancer-related mortality,</li> <li>● adverse events,</li> <li>● HCC recurrence,</li> <li>● length of hospital stay.</li> </ul>	
Notes		
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote: “randomization method with a computer”

**Huang 2010** (Continued)

Allocation concealment (selection bias)	Low risk	Quote: "Physicians received the envelope for each patient in the registry sequence kept in a container given by the statistician and kept by the chief nurse of our center."
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "Because of the nature of the interventions, the double-blind technique was not used"
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "Because of the nature of the interventions, the double-blind technique was not used"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias)	Low risk	Comment: important clinical outcomes were reported.
For-profit bias	Low risk	Quote: "This study has not received any support from industry or private corporations."
Other bias	Low risk	Comment: no other bias noted.

**Koda 2001**

Methods	Randomised clinical trial
Participants	<p>Country: Japan            Number randomised: 52            Postrandomisation dropouts: not stated            Revised sample size: 52            Average age: 66 years            Females: 22 (42.3%)            Cirrhosis: 46 (88.5%)            Very early HCC: not stated            Portal hypertension: not stated            Viral aetiology: 49 (94.2%)            Immunotherapy/antiviral adjuvant therapy: not stated            Average follow-up period in months (for all groups): mean: 30            Criteria for early or very early HCC and other inclusion criteria:</p> <ul style="list-style-type: none"> <li>● 1 to 3 nodules, <math>\leq</math> 3 cm</li> <li>● No portal thrombosis</li> <li>● No extrahepatic metastases</li> </ul>
Interventions	<p>Participants were randomly assigned to 2 groups:            Group 1: TACE plus PEI (n = 26).            Further details: TACE using iodised oil, epirubicin hydrochloride, and gelatin sponge;            PEI using 1 to 12 mL absolute alcohol per session.            Group 2: PEI (n = 26).</p>

**Koda 2001** (Continued)

	Further details: PEI using 1 to 12 mL absolute alcohol per session
Outcomes	The outcomes reported were: <ul style="list-style-type: none"> <li>• mortality,</li> <li>• cancer-related mortality,</li> <li>• adverse events.</li> </ul>
Notes	Reasons for postrandomisation dropouts: not stated

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: this information was not available.
Allocation concealment (selection bias)	Unclear risk	Quote: "sealed-envelope method" Comment: further details were not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: this information was not available.
Selective reporting (reporting bias)	Low risk	Comment: important clinical outcomes were reported.
For-profit bias	Unclear risk	Comment: this information was not available.
Other bias	Low risk	Comment: no other bias noted.

**Lee 2014**

Methods	Randomised clinical trial
Participants	Country: South Korea Number randomised: 63 Postrandomisation dropouts: not stated Revised sample size: 63 Average age: not stated Females: not stated Cirrhosis: not stated Very early HCC: 0 (0%) Portal hypertension: not stated

	<p>Viral aetiology: not stated</p> <p>Immunotherapy/antiviral adjuvant therapy: not stated</p> <p>Average follow-up period in months (for all groups): not stated</p> <p>Criteria for early or very early HCC and other inclusion criteria:</p> <ul style="list-style-type: none"> <li>• Single nodule 2 to 4 cm</li> </ul>
Interventions	<p>Participants were randomly assigned to 2 groups:</p> <p>Group 1: surgery (n = 29).</p> <p>Further details: not stated whether surgery was open or laparoscopic resection.</p> <p>Group 2: radiofrequency ablation (n = 34).</p> <p>Further details not available.</p>
Outcomes	<p>The outcomes reported were:</p> <ul style="list-style-type: none"> <li>• mortality,</li> <li>• adverse events,</li> <li>• HCC recurrence.</li> </ul>
Notes	Reasons for postrandomisation dropouts: not stated

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: this information was not available.
Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: this information was not available.
Selective reporting (reporting bias)	Low risk	Comment: important clinical outcomes were reported.
For-profit bias	High risk	Comment: grant/research support: Green Cross, Chong Kun Dang Pharm, Novartis, SK Chemicals
Other bias	Low risk	Comment: no other bias noted.

**Lencioni 2003**

Methods	Randomised clinical trial
Participants	<p>Country: Italy            Number randomised: 104            Postrandomisation dropouts: 2 (1.9%)            Revised sample size: 102            Average age: 68 years            Females: 36 (35.3%)            Cirrhosis: 102 (100%)            Very early HCC: not stated            Portal hypertension: not stated            Viral aetiology: 82 (80.4%)            Immunotherapy/antiviral adjuvant therapy: not stated            Average follow-up period in months (for all groups): mean: 23 months            Criteria for early or very early HCC and other inclusion criteria:</p> <ul style="list-style-type: none"> <li>• Milan criteria</li> <li>• Child class A or B</li> <li>• No vascular invasion</li> <li>• No distant metastases</li> </ul>
Interventions	<p>Participants were randomly assigned to 2 groups:            Group 1: PEI (n = 50).            Further details: PEI using 2 to 10 mL 95% alcohol per session.            Group 2: radiofrequency ablation (n = 52).            Further details: radiofrequency ablation using 500L RITA Medical Systems</p>
Outcomes	<p>The outcomes reported were:</p> <ul style="list-style-type: none"> <li>• mortality,</li> <li>• cancer-related mortality,</li> <li>• adverse events.</li> </ul>
Notes	<p>Reasons for postrandomisation dropouts:</p> <ol style="list-style-type: none"> <li>1. Tumour size &gt; 5 cm.</li> <li>2. Extrahepatic cancer identified retrospectively.</li> </ol>

***Risk of bias***

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote: "computer-generated randomization list"
Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available.

**Lencioni 2003** (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	High risk	Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias)	Low risk	Comment: important clinical outcomes were reported.
For-profit bias	Unclear risk	Comment: this information was not available.
Other bias	Low risk	Comment: no other bias noted.

**Lin 2005**

Methods	Randomised clinical trial
Participants	<p>Country: Taiwan            Number randomised: 187            Postrandomisation dropouts: 0 (0%)            Revised sample size: 187            Average age: 61 years            Females: 66 (35.3%)            Cirrhosis: 187 (100%)            Very early HCC: not stated            Portal hypertension: not stated            Viral aetiology: 184 (98.4%)            Immunotherapy/antiviral adjuvant therapy: not stated            Average follow-up period in months (for all groups): mean: 27 months            Criteria for early or very early HCC and other inclusion criteria:</p> <ul style="list-style-type: none"> <li>• 1. 1 to 3 nodules, <math>\leq</math> 3 cm</li> <li>• 2. No vascular invasion</li> <li>• 3. No extrahepatic metastases</li> <li>• 4. Child Pugh class A or B</li> </ul>
Interventions	<p>Participants were randomly assigned to 3 groups:            Group 1: radiofrequency ablation (n = 62).            Further details: radiofrequency ablation using RF 2000 (RadioTherapeutics).            Group 2: PEI (n = 62).            Further details: PEI using 2 to 10 mL absolute alcohol per session.            Group 3: percutaneous acetic acid injection (n = 63).            Further details: percutaneous acetic acid injection using 1 to 3 mL 50% acetic acid</p>
Outcomes	<p>The outcomes reported were:</p> <ul style="list-style-type: none"> <li>• mortality,</li> <li>• cancer-related mortality,</li> <li>• adverse events.</li> </ul>

Lin 2005 (Continued)

Notes		
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "computer randomisation list"
Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias)	Low risk	Comment: important clinical outcomes were reported.
For-profit bias	Unclear risk	Comment: this information was not available.
Other bias	Low risk	Comment: no other bias noted.

Orlacchio 2014

Methods	Randomised clinical trial
Participants	<p>Country: Italy            Number randomised: 30            Postrandomisation dropouts: 0 (0%)            Revised sample size: 30            Average age: 72 years            Females: 9 (30%)            Cirrhosis: 30 (100%)            Very early HCC: not stated            Portal hypertension: 30 (100%)            Viral aetiology: 27 (90%)            Immunotherapy/antiviral adjuvant therapy: not stated            Average follow-up period in months (for all groups): all participants were followed up for 12 months            Criteria for early or very early HCC and other inclusion criteria:</p> <ul style="list-style-type: none"> <li>● Single nodule &lt; 4 cm in diameter</li> <li>● Child-Pugh class A or B</li> </ul>

**Orlacchio 2014** (Continued)

Interventions	Participants were randomly assigned to 2 groups: Group 1: laser (n = 15). Further details: laser using EchoLaser XVG system. Group 2: radiofrequency ablation (n = 15). Further details: radiofrequency ablation using RF 3000, Boston Scientific Corporation
Outcomes	The outcomes reported were: <ul style="list-style-type: none"> <li>• mortality,</li> <li>• adverse events.</li> </ul>
Notes	Authors provided additional information in February 2017.

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "randomisation software was used to allocate each patient to a treatment group"
Allocation concealment (selection bias)	Unclear risk	Quote: "randomisation software was used to allocate each patient to a treatment group" Comment: further details were not available.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Comment: participants and personnel were not blinded (based on author replies)
Blinding of outcome assessment (detection bias) All outcomes	High risk	Comment: outcome assessors were not blinded (based on author replies)
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias)	Low risk	Comment: important clinical outcomes were reported.
For-profit bias	Low risk	Comment: no special source of funding (author replies)
Other bias	Low risk	Comment: no other bias noted.

**Shibata 2002**

Methods	Randomised clinical trial
Participants	Country: Japan Number randomised: 72 Postrandomisation dropouts: 0 (0%) Revised sample size: 72

Shibata 2002 (Continued)

	<p>Average age: 63 years          Females: 22 (30.6%)          Cirrhosis: 72 (100%)          Very early HCC: not stated          Portal hypertension: not stated          Viral aetiology: 71 (98.6%)          Immunotherapy/antiviral adjuvant therapy: not stated          Average follow-up period in months (for all groups): mean: 18 months          Criteria for early or very early HCC and other inclusion criteria:</p> <ul style="list-style-type: none"> <li>• 1 to 3 nodules, <math>\leq 3</math> cm or single nodule <math>&lt; 4</math> cm</li> <li>• No portal thrombosis</li> <li>• No extrahepatic metastases</li> </ul>	
Interventions	<p>Participants were randomly assigned to 2 groups:          Group 1: microwave ablation (n = 36).          Further details: microwave ablation with Microtaze.          Group 2: radiofrequency ablation (n = 36).          Further details: radiofrequency ablation using RF2000 (Radionics)</p>	
Outcomes	<p>The outcomes reported were: adverse events.</p>	
Notes		
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Comment: this information was not available.
Allocation concealment (selection bias)	Unclear risk	Quote: "sealed-envelope method" Comment: further details were not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias)	High risk	Comment: important clinical outcomes expected to be measured in such trials were not reported
For-profit bias	Unclear risk	Comment: this information was not available.

Shibata 2002 (Continued)

Other bias	Low risk	Comment: no other bias noted.
------------	----------	-------------------------------

Shiina 2005

Methods	Randomised clinical trial	
Participants	<p>Country: Japan            Number randomised: 232            Postrandomisation dropouts: 0 (0%)            Revised sample size: 232            Average age: not stated            Females: 66 (28.4%)            Cirrhosis: 198 (85.3%)            Very early HCC: not stated            Portal hypertension: not stated            Viral aetiology: 217 (93.5%)            Immunotherapy/antiviral adjuvant therapy: not stated            Average follow-up period in months (for all groups): median: 37 months            Criteria for early or very early HCC and other inclusion criteria:</p> <ul style="list-style-type: none"> <li>• 1 to 3 nodules</li> <li>• No vascular invasion</li> <li>• No extrahepatic metastases</li> <li>• Child-Pugh class A or B</li> </ul>	
Interventions	<p>Participants were randomly assigned to 2 groups:            Group 1: PEI (n = 114).            Further details: PEI using 0.5 mL to 1 mL per site (alcohol percentage not stated).            Group 2: radiofrequency ablation (n = 118).            Further details: radiofrequency ablation using CC-1 Cosman Coagulator (Radionics)</p>	
Outcomes	<p>The outcomes reported were:</p> <ul style="list-style-type: none"> <li>• mortality,</li> <li>• cancer-related mortality,</li> <li>• adverse events,</li> <li>• HCC recurrence,</li> <li>• length of hospital stay.</li> </ul>	
Notes		
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote: "computer-generated random numbers"
Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.

**Shiina 2005** (Continued)

Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: “Double-blind technique was not used because of the nature of the interventions”
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: “Double-blind technique was not used because of the nature of the interventions”
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias)	Low risk	Comment: important clinical outcomes were reported.
For-profit bias	Unclear risk	Quote: “Grants-in-Aid from the Ministry of Education, Science, Sports, and Culture of Japan” Comment: not clear how the remaining part of the study was funded
Other bias	Low risk	Comment: no other bias noted.

HCC: hepatocellular carcinoma; PEI: percutaneous ethanol injection; RFA: radiofrequency ablation; TACE: transarterial chemoembolisation; TAE: transarterial embolisation

**Characteristics of excluded studies** [ordered by study ID]

Study	Reason for exclusion
<a href="#">Abdelaziz 2014</a>	Not in very early or early hepatocellular carcinoma
<a href="#">Azab 2011</a>	Not in very early or early hepatocellular carcinoma
<a href="#">Casaccia 2015</a>	Not a randomised clinical trial
<a href="#">Chen 2014</a>	Not in very early or early hepatocellular carcinoma
<a href="#">Feng 2012</a>	Not in very early or early hepatocellular carcinoma
<a href="#">Ferrari 2007</a>	Not in very early or early hepatocellular carcinoma
<a href="#">Fukushima 2015</a>	Not in very early or early hepatocellular carcinoma
<a href="#">Gallo 1998</a>	Not in very early or early hepatocellular carcinoma
<a href="#">Goldberg 2002</a>	Not in very early or early hepatocellular carcinoma

(Continued)

Habib 2002	Not in very early or early hepatocellular carcinoma
Hirakawa 2013	Variations in radiofrequency ablation
Hou 2009	Not in very early or early hepatocellular carcinoma
Huang 2005	Inadequate randomisation (groups were adjusted to equalise numbers)
Huo 2003	Not a randomised clinical trial
Hyun 2016	Not a randomised clinical trial
Kobayashi 2007	Not in very early or early hepatocellular carcinoma
Kuansheng 2011	Not in very early or early hepatocellular carcinoma
Lau 1999	Not in very early or early hepatocellular carcinoma
Lau 2008	Not in very early or early hepatocellular carcinoma
Lin 2004	Not in very early or early hepatocellular carcinoma
Livraghi 1999	Not a randomised clinical trial
Lo 2007	Not in very early or early hepatocellular carcinoma
Lu 2006a	In the control group, the ablation was performed with either radiofrequency ablation or microwave ablation and this was not determined at random
Mizuki 2010	Not in very early or early hepatocellular carcinoma
Muehlbacher 2014	Not in very early or early hepatocellular carcinoma
Ohnishi 1998	Not in very early or early hepatocellular carcinoma
Okusaka 2011	Recurrent hepatocellular carcinoma. Unable to determine disease stage prior to initial treatment
Peng 2012	Recurrent hepatocellular carcinoma. Unable to determine disease stage prior to initial treatment
Pinter 2015	Not in very early or early hepatocellular carcinoma
Shen 2005	Not in very early or early hepatocellular carcinoma
Shibata 2006	Not a randomised clinical trial
Shibata 2009	Not a randomised clinical trial

(Continued)

Shiozawa 2015	Not a randomised clinical trial
Sun 2016	Not a randomised clinical trial
van Malenstein 2011	Not in very early or early hepatocellular carcinoma
Wu 2015	Variations in surgical resection
Xu 2012a	Randomised after resection. Unable to determine disease stage prior to surgery
Xu 2013	Randomised after resection. Unable to determine disease stage prior to initial treatment
Xu 2015	Not in very early or early hepatocellular carcinoma
Yi 2014	In this randomised clinical trial, the decision to perform radiofrequency ablation or microwave ablation was not random
Yu 2014	Not in very early or early hepatocellular carcinoma
Yu 2016	Not in very early or early hepatocellular carcinoma
Zhang 2002	Not a randomised clinical trial
Zhang 2007	Not in very early or early hepatocellular carcinoma

## DATA AND ANALYSES

### Comparison 1. Surgery versus radiofrequency ablation

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality at maximal follow-up	4	574	Hazard Ratio (Fixed, 95% CI)	0.80 [0.60, 1.08]
2 Cancer-related mortality at maximal follow-up	1	230	Odds Ratio (M-H, Fixed, 95% CI)	0.35 [0.19, 0.65]
3 Mortality (> 1 year)	1	230	Odds Ratio (M-H, Fixed, 95% CI)	0.39 [0.22, 0.68]
4 Serious adverse events (number of participants)	1	120	Odds Ratio (M-H, Fixed, 95% CI)	17.96 [2.28, 141.60]
5 Serious adverse events (number of events)	2	391	Rate Ratio (Fixed, 95% CI)	7.02 [2.29, 21.46]
6 Any adverse events (number of participants)	2	183	Odds Ratio (M-H, Random, 95% CI)	4.09 [0.61, 27.41]
7 Any adverse events (number of events)	2	391	Rate Ratio (Fixed, 95% CI)	4.42 [2.74, 7.15]
8 HCC recurrence (local or distal)	3	413	Odds Ratio (M-H, Fixed, 95% CI)	0.53 [0.35, 0.78]
9 HCC recurrence (recurrence in liver)	2	350	Odds Ratio (M-H, Fixed, 95% CI)	0.49 [0.31, 0.78]
10 Length of hospital stay	3	530	Mean Difference (IV, Fixed, 95% CI)	8.42 [7.84, 9.01]
11 Mortality at maximal follow-up (sensitivity analysis)	3		Hazard Ratio (Fixed, 95% CI)	0.68 [0.47, 1.00]

### Comparison 2. Non-surgical interventions

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality at maximal follow-up	10		Hazard Ratio (Fixed, 95% CI)	Subtotals only
1.1 Laser versus radiofrequency ablation	1	140	Hazard Ratio (Fixed, 95% CI)	1.77 [0.85, 3.68]
1.2 Percutaneous acetic acid injection versus radiofrequency ablation	1	125	Hazard Ratio (Fixed, 95% CI)	1.77 [1.12, 2.79]
1.3 Percutaneous alcohol injection versus radiofrequency ablation	5	882	Hazard Ratio (Fixed, 95% CI)	1.49 [1.18, 1.88]
1.4 Radiofrequency ablation plus percutaneous alcohol injection versus radiofrequency ablation	1	86	Hazard Ratio (Fixed, 95% CI)	0.66 [0.41, 1.06]

1.5 Transarterial chemoembolisation plus radiofrequency ablation versus radiofrequency ablation	1	44	Hazard Ratio (Fixed, 95% CI)	1.12 [0.48, 2.58]
1.6 Percutaneous alcohol injection versus percutaneous acetic acid injection	1	125	Hazard Ratio (Fixed, 95% CI)	1.15 [0.79, 1.65]
1.7 Transarterial chemoembolisation plus percutaneous alcohol injection versus percutaneous alcohol injection	2	202	Hazard Ratio (Fixed, 95% CI)	0.81 [0.65, 1.01]
<b>2 Cancer-related mortality at maximal follow-up</b>	5		Odds Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1 Laser versus radiofrequency ablation	1	140	Odds Ratio (M-H, Fixed, 95% CI)	1.26 [0.49, 3.27]
2.2 Percutaneous acetic acid injection versus radiofrequency ablation	1	125	Odds Ratio (M-H, Fixed, 95% CI)	2.42 [0.70, 8.31]
2.3 Percutaneous alcohol injection versus radiofrequency ablation	3	458	Odds Ratio (M-H, Fixed, 95% CI)	2.18 [1.22, 3.89]
2.4 Percutaneous alcohol injection versus percutaneous acetic acid injection	1	125	Odds Ratio (M-H, Fixed, 95% CI)	1.15 [0.43, 3.07]
2.5 Transarterial chemoembolisation plus percutaneous alcohol injection versus percutaneous alcohol injection	1	52	Odds Ratio (M-H, Fixed, 95% CI)	0.07 [0.00, 1.41]
<b>3 Mortality (&gt; 1 year)</b>	6		Odds Ratio (M-H, Fixed, 95% CI)	Subtotals only
3.1 Laser versus radiofrequency ablation	1	140	Odds Ratio (M-H, Fixed, 95% CI)	1.51 [0.73, 3.12]
3.2 Percutaneous acetic acid injection versus radiofrequency ablation	1	124	Odds Ratio (M-H, Fixed, 95% CI)	1.96 [0.82, 4.72]
3.3 Percutaneous alcohol injection versus radiofrequency ablation	4	598	Odds Ratio (M-H, Fixed, 95% CI)	1.69 [1.15, 2.49]
3.4 Percutaneous alcohol injection versus percutaneous acetic acid injection	1	125	Odds Ratio (M-H, Fixed, 95% CI)	1.21 [0.54, 2.70]
3.5 Transarterial chemoembolisation plus percutaneous alcohol injection versus percutaneous alcohol injection	1	52	Odds Ratio (M-H, Fixed, 95% CI)	0.41 [0.11, 1.58]
<b>4 Serious adverse events (number of participants)</b>	11		Odds Ratio (M-H, Fixed, 95% CI)	Subtotals only
4.1 Laser versus radiofrequency ablation	2	170	Odds Ratio (M-H, Fixed, 95% CI)	1.0 [0.06, 16.31]

4.2 Microwave ablation versus radiofrequency ablation	1	72	Odds Ratio (M-H, Fixed, 95% CI)	4.38 [0.46, 41.22]
4.3 Percutaneous acetic acid injection versus radiofrequency ablation	1	125	Odds Ratio (M-H, Fixed, 95% CI)	0.13 [0.01, 2.65]
4.4 Percutaneous alcohol injection versus radiofrequency ablation	3	365	Odds Ratio (M-H, Fixed, 95% CI)	0.67 [0.19, 2.40]
4.5 Radiofrequency ablation plus chemotherapy versus radiofrequency ablation	1	27	Odds Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.6 Radiofrequency ablation plus percutaneous alcohol injection versus radiofrequency ablation	1	86	Odds Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.7 Transarterial chemoembolisation plus radiofrequency ablation versus radiofrequency ablation	2	84	Odds Ratio (M-H, Fixed, 95% CI)	2.11 [0.18, 25.35]
4.8 Percutaneous alcohol injection versus percutaneous acetic acid injection	1	125	Odds Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.9 Transarterial chemoembolisation plus percutaneous alcohol injection versus percutaneous alcohol injection	1	52	Odds Ratio (M-H, Fixed, 95% CI)	5.41 [0.25, 118.34]
5 Serious adverse events (number of events)	2		Rate Ratio (Fixed, 95% CI)	Totals not selected
5.1 Percutaneous alcohol injection versus radiofrequency ablation	1		Rate Ratio (Fixed, 95% CI)	0.0 [0.0, 0.0]
5.2 Transarterial chemoembolisation plus radiofrequency ablation versus radiofrequency ablation	1		Rate Ratio (Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Any adverse events (number of participants)	3		Odds Ratio (M-H, Fixed, 95% CI)	Subtotals only
6.1 Percutaneous acetic acid injection versus radiofrequency ablation	1	125	Odds Ratio (M-H, Fixed, 95% CI)	0.39 [0.10, 1.59]
6.2 Percutaneous alcohol injection versus radiofrequency ablation	3	548	Odds Ratio (M-H, Fixed, 95% CI)	0.88 [0.43, 1.81]
6.3 Percutaneous alcohol injection versus percutaneous acetic acid injection	1	125	Odds Ratio (M-H, Fixed, 95% CI)	0.33 [0.03, 3.24]
7 Any adverse events (number of events)	6		Rate Ratio (Fixed, 95% CI)	Subtotals only
7.1 Laser versus radiofrequency ablation	2	170	Rate Ratio (Fixed, 95% CI)	0.83 [0.57, 1.20]


7.2 Percutaneous alcohol injection versus radiofrequency ablation	2	334	Rate Ratio (Fixed, 95% CI)	0.90 [0.71, 1.14]
7.3 Transarterial chemoembolisation plus radiofrequency ablation versus radiofrequency ablation	1	40	Rate Ratio (Fixed, 95% CI)	1.30 [0.78, 2.14]
7.4 Transarterial chemoembolisation plus percutaneous alcohol injection versus percutaneous alcohol injection	1	52	Rate Ratio (Fixed, 95% CI)	0.53 [0.42, 0.67]
<b>8 HCC recurrence (local or distal)</b>	3		Odds Ratio (M-H, Fixed, 95% CI)	Subtotals only
8.1 Laser versus radiofrequency ablation	1	140	Odds Ratio (M-H, Fixed, 95% CI)	0.88 [0.44, 1.76]
8.2 Percutaneous alcohol injection versus radiofrequency ablation	2	371	Odds Ratio (M-H, Fixed, 95% CI)	1.58 [1.02, 2.45]
<b>9 HCC recurrence (recurrence in liver)</b>	4		Odds Ratio (M-H, Fixed, 95% CI)	Subtotals only
9.1 Laser versus radiofrequency ablation	1	140	Odds Ratio (M-H, Fixed, 95% CI)	0.86 [0.39, 1.86]
9.2 Percutaneous alcohol injection versus radiofrequency ablation	1	232	Odds Ratio (M-H, Fixed, 95% CI)	1.70 [0.96, 3.00]
9.3 Radiofrequency ablation plus chemotherapy versus radiofrequency ablation	1	27	Odds Ratio (M-H, Fixed, 95% CI)	0.36 [0.07, 1.82]
9.4 Transarterial chemoembolisation plus radiofrequency ablation versus radiofrequency ablation	1	40	Odds Ratio (M-H, Fixed, 95% CI)	1.22 [0.35, 4.24]
<b>10 Length of hospital stay</b>	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
10.1 Percutaneous alcohol injection versus radiofrequency ablation	1	232	Mean Difference (IV, Fixed, 95% CI)	15.3 [13.23, 17.37]

### Analysis 1.1. Comparison 1 Surgery versus radiofrequency ablation, Outcome 1 Mortality at maximal follow-up.

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 1 Surgery versus radiofrequency ablation

Outcome: 1 Mortality at maximal follow-up




**Analysis I.2. Comparison I Surgery versus radiofrequency ablation, Outcome 2 Cancer-related mortality at maximal follow-up.**

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: I Surgery versus radiofrequency ablation

Outcome: 2 Cancer-related mortality at maximal follow-up




**Analysis I.3. Comparison I Surgery versus radiofrequency ablation, Outcome 3 Mortality (> 1 year).**

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: I Surgery versus radiofrequency ablation

Outcome: 3 Mortality (> 1 year)




### Analysis 1.4. Comparison 1 Surgery versus radiofrequency ablation, Outcome 4 Serious adverse events (number of participants).

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 1 Surgery versus radiofrequency ablation

Outcome: 4 Serious adverse events (number of participants)




### Analysis 1.5. Comparison 1 Surgery versus radiofrequency ablation, Outcome 5 Serious adverse events (number of events).

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 1 Surgery versus radiofrequency ablation

Outcome: 5 Serious adverse events (number of events)




### Analysis 1.6. Comparison 1 Surgery versus radiofrequency ablation, Outcome 6 Any adverse events (number of participants).

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 1 Surgery versus radiofrequency ablation

Outcome: 6 Any adverse events (number of participants)




**Analysis 1.7. Comparison 1 Surgery versus radiofrequency ablation, Outcome 7 Any adverse events (number of events).**

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 1 Surgery versus radiofrequency ablation

Outcome: 7 Any adverse events (number of events)




**Analysis 1.8. Comparison 1 Surgery versus radiofrequency ablation, Outcome 8 HCC recurrence (local or distal).**

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 1 Surgery versus radiofrequency ablation

Outcome: 8 HCC recurrence (local or distal)




**Analysis I.9. Comparison I Surgery versus radiofrequency ablation, Outcome 9 HCC recurrence (recurrence in liver).**

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: I Surgery versus radiofrequency ablation

Outcome: 9 HCC recurrence (recurrence in liver)




**Analysis I.10. Comparison I Surgery versus radiofrequency ablation, Outcome 10 Length of hospital stay.**

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: I Surgery versus radiofrequency ablation

Outcome: 10 Length of hospital stay




**Analysis 1.11. Comparison 1 Surgery versus radiofrequency ablation, Outcome 11 Mortality at maximal follow-up (sensitivity analysis).**

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 1 Surgery versus radiofrequency ablation

Outcome: 11 Mortality at maximal follow-up (sensitivity analysis)





## Analysis 2.1. Comparison 2 Non-surgical interventions, Outcome 1 Mortality at maximal follow-up.

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 2 Non-surgical interventions

Outcome: 1 Mortality at maximal follow-up






### Analysis 2.2. Comparison 2 Non-surgical interventions, Outcome 2 Cancer-related mortality at maximal follow-up.


Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 2 Non-surgical interventions

Outcome: 2 Cancer-related mortality at maximal follow-up



(Continued . . .)




### Analysis 2.3. Comparison 2 Non-surgical interventions, Outcome 3 Mortality (> 1 year).

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 2 Non-surgical interventions

Outcome: 3 Mortality (> 1 year)




**Analysis 2.4. Comparison 2 Non-surgical interventions, Outcome 4 Serious adverse events (number of participants).**


Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 2 Non-surgical interventions

Outcome: 4 Serious adverse events (number of participants)



(Continued ...)



**Analysis 2.5. Comparison 2 Non-surgical interventions, Outcome 5 Serious adverse events (number of events).**

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 2 Non-surgical interventions

Outcome: 5 Serious adverse events (number of events)

Study or subgroup	Intervention	Control	log [Rate Ratio] (SE)	Rate Ratio	Rate Ratio
	N	N		IV,Fixed,95% CI	IV,Fixed,95% CI
<b>1 Percutaneous alcohol injection versus radiofrequency ablation</b>					
Shiina 2005	114	118	-0.2532 (0.763763)		0.78 [ 0.17, 3.47 ]
<b>2 Transarterial chemoembolisation plus radiofrequency ablation versus radiofrequency ablation</b>					
Aikata 2006	21	23	0 (0)		Not estimable


0.05 0.2 5 20  
Favours intervention Favours control

## Analysis 2.6. Comparison 2 Non-surgical interventions, Outcome 6 Any adverse events (number of participants).

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 2 Non-surgical interventions

Outcome: 6 Any adverse events (number of participants)




**Analysis 2.7. Comparison 2 Non-surgical interventions, Outcome 7 Any adverse events (number of events).**

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 2 Non-surgical interventions

Outcome: 7 Any adverse events (number of events)




## Analysis 2.8. Comparison 2 Non-surgical interventions, Outcome 8 HCC recurrence (local or distal).

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 2 Non-surgical interventions

Outcome: 8 HCC recurrence (local or distal)




## Analysis 2.9. Comparison 2 Non-surgical interventions, Outcome 9 HCC recurrence (recurrence in liver).

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 2 Non-surgical interventions

Outcome: 9 HCC recurrence (recurrence in liver)




## Analysis 2.10. Comparison 2 Non-surgical interventions, Outcome 10 Length of hospital stay.

Review: Management of people with early- or very early-stage hepatocellular carcinoma

Comparison: 2 Non-surgical interventions

Outcome: 10 Length of hospital stay



## ADDITIONAL TABLES

Table 1. Characteristics of included studies arranged according to intervention and control

Study name	Number of participants randomised	Postrandomisation dropouts	Number of participants for whom outcome was reported	Intervention(s)	Control	Average follow-up period (months)
<b>In people who were eligible for surgery</b>						
Chen 2006	180	19	161	Surgery	Radiofrequency ablation	29
Huang 2010	230	0	230	Surgery	Radiofrequency ablation	42
Fang 2014	120	Not stated	120	Surgery	Radiofrequency ablation	40
Lee 2014	63	Not stated	63	Surgery	Radiofrequency ablation	Not stated
<b>In people who were not eligible for surgery</b>						

**Table 1. Characteristics of included studies arranged according to intervention and control** (Continued)

Bolondi 1996	150	Not stated	150	Percutaneous alcohol injection plus transarterial chemoembolisation	Percutaneous alcohol injection	19
Koda 2001	52	Not stated	52	Transarterial chemoembolisation plus percutaneous alcohol injection	Percutaneous alcohol injection	30
Lin 2005	187	0	187	Radiofrequency ablation	Percutaneous alcohol injection, percutaneous acetic acid injection	27
Orlacchio 2014	30	0	30	Laser	Radiofrequency ablation	12
Costanzo 2015	140	0	140	Laser	Radiofrequency ablation	Not stated
Shibata 2002	72	0	72	Microwave ablation	Radiofrequency ablation	18
Lencioni 2003	104	2	102	Percutaneous alcohol injection	Radiofrequency ablation	23
Shiina 2005	232	0	232	Percutaneous alcohol injection	Radiofrequency ablation	37
Brunello 2008	139	0	139	Percutaneous alcohol injection	Radiofrequency ablation	36
Giorgio 2011	285	0	285	Percutaneous alcohol injection	Radiofrequency ablation	37
Gan 2004	38	11	27	Radiofrequency ablation plus chemotherapy	Radiofrequency ablation	12
Chen 2005	86	Not stated	86	Radiofrequency ablation plus percutaneous alco-	Radiofrequency ablation	Not stated

**Table 1. Characteristics of included studies arranged according to intervention and control** (Continued)

				hol injection		
Aikata 2006	44	Not stated	44	Transarterial chemoembolisation plus radiofrequency ablation	Radiofrequency ablation	Not stated
El Kady 2013	40	0	40	Transarterial chemoembolisation plus radiofrequency ablation	Radiofrequency ablation	6

**Table 2. Risk of bias in studies arranged according to intervention and control**

Study name	Random sequence generation	Allocation concealment	Blinding of participants and health professionals	Blinding of outcome assessors	Incomplete outcome data bias	Selective outcome reporting	For-profit bias	Other bias
<b>In people who were eligible for surgery</b>								
Chen 2006	Low	Unclear	Unclear	Unclear	High	Low	Low	Low
Huang 2010	Unclear	Unclear	Unclear	Unclear	Unclear	Low	Low	Low
Fang 2014	Low	Low	High	High	Low	Low	Low	Low
Lee 2014	Unclear	Unclear	Unclear	Unclear	Unclear	Low	High	Low
<b>In people who were not eligible for surgery</b>								
Bolondi 1996	Unclear	Unclear	Unclear	Unclear	Unclear	High	Unclear	Low
Koda 2001	Unclear	Unclear	Unclear	Unclear	Unclear	Low	Unclear	Low
Lin 2005	Low	Unclear	Unclear	Unclear	Low	Low	Unclear	Low
Orlacchio 2014	Low	Unclear	High	High	Low	Low	Low	Low
Costanzo 2015	Low	Unclear	High	High	Low	Low	Low	Low

**Table 2. Risk of bias in studies arranged according to intervention and control** (Continued)

Shibata 2002	Unclear	Unclear	Unclear	Unclear	Low	High	Unclear	Low
Lencioni 2003	Low	Unclear	Unclear	Unclear	High	Low	Unclear	Low
Shiina 2005	Low	Unclear	High	High	Low	Low	Unclear	Low
Brunello 2008	Low	Low	High	High	Low	Low	Low	Low
Giorgio 2011	Low	Low	Unclear	Low	Low	Low	Low	Low
Gan 2004	Unclear	Unclear	Unclear	Unclear	High	High	Unclear	Low
Chen 2005	Unclear	Unclear	Unclear	Unclear	Unclear	Low	Unclear	Low
Aikata 2006	Unclear	Unclear	Unclear	Unclear	Unclear	Low	Unclear	Low
El Kady 2013	Low	Unclear	Unclear	Unclear	Low	Low	Low	Low

## APPENDICES

### Appendix I. Barcelona Clinic Liver Cancer (BCLC) staging classification

Stage 0: very early hepatocellular carcinoma (HCC) (single tumour less than 2 cm).

Stage A: early HCC (single tumour or three tumours less than 3 cm in maximum diameter).

Stage B: intermediate HCC (multiple large tumours).

Stage C: advanced HCC (vascular invasion or extrahepatic spread).

Stage D: end-stage HCC (poor performance status or Child-Pugh C liver functional status (based on bilirubin levels, albumin levels, prothrombin time or international normalised ratio (INR), presence of ascites, and presence of hepatic encephalopathy)).

Simplified from sources: [Llovet 1999](#); [Llovet 2003](#).

## Appendix 2. Milan criteria

1. Single lesion less than 5 cm in diameter.
2. Two or three lesions less than 3 cm in maximum diameter.
3. No preoperative evidence or suspicion of invasion of blood vessels or lymph nodes by tumour.
4. No preoperative evidence of extrahepatic metastases.

To meet the Milan criteria a person must fulfil either criteria numbers 1, 3, and 4 or criteria numbers 2, 3, and 4. Simplified from source: [Mazzaferro 1996](#).

## Appendix 3. Methods for network meta-analysis if we find this is possible in the future

### Measures of treatment effect

#### *Relative treatment effects*

For dichotomous variables (e.g. proportion of participants with serious adverse events or any adverse events), we will calculate the odds ratio with 95% credible interval (or Bayesian confidence interval) ([Severini 1993](#)). For continuous variables (e.g. quality of life reported on the same scale), we will calculate the mean difference with 95% credible interval. We will use standardised mean difference values with 95% credible interval for quality of life if included trials use different scales. For count outcomes (e.g. number of adverse events and serious adverse events), we will calculate the rate ratio with 95% credible interval. For time-to-event data (e.g. mortality at maximal follow-up), we will calculate hazard ratio with 95% credible interval.

#### *Relative ranking*

We will estimate the ranking probabilities for all treatments of being at each possible rank for each intervention. We will then obtain the surface under the cumulative ranking curve (SUCRA) (cumulative probability) and rankogram ([Salanti 2011](#); [Chaimani 2013](#)).

### Unit of analysis issues

We will collect data for all trial treatment groups that meet the inclusion criteria. The codes for analysis we will use account for the correlation between the effect sizes from trials with more than two groups.

### Assessment of heterogeneity

We will assess clinical and methodological heterogeneity by carefully examining the characteristics and design of included trials. We will assess the presence of clinical heterogeneity by comparing effect estimates under different categories of potential effect modifiers. Different study designs and risk of bias may contribute to methodological heterogeneity.

We will assess the statistical heterogeneity by comparing the results of the fixed-effect model meta-analysis and the random-effects model meta-analysis, between-study standard deviation ( $\tau^2$  and comparing this with values reported in the study of the distribution of between-study heterogeneity) ([Turner 2012](#)), and by calculating  $I^2$  (using [Stata/SE 14.2](#)). If we identify substantial heterogeneity (i.e. clinical, methodological, or statistical), we will explore this heterogeneity and address it in a subgroup analysis (see 'Subgroup analysis and investigation of heterogeneity for network meta-analysis' section below).

### Assessment of transitivity across treatment comparisons

We will evaluate the plausibility of transitivity assumption (the assumption that the participants included in the different studies with different immunosuppressive regimens can be considered to be a part of a multi-arm randomised clinical trial and could potentially have been randomised to any of the treatments) ([Salanti 2012](#)). In other words, any participant that meets the inclusion criteria is, in principle, equally likely to be randomised to any of the above eligible interventions. If there is any concern that the clinical safety and

effectiveness are dependent upon the effect modifiers, we will continue to do traditional Cochrane pairwise comparisons and we will not perform a network meta-analysis on all participant subgroups.

### **Assessment of reporting biases**

For the network meta-analysis, we will judge the reporting bias by the completeness of the search (i.e. searching various databases and including conference abstracts), as we do not currently find any meaningful order to perform a comparison-adjusted funnel plot as suggested by [Chaimani 2012](#). However, if we find any meaningful order, for example the control group used depended upon the year of conduct of the trial, we will use comparison-adjusted funnel plot as suggested by [Chaimani 2012](#).

### **Data synthesis**

#### *Methods for indirect and mixed comparisons*

We will conduct network meta-analyses to compare multiple interventions simultaneously for each of the primary and secondary outcomes. Network meta-analysis combines direct evidence within trials and indirect evidence across trials ([Mills 2012](#)). We will obtain a network plot to ensure that the trials were connected by treatments using *Stata/SE 14.2* ([Chaimani 2013](#)). We will exclude any trials that were not connected to the network. We will conduct a Bayesian network meta-analysis using the Markov chain Monte Carlo method in *OpenBUGS 3.2.3* as per guidance from the National Institute for Health and Care Excellence (NICE) Decision Support Unit (DSU) documents ([Dias 2014a](#)). We will model the treatment contrast (i.e. log odds ratio for binary outcomes, mean difference or standardised mean difference for continuous outcomes, log rate ratio for count outcomes, and log hazard ratio for time-to-event outcomes) for any two interventions ('functional parameters') as a function of comparisons between each individual intervention and an arbitrarily selected reference group ('basic parameters') using appropriate likelihood functions and links ([Lu 2006b](#)). We will use binomial likelihood and logit link for binary outcomes, Poisson likelihood and log link for count outcomes, binomial likelihood and complementary log-log link for time-to-event outcomes, and normal likelihood and identity link for continuous outcomes. We will perform a fixed-effect model and random-effects model for the network meta-analysis. We will report both models for comparison with the reference group in a forest plot. For pairwise comparison, we will report the fixed-effect model if the two models reported similar results; otherwise, we will report the more conservative model.

We will use a hierarchical Bayesian model using three different initial values employing codes provided by NICE DSU ([Dias 2014a](#)). We will use a normal distribution with large variance (10,000) for treatment effect priors (vague or flat priors). For the random-effects model, we will use a prior distributed uniformly (limits: 0 to 5) for between-trial standard deviation but assumed similar between-trial standard deviation across treatment comparisons ([Dias 2014a](#)). We will use a 'burn-in' of 5000 simulations, check for convergence visually, and run the models for another 10,000 simulations to obtain effect estimates. If we do not obtain convergence, we will increase the number of simulations for 'burn-in'. If we still do not obtain convergence, we will use alternate initial values and priors employing methods suggested by [van Valkenhoef 2012](#). We will also estimate the probability that each intervention ranks at one of the possible positions using the NICE DSU codes ([Dias 2014a](#)).

#### *Assessment of inconsistency*

We will assess inconsistency (statistical evidence of the violation of transitivity assumption) by fitting both an inconsistency model and a consistency model. We will use the inconsistency models employed in the NICE DSU manual, as we plan to use a common between-study deviation for the comparisons ([Dias 2014b](#)). In addition, we will use the design-by-treatment full interaction model and IF (inconsistency factor) plots to assess inconsistency ([Higgins 2012](#); [Chaimani 2013](#)). In the presence of inconsistency, we will assess whether the inconsistency is due to clinical or methodological heterogeneity by performing separate analyses for each of the different subgroups mentioned in the 'Subgroup analysis and investigation of heterogeneity for network meta-analysis' section below.

If there is evidence of inconsistency, we will identify areas in the network where substantial inconsistency might be present in terms of clinical and methodological diversities between trials and, when appropriate, limit network meta-analysis to a more compatible subset of trials.

### **Direct comparison**

We will perform the direct comparisons using the same codes and the same technical details.

### **Sample size calculations**

To control for the risk of random errors, we will interpret the information with caution when the accrued sample size in the network meta-analysis (i.e. across all treatment comparisons) is less than the required sample size (required information size). For calculation of the required information size, see [Appendix 5](#).

### **Subgroup analysis and investigation of heterogeneity for network meta-analysis**

We will assess the differences in the effect estimates between the subgroups listed in the 'Subgroup analysis and investigation of heterogeneity' section using meta-regression with the help of the OpenBUGS code if we include a sufficient number of trials ([Dias 2012a](#)). We will use the potential modifiers as study level covariates for meta-regression. We will calculate a single common interaction term ([Dias 2012a](#)). If the 95% credible intervals of the interaction term do not overlap zero, we will consider this as evidence of difference in subgroups.

### **Presentation of results**

We will present the effect estimates with 95% credible interval for each pairwise comparison calculated from the direct comparisons and network meta-analysis. We will also present the cumulative probability of the treatment ranks (i.e. the probability that the treatment is within the top two, the probability that the treatment is within the top three, etc.) in graphs (SUCRA) ([Salanti 2011](#)). We will also plot the probability that each treatment is best, second best, third best, etc. for each of the different outcomes (rankograms), which are generally considered more informative ([Salanti 2011](#); [Dias 2012b](#)).

We will present the 'Summary of findings' tables for mortality. In [Summary of findings for the main comparison](#), we will follow the approach suggested by [Puhan 2014](#). We will first calculate the direct and indirect effect estimates and 95% credible intervals using the node-splitting approach ([Dias 2010](#)), that is calculate the direct estimate for each comparison by including only trials in which there was direct comparison of treatments and the indirect estimate for each comparison by excluding the trials in which there was direct comparison of treatments. We will then rate the quality of direct and indirect effect estimates using GRADE, which takes into account the risk of bias, inconsistency, directness of evidence, imprecision, and publication bias ([Guyatt 2011](#)). Next we will present the estimates of the network meta-analysis and rate the quality of network meta-analysis effect estimates as the best quality of evidence between the direct and indirect estimates ([Puhan 2014](#)). In addition, in the same table, we will present illustrations and information on the number of trials and participants as per the standard 'Summary of findings' table.

## **Appendix 4. Search strategies**

<b>Database</b>	<b>Time span</b>	<b>Search strategy</b>
The Central Register of Controlled Trials (CENTRAL) in the Cochrane Library	Issue 8, 2016	#1 MeSH descriptor: [Carcinoma, Hepatocellular] explode all trees #2 (((hepat* or liver) and carcinoma*) or hepatocellular carcinoma or hepatocarcinoma or hepatoma or HCC or "primary liver cancer") #3 #1 or #2 #4 (early or small) #5 #3 and #4

(Continued)

MEDLINE (OvidSP)	January 1947 to September 2016	<ol style="list-style-type: none"> <li>1. exp Carcinoma, Hepatocellular/</li> <li>2. (((hepat* or liver) and carcinoma*) or hepatocellular caricoma or hepatocarcinoma or hepatoma or HCC or “primary liver cancer”).ti,ab</li> <li>3. 1 or 2</li> <li>4. (early or small).ti,ab.</li> <li>5. 3 and 4</li> <li>6. randomized controlled trial.pt.</li> <li>7. controlled clinical trial.pt.</li> <li>8. randomized.ab.</li> <li>9. placebo.ab.</li> <li>10. drug therapy.fs.</li> <li>11. randomly.ab.</li> <li>12. trial.ab.</li> <li>13. groups.ab.</li> <li>14. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13</li> <li>15. exp animals/ not humans.sh.</li> <li>16. 14 not 15</li> <li>17. 5 and 16</li> </ol>
Embase (OvidSP)	January 1974 to September 2016	<ol style="list-style-type: none"> <li>1. exp liver cell carcinoma/</li> <li>2. (((hepat* or liver) and carcinoma*) or hepatocellular caricoma or hepatocarcinoma or hepatoma or HCC or “primary liver cancer”).ti,ab</li> <li>3. 1 or 2</li> <li>4. (early or small).ti,ab.</li> <li>5. 3 and 4</li> <li>6. exp crossover-procedure/ or exp double-blind procedure/ or exp randomized controlled trial/ or single-blind procedure/</li> <li>7. ((((((random* or factorial* or crossover* or cross over* or cross-over* or placebo* or double*) adj blind*) or single*) adj blind*) or assign* or allocat* or volunteer*).af</li> <li>8. 6 or 7</li> <li>9. 5 and 8</li> </ol>
Science Citation Index Expanded (Web of Knowledge)	January 1945 to September 2016	<p>#1 TS=(((hepat* or liver) and carcinoma*) or hepatocellular caricoma or hepatocarcinoma or hepatoma or HCC or “primary liver cancer”)</p> <p>#2 TS=(early or small)</p> <p>#3 TS=(random* OR rct* OR crossover OR masked OR blind* OR placebo* OR meta-analysis OR systematic review* OR meta-analys*)</p> <p>#4 #1 AND #2 AND #3</p>
World Health Organization International Clinical Trials Registry Platform Search Portal (	September 2016	<p>Title: (early or small)</p> <p>Condition: “hepatocellular carcinoma” or “primary liver cancer” or “liver cell cancer” or hepatoma</p>

(Continued)

<a href="https://apps.who.int/trialsearch/Default.aspx">apps.who.int/trialsearch/Default.aspx</a>		
<a href="https://clinicaltrials.gov">ClinicalTrials.gov</a>	September 2016	early OR small   Interventional Studies   “hepatocellular carcinoma” OR “primary liver cancer” OR “liver cell cancer” OR hepatoma   Phase 2, 3, 4

## Appendix 5. Sample size calculation

On average, 50% of people with early hepatocellular carcinoma are alive at five years. The required information size based on a control group proportion of 5%, a relative risk reduction of 20% in the intervention group, type I error of 5%, and type II error of 50% is 774 participants. Network analyses are more prone to the risk of random errors than direct comparisons (Del Re 2013). Accordingly, a greater sample size is required in indirect comparisons than in direct comparisons (Thorlund 2012). The power and precision in indirect comparisons depends upon various factors, such as the number of participants included under each comparison and the heterogeneity between the trials (Thorlund 2012). If there is no heterogeneity across the trials, the sample size in indirect comparisons would be equivalent to the sample size in direct comparisons. The effective indirect sample size can be calculated using the number of participants included in each direct comparison (Thorlund 2012). For example, a sample size of 2500 participants in the direct comparison A versus C ( $n_{AC}$ ) and a sample size of 7500 participants in the direct comparison B versus C ( $n_{BC}$ ) results in an effective indirect sample size of 1876 participants. However, in the presence of heterogeneity within the comparisons, the required sample size is higher. In the above scenario, for an  $I^2$  statistic for each of the comparisons A versus C ( $I_{AC}^2$ ) and B versus C ( $I_{BC}^2$ ) of 25%, the effective indirect sample size is 1407 participants. For an  $I^2$  statistic for each of the comparisons A versus C and B versus C of 50%, the effective indirect sample size is 938 participants (Thorlund 2012). If there were only three groups, and the sample size in the trials is more than the required information size, we planned to calculate the effective indirect sample size using the following generic formula (Thorlund 2012):

$$((n_{AC} \times (1 - I_{AC}^2)) \times (n_{BC} \times (1 - I_{BC}^2))) / ((n_{AC} \times (1 - I_{AC}^2)) + (n_{BC} \times (1 - I_{BC}^2))).$$

There is currently no method to calculate the effective indirect sample size for a network analysis involving more than three intervention groups.

## WHAT'S NEW

Date	Event	Description
12 April 2017	Amended	The Cochrane Central Editorial Unit requested removal of the 'attempted network meta-analysis' phrase from the end of the review title, as this further description of the review might create confusion in the reader. Although we followed the planned methodology for network meta-analysis, it was not possible to assess whether the potential effect modifiers were similar across different comparisons. Therefore, we did not perform the network meta-analysis and instead assessed the comparative benefits and harms of different interventions versus each other or versus sham or no intervention using standard Cochrane methodology

## CONTRIBUTIONS OF AUTHORS

Avik Majumdar, Davide Roccarina, and Kurinchi Gurusamy selected the studies and extracted the data. Avik Majumdar completed the 'Characteristics of included studies' and 'Characteristics of excluded studies' tables. Kurinchi Gurusamy wrote the review. Avik Majumdar, Davide Roccarina, Emmanuel Tsochatzis, Brian Davidson, and Douglas Thorburn commented critically on the review. All review authors approved this version before publication.

## DECLARATIONS OF INTEREST

This report is independent research funded by the National Institute for Health Research (NIHR Cochrane Programme Grants, 13/89/03 - Evidence-based diagnosis and management of upper digestive, hepato-biliary, and pancreatic disorders). The views expressed in this publication are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR, or the Department of Health.

Astellas Pharma funded Douglas Thorburn for his attendance at the International Liver Transplantation Society meeting in 2014. Douglas Thorburn also received GBP 25,000 from Boston Scientific to fund a clinical research fellow in 2013. Emmanuel Tsochatzis has participated in advisory boards for AstraZeneca and ViiV Healthcare. Avik Majumdar, Davide Roccarina, Kurinchi Gurusamy and Brian Davidson have no financial disclosures. There are no other financial disclosures to report.

## SOURCES OF SUPPORT

### Internal sources

- University College London, UK.

### External sources

- National Institute for Health Research, UK.

## DIFFERENCES BETWEEN PROTOCOL AND REVIEW

- It was not possible to assess whether the potential effect modifiers were similar across different comparisons, therefore we did not perform the network meta-analysis and assessed the comparative benefits and harms of different interventions using standard Cochrane methodology. The methodology that we plan to use if we conduct a network meta-analysis in future is available in [Appendix 3](#).

- We performed Trial Sequential Analysis in addition to the conventional method of assessing the risk of random errors using P value.

## NOTES

Considerable overlap is evident in the [Methods](#) section of this review and that of several other reviews written by the same group of authors.

## INDEX TERMS

### Medical Subject Headings (MeSH)

Acetic Acid [therapeutic use]; Carcinoma, Hepatocellular [mortality; \*pathology; \*therapy]; Catheter Ablation [mortality]; Cause of Death; Chemoembolization, Therapeutic [methods; mortality]; Ethanol [therapeutic use]; Laser Therapy [adverse effects; mortality]; Liver Neoplasms [mortality; \*pathology; \*therapy]; Microwaves [therapeutic use]; Network Meta-Analysis; Odds Ratio; Postoperative Complications [epidemiology]; Randomized Controlled Trials as Topic; Tumor Burden

### MeSH check words

Humans